var title_f14_10_14496="Two hepatic adenomas MRI";
var content_f14_10_14496=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F79542&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F79542&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Hepatic adenomas",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 395px; height: 259px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This gadolinum enhanced magnetic resonance image of the liver acquired during the early bolus phase of contrast administration demonstrates two enhancing masses in the liver, one in the left lateral segment, the second immediately anterior to the right portal vein (arrows). The enhancement characterisitcis are non-specific and are seen with any vascular tumor of the liver.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jonathan Kruskal, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_10_14496=[""].join("\n");
var outline_f14_10_14496=null;
var title_f14_10_14497="Calculator: Epoprostenol (Flolan) Infusion Rate Calculator";
var content_f14_10_14497=[" <div id=\"topicText\">",
"  <div id=\"mc3k\">",
"   <form action=\"\" id=\"EpoprostenolInfusion_form\" name=\"EpoprostenolInfusion_form\" onkeydown=\"clrResults();\" onkeyup=\"EpoprostenolInfusion_fx();\" onsubmit=\"return false;\">",
"    <table cellpadding=\"4\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\" width=\"100%\">",
"     <tr>",
"      <td bgcolor=\"#eeeeee\" width=\"1%\">",
"       <br/>",
"      </td>",
"      <td align=\"left\" bgcolor=\"#eeeeee\">",
"       <span class=\"medCalcFontTitleBox\">",
"        Calculator: Epoprostenol (Flolan) Infusion Rate Calculator",
"       </span>",
"      </td>",
"     </tr>",
"    </table>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <center>",
"     <table cellpadding=\"10\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\">",
"      <tr>",
"       <td align=\"left\" bgcolor=\"#6c9a9c\">",
"        <span class=\"medCalcFontFormuli\">",
"         InfusionRate = Dose * Weight * 60 / Concentration",
"        </span>",
"       </td>",
"      </tr>",
"     </table>",
"     <br/>",
"     &nbsp;",
"     <br/>",
"     <table cellpadding=\"6\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\" width=\"95%\">",
"      <tr>",
"       <td align=\"right\" width=\"50%\">",
"        <center>",
"         <span class=\"medCalcFontIO\">",
"          Input:",
"         </span>",
"         <br/>",
"         &nbsp;",
"         <br/>",
"         <table cellpadding=\"3\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\">",
"          <tr>",
"           <td align=\"right\" width=\"42%\">",
"            <span class=\"medCalcFontOneBold\">",
"             Dose",
"            </span>",
"           </td>",
"           <td align=\"left\" nowrap=\"nowrap\" valign=\"top\" width=\"5%\">",
"            &nbsp;",
"            <input name=\"Dose_param\" onblur=\"EpoprostenolInfusion_fx(); minMaxCheck();\" onchange=\"EpoprostenolInfusion_fx();\" size=\"6\" type=\"text\" value=\"\"/>",
"           </td>",
"           <td align=\"left\" valign=\"top\" width=\"115\">",
"            <select class=\"medCalcFontSelect\" name=\"Dose_unit\" onchange=\"EpoprostenolInfusion_fx();\" style=\"width:105px;\">",
"             <option selected=\"selected\" value=\"1|0|ng/kg/min\">",
"              ng/kg/min",
"             </option>",
"            </select>",
"           </td>",
"          </tr>",
"          <tr>",
"           <td align=\"right\" width=\"42%\">",
"            <span class=\"medCalcFontOneBold\">",
"             Weight",
"            </span>",
"           </td>",
"           <td align=\"left\" nowrap=\"nowrap\" valign=\"top\" width=\"5%\">",
"            &nbsp;",
"            <input name=\"Weight_param\" onblur=\"EpoprostenolInfusion_fx(); minMaxCheck();\" onchange=\"EpoprostenolInfusion_fx();\" size=\"6\" type=\"text\" value=\"\"/>",
"           </td>",
"           <td align=\"left\" valign=\"top\" width=\"115\">",
"            <select class=\"medCalcFontSelect\" name=\"Weight_unit\" onchange=\"EpoprostenolInfusion_fx();\" style=\"width:105px;\">",
"             <option value=\"0.001|0|gm\">",
"              gm",
"             </option>",
"             <option selected=\"selected\" value=\"1|0|kg\">",
"              kg",
"             </option>",
"             <option value=\"0.45359237|0|lb\">",
"              lb",
"             </option>",
"             <option value=\"1e-06|0|mg\">",
"              mg",
"             </option>",
"            </select>",
"           </td>",
"          </tr>",
"          <tr>",
"           <td align=\"right\" width=\"42%\">",
"            <span class=\"medCalcFontOneBold\">",
"             Concentration",
"            </span>",
"           </td>",
"           <td align=\"left\" nowrap=\"nowrap\" valign=\"top\" width=\"5%\">",
"            &nbsp;",
"            <input name=\"Concentration_param\" onblur=\"EpoprostenolInfusion_fx(); minMaxCheck();\" onchange=\"EpoprostenolInfusion_fx();\" size=\"6\" type=\"text\" value=\"\"/>",
"           </td>",
"           <td align=\"left\" valign=\"top\" width=\"115\">",
"            <select class=\"medCalcFontSelect\" name=\"Concentration_unit\" onchange=\"EpoprostenolInfusion_fx();\" style=\"width:105px;\">",
"             <option value=\"1000000|0|gm/L\">",
"              gm/L",
"             </option>",
"             <option value=\"10000000|0|gm/dL\">",
"              gm/dL",
"             </option>",
"             <option value=\"10|0|mcg/dL\">",
"              mcg/dL",
"             </option>",
"             <option value=\"1000|0|mcg/mL\">",
"              mcg/mL",
"             </option>",
"             <option value=\"10000|0|mg%\">",
"              mg%",
"             </option>",
"             <option value=\"10000|0|mg/dL\">",
"              mg/dL",
"             </option>",
"             <option value=\"1000000|0|mg/mL\">",
"              mg/mL",
"             </option>",
"             <option selected=\"selected\" value=\"1|0|ng/mL\">",
"              ng/mL",
"             </option>",
"            </select>",
"           </td>",
"          </tr>",
"         </table>",
"        </center>",
"       </td>",
"       <td align=\"left\" bgcolor=\"#eeeeee\">",
"        <center>",
"         <span class=\"medCalcFontIO\">",
"          Result:",
"         </span>",
"         <br/>",
"         &nbsp;",
"         <br/>",
"         <table bgcolor=\"#eeeeee\" cellspacing=\"4\" summary=\"MedCalc 3000 Table\">",
"          <tr>",
"           <td align=\"right\">",
"            <span class=\"medCalcFontOneBold\">",
"             Infusion Rate",
"            </span>",
"           </td>",
"           <td nowrap=\"nowrap\" valign=\"top\">",
"            &nbsp;",
"            <input name=\"Infusion_Rate_param\" size=\"6\" type=\"text\"/>",
"           </td>",
"           <td valign=\"top\">",
"            <span class=\"medCalcFontOne\">",
"             <select class=\"medCalcFontSelect\" name=\"Infusion_Rate_unit\" onchange=\"EpoprostenolInfusion_fx();\" style=\"width:105px;\">",
"              <option value=\"59999.999988|0|L/min\">",
"               L/min",
"              </option>",
"              <option value=\"3599999.99928|0|L/sec\">",
"               L/sec",
"              </option>",
"              <option selected=\"selected\" value=\"1|0|mL/hr\">",
"               mL/hr",
"              </option>",
"              <option value=\"59.999999988|0|mL/min\">",
"               mL/min",
"              </option>",
"              <option value=\"3599.99999928|0|mL/sec\">",
"               mL/sec",
"              </option>",
"             </select>",
"            </span>",
"           </td>",
"          </tr>",
"          <tr>",
"           <td colspan=\"3\">",
"            &nbsp;",
"            <br/>",
"           </td>",
"          </tr>",
"          <tr>",
"           <td align=\"center\" colspan=\"3\">",
"            <span class=\"medCalcFontOneBold\">",
"             Decimal Precision:",
"            </span>",
"            <select class=\"medCalcFontSelect\" name=\"decpts\" onchange=\"EpoprostenolInfusion_fx();\">",
"             <option>",
"              0",
"             </option>",
"             <option>",
"              1",
"             </option>",
"             <option selected=\"selected\">",
"              2",
"             </option>",
"             <option>",
"              3",
"             </option>",
"            </select>",
"           </td>",
"          </tr>",
"         </table>",
"        </center>",
"       </td>",
"      </tr>",
"     </table>",
"    </center>",
"    <span class=\"medCalcFontOneBold\">",
"     Notes",
"    </span>",
"    <ul class=\"medCalcFontOne\">",
"     <li>",
"      <font color=\"#aa0000\">",
"       The default unit of measure for weight is kilograms.  Please verify that the correct unit of measure has been selected.",
"      </font>",
"     </li>",
"    </ul>",
"   </form>",
"  </div>",
" </div>",
" <div id=\"topicAgreement\">",
"  Use of UpToDate is subject to the",
"  <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"   Subscription and License Agreement",
"  </a>",
"  .",
" </div>",
" <div id=\"printDisclaimer\">",
"  Information on this page may not appear correctly if printed.",
" </div>",
" <div id=\"disclaimerCalculator\">",
"  <div class=\"medCalcFontTwo\">",
"   <p class=\"header\">",
"    Legal Notices and Disclaimer",
"   </p>",
"   <p>",
"    All information contained in and produced by the MedCalc 3000 system is provided",
"			for educational purposes only. This information should not be used for the diagnosis or treatment",
"			of any health problem or disease.",
"    <b>",
"     THIS INFORMATION IS NOT INTENDED TO REPLACE CLINICAL JUDGMENT OR",
"			GUIDE INDIVIDUAL PATIENT CARE IN ANY MANNER.",
"    </b>",
"    <a class=\"medCalcDisclaimerLink\" href=\"./med-calc-disclaimer\">",
"     Click here for",
"				full notice and disclaimer.",
"    </a>",
"   </p>",
"   <p class=\"copy\">",
"    MedCalc 3000 is Copyright &copy; 1998-2013 Foundation Internet Services",
"   </p>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_10_14497=[" /* <![CDATA[ */",
"",
"",
"function log(i){",
"return Math.log(i) * Math.LOG10E;   ",
"}",
"",
"function ln(i){",
"return Math.log(i);",
"}",
"",
"function sq(i){",
"return i * i;",
"}",
"",
"function sqr(i){",
"return Math.sqrt(i);",
"}",
"",
"",
"function power(x,y){",
"return Math.pow(x,y);",
"}",
"",
"function eTo(x){",
"return Math.exp(x);",
"}",
"",
"",
"function fixDP(r, dps) {",
"if (isNaN(r)) return \"NaN\";",
"var msign = '';",
"if (r < 0) msign = '-';",
"x = Math.abs(r);",
"if (x > Math.pow(10, 21)) return msign + x.toString();",
"var m = Math.round(x * Math.pow(10, dps)).toString();",
"if (dps == 0) return msign + m;",
"while (m.length <= dps) m = \"0\" + m;",
"return msign + m.substring(0, m.length - dps) + \".\" + m.substring(m.length - dps);",
"}",
"",
"var currenttimeout;",
"",
"",
"var calctxt = ''; ",
"var xmltxt = ''; ",
"var htmtxt = ''; ",
"",
"",
"",
"function EpoprostenolInfusion_fx() {",
"",
"currenttimeout = self.setTimeout('minMaxCheck();', 3000);",
"",
"with(document.EpoprostenolInfusion_form){",
"",
"",
"doCalc = true;",
"if (Dose_param.value.indexOf(',') >= 0){ Dose_param.value = ''; doCalc = false; alert('Comma character not allowed'); }",
"param_value = parseFloat(Dose_param.value);",
"if (isNaN(param_value)){param_value = \"\"; doCalc = false;}",
"unit_parts = Dose_unit.options[Dose_unit.selectedIndex].value.split('|');",
"Dose = param_value * parseFloat(unit_parts[0]) + parseFloat(unit_parts[1]);",
"if (Weight_param.value.indexOf(',') >= 0){ Weight_param.value = ''; doCalc = false; alert('Comma character not allowed'); }",
"param_value = parseFloat(Weight_param.value);",
"if (isNaN(param_value)){param_value = \"\"; doCalc = false;}",
"unit_parts = Weight_unit.options[Weight_unit.selectedIndex].value.split('|');",
"Weight = param_value * parseFloat(unit_parts[0]) + parseFloat(unit_parts[1]);",
"if (Concentration_param.value.indexOf(',') >= 0){ Concentration_param.value = ''; doCalc = false; alert('Comma character not allowed'); }",
"param_value = parseFloat(Concentration_param.value);",
"if (isNaN(param_value)){param_value = \"\"; doCalc = false;}",
"unit_parts = Concentration_unit.options[Concentration_unit.selectedIndex].value.split('|');",
"Concentration = param_value * parseFloat(unit_parts[0]) + parseFloat(unit_parts[1]);",
"dp = decpts.options[decpts.selectedIndex].text;",
"Infusion_Rate =  Dose * Weight * 60 / Concentration;",
"",
"unit_parts = Infusion_Rate_unit.options[Infusion_Rate_unit.selectedIndex].value.split('|');",
"if (doCalc) Infusion_Rate_param.value = fixDP((Infusion_Rate - parseFloat(unit_parts[1])) / parseFloat(unit_parts[0]), dp);",
"",
"",
"",
"",
"",
"}",
"",
"}",
"",
"function minMaxCheck(){",
"",
"if (currenttimeout) self.clearTimeout(currenttimeout);",
"",
"with(document.EpoprostenolInfusion_form){",
"",
"",
"",
"}",
"",
"}",
"",
"",
"function clrResults(){",
"",
"if (currenttimeout) self.clearTimeout(currenttimeout);",
"",
"with(document.EpoprostenolInfusion_form){",
"",
"Infusion_Rate_param.value = '';",
"",
"",
"}",
"",
"}",
"",
"",
"",
"",
"",
"",
"",
"",
"",
"",
"",
"/* ]]> */"].join("\n");
var outline_f14_10_14497=null;
var title_f14_10_14498="Snellen chart";
var content_f14_10_14498=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F50810&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F50810&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Snellen chart to test visual acuity",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 372px; height: 572px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_10_14498=[""].join("\n");
var outline_f14_10_14498=null;
var title_f14_10_14499="Patient information: Rubella (The Basics)";
var content_f14_10_14499=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"14\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/83164\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_picture\" href=\"UTD.htm?10/51/11057\">",
"         Rubella rash",
"        </a>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?11/48/12035\">",
"         Patient information: Vaccines (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?7/52/8003\">",
"         Patient information: Vaccines and pregnancy (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?38/25/39318\">",
"         Patient information: Adult vaccines (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?17/7/17522\">",
"         Patient information: Vaccination during pregnancy (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?17/42/18084\">",
"         Patient information: Why does my child need vaccines? (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Rubella (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/rubella-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H19517130\">",
"      <span class=\"h1\">",
"       What is rubella?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Rubella is an infection that causes a red rash on the face and body (",
"      <a class=\"graphic graphic_picture graphicRef83125 \" href=\"UTD.htm?10/51/11057\">",
"       picture 1",
"      </a>",
"      ). It is caused by infection with the rubella virus. Other names for rubella are &ldquo;German measles&rdquo; and &ldquo;three-day measles.&rdquo; &nbsp;",
"     </p>",
"     <p>",
"      Rubella used to be much more common than it is now. Now, there is a vaccine (a shot) that helps keep people from getting infected. The vaccine is called the measles, mumps, and rubella (MMR) vaccine. It protects against all 3 infections.",
"     </p>",
"     <p>",
"      Rubella can be very dangerous for unborn babies. If a pregnant woman gets rubella, her baby could die or be born too early. Or, the baby could have serious birth defects. These include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Hearing loss",
"       </li>",
"       <li>",
"        Life-long learning problems",
"       </li>",
"       <li>",
"        Being too small for his or her age",
"       </li>",
"       <li>",
"        Heart problems",
"       </li>",
"       <li>",
"        Eye problems",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      The baby is more likely to have problems if a woman gets rubella in the first half of pregnancy.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H19517145\">",
"      <span class=\"h1\">",
"       What are the symptoms of rubella?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The symptoms of rubella are usually mild. They are different for children and adults.",
"     </p>",
"     <p>",
"      In children, the most common symptoms include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        A rash &ndash; This usually starts on the face. It spreads to the rest of the body in about 24 hours.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"hyphen-block\">",
"       <li>",
"        A rubella rash usually goes away in about 3 days. But it can last as long as 8 days. &nbsp;",
"       </li>",
"       <li>",
"        Some children have red, irritated eyes, a rash in the mouth, or both.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Mild fever",
"       </li>",
"       <li>",
"        Swollen glands",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Adults who get rubella can have:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        A rash, fever, and swollen glands &ndash; These can be like the symptoms in children. &nbsp;",
"       </li>",
"       <li>",
"        A sick feeling, like with the flu",
"       </li>",
"       <li>",
"        Pain in the joints &ndash; This is often in the knees, wrists, and fingers.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"hyphen-block\">",
"       <li>",
"        Pain in the joints is more common in teenagers and women than in adult men. &nbsp;",
"       </li>",
"       <li>",
"        The joint pain can last a month or longer, even after the rash goes away.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Red, irritated eyes",
"       </li>",
"       <li>",
"        Pain and swelling in the testicles (in men) &nbsp;",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Adults often feel sicker from rubella than children do.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H19517160\">",
"      <span class=\"h1\">",
"       How does rubella spread?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If you have not had rubella or the rubella vaccine, you can catch rubella by being close to someone who is infected. For example, you might catch it from touching the person or a lot of things he or she touches.",
"      <strong>",
"      </strong>",
"      Most people in the United States have had the rubella vaccine, but some people have not.",
"     </p>",
"     <p>",
"      If you or your child has rubella, you can help keep it from spreading. You should:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Stay home or keep your child home for 7 days after the rash starts.",
"       </li>",
"       <li>",
"        Wash your hands often, or use an alcohol hand rub.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H19517177\">",
"      <span class=\"h1\">",
"       Is there a test for rubella?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. Doctors can do a blood test to look for the rubella virus. But most people don&rsquo;t need it. A doctor or nurse can usually tell if someone has rubella by doing an exam and learning about the symptoms.",
"     </p>",
"     <p>",
"      If the doctor or nurse thinks a baby was born with rubella, he or she will do a blood test to check. In a child or adult, a blood test might help if doctors are not sure rubella is the cause of symptoms. If you are pregnant and think you might have rubella, you can get a blood test to find out.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H19517192\">",
"      <span class=\"h1\">",
"       How is rubella treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;There is no treatment for rubella. Most people get better on their own with no problems.",
"     </p>",
"     <p>",
"      You or your child can take over-the counter medicines to help with symptoms, such as fever. But you must NEVER give",
"      <a class=\"drug drug_patient\" href=\"UTD.htm?6/12/6342?source=see_link\">",
"       aspirin",
"      </a>",
"      to a child younger than 18 years old. In children, aspirin can cause a dangerous condition called Reye syndrome.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H19517207\">",
"      <span class=\"h1\">",
"       Can rubella be prevented?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. The rubella vaccine prevents infection.",
"     </p>",
"     <p>",
"      All children should get the rubella vaccine when they are 12 to 15 months old. Then they should get a second shot when they are 4 to 6 years old. A child should have the second shot before he or she starts school.",
"     </p>",
"     <p>",
"      Adults who did not get the rubella vaccine as children should get at least 1 shot. This is very important for women who plan to get pregnant.",
"     </p>",
"     <p>",
"      Women cannot get the rubella vaccine when they are pregnant. Because rubella is dangerous to unborn babies, it is important for everyone to get the vaccine. This lowers the risk that a pregnant woman will get rubella.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H19517222\">",
"      <span class=\"h1\">",
"       What if I want to get pregnant?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If you want to get pregnant, be sure your rubella vaccine is up to date. This means knowing if you got the rubella vaccine in the past. If you are not sure, your doctor or nurse can do a blood test to check.",
"     </p>",
"     <p>",
"      The rubella vaccine must be given before pregnancy. After you get it, wait at least 4 weeks before you try to get pregnant.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H19517237\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?11/48/12035?source=see_link\">",
"       Patient information: Vaccines (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?7/52/8003?source=see_link\">",
"       Patient information: Vaccines and pregnancy (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?38/25/39318?source=see_link\">",
"       Patient information: Adult vaccines (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?17/7/17522?source=see_link\">",
"       Patient information: Vaccination during pregnancy (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?17/42/18084?source=see_link\">",
"       Patient information: Why does my child need vaccines? (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?14/10/14499?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 83164 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-61.55.141.10-EC79731216-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_10_14499=[""].join("\n");
var outline_f14_10_14499=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19517130\">",
"      What is rubella?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19517145\">",
"      What are the symptoms of rubella?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19517160\">",
"      How does rubella spread?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19517177\">",
"      Is there a test for rubella?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19517192\">",
"      How is rubella treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19517207\">",
"      Can rubella be prevented?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19517222\">",
"      What if I want to get pregnant?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19517237\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/83164\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?10/51/11057\">",
"      Rubella rash",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?38/25/39318?source=related_link\">",
"      Patient information: Adult vaccines (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?17/7/17522?source=related_link\">",
"      Patient information: Vaccination during pregnancy (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?11/48/12035?source=related_link\">",
"      Patient information: Vaccines (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?7/52/8003?source=related_link\">",
"      Patient information: Vaccines and pregnancy (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?17/42/18084?source=related_link\">",
"      Patient information: Why does my child need vaccines? (Beyond the Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f14_10_14500="Triamcinolone (topical): Pediatric drug information";
var content_f14_10_14500=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"14\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Triamcinolone (topical): Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?31/30/32229?source=see_link\">",
"    see \"Triamcinolone (topical): Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?35/46/36580?source=see_link\">",
"    see \"Triamcinolone (topical): Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F9606513\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Kenalog&reg;;",
"     </li>",
"     <li>",
"      Oralone&reg;;",
"     </li>",
"     <li>",
"      Pediaderm&trade; TA;",
"     </li>",
"     <li>",
"      Trianex&trade;;",
"     </li>",
"     <li>",
"      Triderm&reg;;",
"     </li>",
"     <li>",
"      Zytopic&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F9606514\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Kenalog&reg;;",
"     </li>",
"     <li>",
"      Oracort;",
"     </li>",
"     <li>",
"      Triaderm",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F10531292\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Anti-inflammatory Agent, Topical",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Corticosteroid, Topical",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Glucocorticoid",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F10531342\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?31/30/32229?source=see_link\">",
"      see \"Triamcinolone (topical): Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Topical: Children and Adults: Apply a thin film 2-3 times/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Topical (dental): Adults: Press a small amount (~",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      4",
"     </sub>",
"     inch) to the lesion until a thin film develops; some lesions may require a larger quantity; apply once daily at bedtime; more severe lesions may require application 2-3 times/day (preferably after meals)",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F9606835\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Aerosol, spray, topical, as acetonide:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Kenalog&reg;: 0.2 mg/2-second spray (63 g, 100 g) [contains dehydrated ethanol 10.3%]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cream, topical, as acetonide: 0.025% (15 g, 80 g, 454 g); 0.1% (15 g, 30 g, 80 g, 454 g); 0.5% (15 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Triderm&reg;: 0.1% (30 g, 85 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cream, topical, as acetonide [kit]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Pediaderm&trade; TA: 0.1% (30 g) [packaged with protective emollient]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Zytopic&trade;: 0.1% (85 g) [packaged with cleanser and moisturizer]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Lotion, topical, as acetonide: 0.025% (60 mL); 0.1% (60 mL); 0.1%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ointment, topical, as acetonide: 0.025% (15 g, 80 g, 454 g); 0.05% (430 g); 0.1% (15 g, 80 g, 454 g); 0.5% (15 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Trianex&trade;: 0.05% (17 g, 85 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Paste, oral topical, as acetonide: 0.1% (5 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oralone&reg;: 0.1% (5 g)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F9606542\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Excludes spray",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F10531348\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Apply sparingly to affected area and gently rub in until disappears; avoid application on face; do not occlude area, unless directed; do not use on open skin; avoid contact with eyes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dental: Apply sparingly; do not rub in; spreading the paste may result in a granular, gritty sensation and crumbling; apply at bedtime to allow contact of the medication with the lesion overnight.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F10531339\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ointment, paste: Store at room temperature.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Spray: Store at room temperature; avoid excessive heat.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F10531293\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Topical: Relief of inflammation and pruritus associated with corticosteroid-responsive dermatoses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Topical (dental paste): Adjunctive treatment and temporary relief of symptoms related to oral inflammatory lesions and ulcerative lesions due to trauma",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F9606493\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Kenalog&reg; may be confused with Ketalar&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Other safety concerns:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       TAC (occasional abbreviation for triamcinolone) is an error-prone abbreviation (mistaken as tetracaine-adrenaline-cocaine)",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F9606582\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Dermatologic: Acneiform eruptions, allergic contact dermatitis, dryness, folliculitis, hypertrichosis, hypopigmentation, miliaria, perioral dermatitis, pruritus, skin atrophy, skin infection (secondary), skin maceration, striae",
"    </p>",
"    <p style=\"text-indent:-4em;margin-left:4em;text-align:justify;\">",
"     Endocrine: HPA axis suppression; metabolic effects (hyperglycemia, hypokalemia)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Local: Burning, irritation",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F10531294\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to triamcinolone or any component; local fungal, viral, or bacterial infections",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F10531295\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Avoid use with occlusive dressing or application to denuded skin or to large surface areas. Avoid using higher than recommended doses; suppression of HPA axis function may occur; prolonged use may result in fungal or bacterial superinfection. Use may be associated with local sensitization.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Avoid using higher than recommended doses; reduction in growth velocity may occur when corticosteroids are administered to pediatric patients by any route (monitor growth)",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F10892649\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypothalamic-pituitary-adrenal (HPA) suppression may occur; acute adrenal insufficiency (adrenal crisis) may occur with abrupt withdrawal after long-term therapy or with stress; withdrawal and discontinuation of corticosteroids should be done carefully; immunosuppression may occur; may cause inhibition of bone growth in pediatric patients",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Adverse systemic effects may occur when topical steroids are used in large areas of the body, denuded areas, for prolonged periods of time, with an occlusive dressing, and/or in infants and small children; infants and small children may be more susceptible to HPA axis suppression or other systemic toxicities due to larger skin surface area to body mass ratio; use with caution in pediatric patients",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13300168\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F9606610\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aldesleukin: Corticosteroids may diminish the antineoplastic effect of Aldesleukin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticorelin: Corticosteroids may diminish the therapeutic effect of Corticorelin. Specifically, the plasma ACTH response to corticorelin may be blunted by recent or current corticosteroid therapy.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: Corticosteroids may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hyaluronidase: Corticosteroids may diminish the therapeutic effect of Hyaluronidase.  Management: Patients receiving corticosteroids (particularly at larger doses) may not experience the desired clinical response to standard doses of hyaluronidase.  Larger doses of hyaluronidase may be required.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Telaprevir: Corticosteroids may decrease the serum concentration of Telaprevir. Telaprevir may increase the serum concentration of Corticosteroids.  Management: Concurrent use of telaprevir and systemic corticosteroids is not recommended.  When possible, consider alternatives.  If used together, employ extra caution and monitor closely for excessive corticosteroid effects and diminished telaprevir effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F9606545\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F9887155\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Corticosteroids were found to be teratogenic following topical application in animal reproduction studies. In general, the use of topical corticosteroids during pregnancy is not considered to have significant risk, however, intrauterine growth retardation in the infant has been reported (rare). The use of large amounts or for prolonged periods of time should be avoided.",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F10531340\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Controls the rate of protein synthesis, depresses the migration of polymorphonuclear leukocytes and fibroblasts, reverses capillary permeability, and stabilizes lysosomal membranes at the cellular level to prevent or control inflammation",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F10531341\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Topical corticosteroids are absorbed percutaneously. The extent is dependent on several factors, including epidermal integrity (intact vs abraded skin), formulation, and the use of occlusive dressings.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Half-life: Elimination: 88 minutes; Biologic: 18-36 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Elimination: 40% of dose is excreted in urine; 60% in feces",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F10531364\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?35/46/36580?source=see_link\">",
"      see \"Triamcinolone (topical): Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Notify physician if condition being treated persists or worsens",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16062 Version 25.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-83.177.194.223-2AD339225F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_10_14500=[""].join("\n");
var outline_f14_10_14500=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9606513\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9606514\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10531292\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10531342\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9606835\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9606542\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10531348\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10531339\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10531293\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9606493\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9606582\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10531294\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10531295\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10892649\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13300168\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9606610\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9606545\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9887155\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10531340\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10531341\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10531364\">",
"      Patient Information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/16062\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/16062|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?5/32/5637?source=related_link\">",
"      Triamcinolone (nasal): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?16/10/16548?source=related_link\">",
"      Triamcinolone (nasal): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?15/56/16260?source=related_link\">",
"      Triamcinolone (nasal): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?7/55/8052?source=related_link\">",
"      Triamcinolone (ophthalmic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?19/31/19955?source=related_link\">",
"      Triamcinolone (ophthalmic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?16/36/16963?source=related_link\">",
"      Triamcinolone (ophthalmic): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?31/1/31768?source=related_link\">",
"      Triamcinolone (systemic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?5/49/5910?source=related_link\">",
"      Triamcinolone (systemic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?27/11/27831?source=related_link\">",
"      Triamcinolone (systemic): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?31/30/32229?source=related_link\">",
"      Triamcinolone (topical): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?35/46/36580?source=related_link\">",
"      Triamcinolone (topical): Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f14_10_14501="Peritoneal dialysis";
var content_f14_10_14501=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Peritoneal dialysis (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?14/10/14501/contributors\">",
"       Author",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/10/14501/contributors\" id=\"au397\">",
"       John M Burkart, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?14/10/14501/contributors\">",
"       Section Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/10/14501/contributors\" id=\"se4403\">",
"       Thomas A Golper, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?14/10/14501/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/10/14501/contributors\" id=\"de1856\">",
"       Alice M Sheridan, MD",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"UTD.htm?14/10/14501?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      OVERVIEW",
"     </span>",
"    </p>",
"    <p>",
"     Peritoneal dialysis (PD) is a procedure that can be used by people whose kidneys are no longer working effectively. The procedure is performed at home and works to remove excess fluid and waste products from the blood.",
"    </p>",
"    <p>",
"     This topic discusses peritoneal dialysis. Other treatments for chronic kidney disease are discussed separately. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?9/26/9635?source=see_link\">",
"      \"Patient information: Dialysis or kidney transplantation &mdash; which is right for me? (Beyond the Basics)\"",
"     </a>",
"     and",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?39/57/40852?source=see_link\">",
"      \"Patient information: Hemodialysis (Beyond the Basics)\"",
"     </a>",
"     and",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?13/5/13398?source=see_link\">",
"      \"Patient information: Chronic kidney disease (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      WHEN WILL I NEED DIALYSIS?",
"     </span>",
"    </p>",
"    <p>",
"     As the kidneys lose their ability to function, fluid, minerals, and waste products that are normally eliminated in the urine begin to build up in the blood. When these problems reach a critical stage, excess fluid and waste must be removed with kidney (renal) replacement therapy.",
"    </p>",
"    <p>",
"     There are two types of dialysis: hemodialysis and peritoneal dialysis. Kidney transplantation may be an option for some patients, although dialysis is the most commonly used treatment. The \"best\" type of dialysis depends upon your abilities, underlying medical illnesses and personal needs. These issues are discussed separately. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?9/26/9635?source=see_link\">",
"      \"Patient information: Dialysis or kidney transplantation &mdash; which is right for me? (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     It usually takes many months or years after kidney disease is first discovered before dialysis is necessary. However, some patients have a rapid decline in kidney function and occasionally severe kidney failure is discovered for the first time in people who were not previously known to have kidney disease. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?13/5/13398?source=see_link\">",
"      \"Patient information: Chronic kidney disease (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     You and your doctor will decide together when to begin dialysis after considering a number of factors, including your kidney function (as measured by blood and urine tests), overall health, and personal preferences.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H3\">",
"     <span class=\"h2\">",
"      Advance planning",
"     </span>",
"     &nbsp;&mdash;&nbsp;People with kidney disease should discuss the possible need for dialysis early in their treatment course. Advance planning allows the physician to choose a therapy that will best meet the patient's lifestyle and needs. In addition, advance planning allows the physician time to plan for the placement of a peritoneal dialysis catheter in the abdomen.",
"    </p>",
"    <p>",
"     After the catheter is placed, the patient and family will be trained by the staff at the home dialysis unit on how to set up the equipment and become familiar with the procedures used in peritoneal dialysis. During most of this \"training\", the patient will actually be doing dialysis.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H4\">",
"     <span class=\"h1\">",
"      PERITONEAL DIALYSIS CATHETER INSERTION",
"     </span>",
"    </p>",
"    <p>",
"     Before peritoneal dialysis can begin, a catheter (thin tube) must be inserted in the abdomen to carry fluid into and out of the abdominal cavity. The catheter is made of a soft, flexible material (usually silicone) and has cuffs (which are like Velcro) that skin tissue grows into to hold the catheter in place. The end of the catheter inside the abdomen has multiple holes to allow fluid to flow in and out.",
"    </p>",
"    <p>",
"     The catheter exit site is typically placed on the left or right of the umbilicus (belly button) although occasionally the catheter exit site may be placed higher up on the abdominal wall or over your sternum. Reasons for this would vary from patient to patient and should be discussed with your doctor; the patient may be given general or local anesthesia before the insertion procedure. (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/63/6136?source=see_link\">",
"      \"Placement and maintenance of the peritoneal dialysis catheter\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     Although the catheter can be used right away, it is best to wait 10 to 14 days after placement before dialysis is performed; this allows the catheter site to heal. In some cases, a small volume of fluid can be exchanged during this time (see",
"     <a class=\"local\" href=\"#H10\">",
"      'How does peritoneal dialysis work?'",
"     </a>",
"     below). Your healthcare provider will provide more detailed instructions.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H5\">",
"     <span class=\"h1\">",
"      PERITONEAL DIALYSIS CATHETER SITE CARE",
"     </span>",
"    </p>",
"    <p>",
"     Care of the catheter and the skin around the catheter (called the catheter site) is important to keep the catheter functioning and also to minimize the risk of developing an infection.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H6\">",
"     <span class=\"h2\">",
"      Care after insertion",
"     </span>",
"     &nbsp;&mdash;&nbsp;After the catheter is inserted, the insertion site is usually covered with a gauze dressing and tape to prevent the catheter from moving and keep the area clean. The dressing is usually changed at the dialysis home training center seven to 10 days after placement. If a dressing change is needed before this time, it should be done by a specially trained peritoneal dialysis nurse using sterile techniques. The catheter should not be moved or handled excessively because this can increase the risk of infection.",
"    </p>",
"    <p>",
"     The area should be kept dry until it is well healed, usually for 10 to 14 days. This means that you should not take a shower or bath or go swimming during this time. A washcloth or sponge may be used to clean the body, although you should be careful to keep the catheter and dressing dry. While healing (two to three weeks), you will be asked to limit lifting and vigorous exercise.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Avoid constipation &mdash; It is important to avoid becoming constipated after the catheter is inserted. Straining to move the bowels can increase the risk of developing a hernia (a weakness in the abdominal muscle). In addition, not moving the bowels regularly can lead to problems with catheter function (slow drain time or difficulty draining the abdomen completely).",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     To avoid constipation, your healthcare provider may recommend a diet that is high in fiber, as well as a stool softener or laxative. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?34/10/34977?source=see_link\">",
"      \"Patient information: Constipation in adults (Beyond the Basics)\"",
"     </a>",
"     and",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?8/39/8817?source=see_link\">",
"      \"Patient information: High-fiber diet (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H7\">",
"     <span class=\"h2\">",
"      Long-term care",
"     </span>",
"     &nbsp;&mdash;&nbsp;After the catheter site has healed (approximately two weeks after insertion), your dialysis nurse will instruct you on catheter exit site care. It will be important to keep the area clean to minimize the risk of skin infection as well as infection inside the abdomen (called peritonitis).",
"    </p>",
"    <p>",
"     The skin around the catheter site should be washed daily or every other day with antibacterial soap or an antiseptic (either povidone iodine or chlorhexidine). The soap should be stored in the original bottle (not poured into another container). Other types of cleansers, such as hydrogen peroxide or alcohol, should",
"     <strong>",
"      NOT",
"     </strong>",
"     be used unless directed by a healthcare provider.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Before cleaning the area, wash your hands with soap and water and put on clean gloves.",
"      </li>",
"      <li>",
"       Hold the catheter still during cleaning, which helps prevent injury to the skin.",
"      </li>",
"      <li>",
"       Do not pick at or remove crusts or scabs at the site.",
"      </li>",
"      <li>",
"       Pat the skin around the site dry after cleaning. A clean cloth or towel is suggested.",
"      </li>",
"      <li>",
"       Apply a prescription antibiotic cream to the skin around the catheter with a cotton-tip swab every time the dressing is changed.",
"      </li>",
"      <li>",
"       Avoid using tapes or dressings that prevent air from reaching the skin. The site should be covered with a sterile gauze dressing, which should be changed every time the site is cleaned. The catheter should be anchored to the skin with tape or a specially designed adhesive.",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     With appropriate catheter placement and exit site care, most PD catheters are problem free and work for many years. If the catheter no longer works or is needed, a minor surgical procedure is required to remove it.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H8\">",
"     <span class=\"h3\">",
"      Appearance",
"     </span>",
"     &nbsp;&mdash;&nbsp;After the first two weeks, the skin around the catheter should not be red or painful. The skin should feel soft. There may be a small amount of thick yellow mucus discharge around the catheter. A crust or scab may form every few days.",
"    </p>",
"    <p>",
"     If the skin is reddened, painful, firm, or there is pus-like discharge around the catheter, there may be an infection. (See",
"     <a class=\"local\" href=\"#H13\">",
"      'Peritoneal dialysis complications'",
"     </a>",
"     below.)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H9\">",
"     <span class=\"h2\">",
"      Care after injury to the catheter site",
"     </span>",
"     &nbsp;&mdash;&nbsp;If there is an injury to the catheter site, such as an accidental pull on the catheter, or if the catheter is moved excessively, a short course of oral antibiotics may be recommended to prevent infection from developing inside the abdomen (peritonitis). Most dialysis units recommend that you call if you injure the catheter site to determine if further evaluation or treatment is needed.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H10\">",
"     <span class=\"h1\">",
"      HOW DOES PERITONEAL DIALYSIS WORK?",
"     </span>",
"    </p>",
"    <p>",
"     In peritoneal dialysis, dialysis fluid (called dialysate) is infused into the abdominal cavity (called the peritoneal cavity) through a catheter. The fluid is held (dwells) within the abdomen for a prescribed period of time; this is called a dwell. The lining of the abdomen (the peritoneum) acts as a membrane to allow excess fluids and waste products to pass from the bloodstream into the dialysate.",
"    </p>",
"    <p>",
"     At times when the abdomen is full of dialysate, you may have a feeling of fullness or bloating, although you should not feel pain. However, most patients have no abnormal sensations and despite the fluid in the abdomen, most people do not look different.",
"    </p>",
"    <p>",
"     When the dwell is completed, the \"used\" dialysate can then be drained out of the abdomen (called an exchange) into a sterile container or into a shower or bathtub. This used fluid contains the excess fluid and waste from the blood, which is usually eliminated in the urine. The peritoneal cavity is then filled again with fresh dialysate.",
"    </p>",
"    <p>",
"     The process may be done manually four to five times during the day by infusing the fluid into the abdomen and later allowing it to run out by gravity. The process of emptying and filling for each exchange takes 30 to 40 minutes when done manually. The exchange may also be done using a machine (called a cycler). In this case the fluid exchanges are done automatically while the patient sleeps.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11\">",
"     <span class=\"h2\">",
"      Types",
"     </span>",
"     &nbsp;&mdash;&nbsp;Several different types of peritoneal dialysis schedules are possible. The \"right\" type of peritoneal dialysis depends upon an individual's situation. (See",
"     <a class=\"local\" href=\"#H12\">",
"      'Which type is right for me?'",
"     </a>",
"     below.)",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Continuous ambulatory peritoneal dialysis (CAPD) involves multiple exchanges during the day (usually three) with an overnight dwell. A machine is not needed and the person can walk around while the fluid is in the abdomen. At bedtime, dialysate is infused and is drained upon awakening. Occasionally, a machine (called a cycler) will be needed to perform an exchange one or more times while sleeping.",
"      </li>",
"      <li>",
"       Continuous cycler peritoneal dialysis (CCPD) is an automated form of Peritoneal Dialysis (APD) in which a machine performs exchanges while the patient sleeps; there may be a long daytime dwell, and occasionally a manual daytime exchange. In developed countries such as the United States, CCPD is performed more commonly than CAPD.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H12\">",
"     <span class=\"h2\">",
"      Which type is right for me?",
"     </span>",
"     &nbsp;&mdash;&nbsp;Patients are often allowed to choose between CAPD and CCPD or APD based upon lifestyle or personal issues. CCPD or APD allows significantly more uninterrupted time for work, family, and social activities than CAPD.",
"    </p>",
"    <p>",
"     There may be changes in treatment type, dwell time, number of exchanges, or type of dialysate after beginning treatment, based upon how the body responds. Periodic blood and urine tests, as well as tests of the used dialysate, are used to fine tune PD treatment. (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/58/1962?source=see_link\">",
"      \"Adequacy of peritoneal dialysis\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H13\">",
"     <span class=\"h1\">",
"      PERITONEAL DIALYSIS COMPLICATIONS",
"     </span>",
"    </p>",
"    <p>",
"     One of the most serious complications of peritoneal dialysis is infection, which can develop in the skin around the catheter or inside the abdominal cavity (called peritonitis). Another potential but less serious complication of peritoneal dialysis is the development of a hernia, a weakness in the abdominal muscle.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H14\">",
"     <span class=\"h2\">",
"      Catheter site infection",
"     </span>",
"     &nbsp;&mdash;&nbsp;The signs of catheter site infection include:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Redness, firmness, or tenderness of the skin around the catheter",
"      </li>",
"      <li>",
"       Pus-like drainage from the area",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H15\">",
"     <span class=\"h2\">",
"      Peritonitis",
"     </span>",
"     &nbsp;&mdash;&nbsp;Peritonitis is the term used to describe an infection of the abdominal cavity. People who use peritoneal dialysis are at risk of peritonitis because bacteria can enter the abdomen through or around the peritoneal dialysis catheter. These infections can usually be treated at home and resolve completely. (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/5/22617?source=see_link\">",
"      \"Clinical manifestations and diagnosis of peritonitis in peritoneal dialysis\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     Left untreated, peritonitis can become a life-threatening infection. Signs of peritonitis may include one or more of the following:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Abdominal pain, which may be mild to severe",
"      </li>",
"      <li>",
"       Cloudy used dialysate fluid",
"      </li>",
"      <li>",
"       Fever (temperature greater than 100.4&ordm;F or 38&ordm;C)",
"      </li>",
"      <li>",
"       Nausea or diarrhea",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H16\">",
"     <span class=\"h2\">",
"      Treatment of infection",
"     </span>",
"     &nbsp;&mdash;&nbsp;If there are any signs of infection, you need to be seen by a healthcare provider and begin treatment as soon as possible. The type of treatment used depends upon the severity and location of the infection. Peritoneal dialysis is usually continued as the infection is being treated.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Catheter site infections are often treated with an antibiotic cream",
"       <span class=\"nowrap\">",
"        and/or",
"       </span>",
"       oral antibiotics, as well as more frequent skin cleaning. Most mild infections resolve with treatment within one to two weeks. If the infection does not resolve, the catheter may need to be removed and replaced. (See",
"       <a class=\"medical medical_review\" href=\"UTD.htm?2/60/3018?source=see_link\">",
"        \"Tunnel and peritoneal catheter exit site infections in continuous peritoneal dialysis\"",
"       </a>",
"       .)",
"      </li>",
"      <li>",
"       Peritonitis usually requires treatment with antibiotics, which are commonly given with the dialysate (eg, intraperitoneal dosing). A change in the dwell time",
"       <span class=\"nowrap\">",
"        and/or",
"       </span>",
"       dialysis prescription is sometimes needed temporarily. Less commonly, the peritoneal dialysis catheter must be removed and the person will be transitioned to hemodialysis. (See",
"       <a class=\"medical medical_review\" href=\"UTD.htm?17/11/17594?source=see_link\">",
"        \"Microbiology and therapy of peritonitis in continuous peritoneal dialysis\"",
"       </a>",
"       .)",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H17\">",
"     <span class=\"h2\">",
"      Hernia",
"     </span>",
"     &nbsp;&mdash;&nbsp;Hernia is the medical term for a weakness in the abdominal muscle. People who use peritoneal dialysis are at risk of developing a hernia for several reasons, including the increased stress on the muscles of the abdomen (as a result of the weight of the dialysate) and the opening in the abdominal muscle created by the peritoneal dialysis catheter. Hernias can develop near the belly button (umbilical hernia), in the groin (inguinal hernia), or near the catheter site (incisional hernia).",
"    </p>",
"    <p>",
"     Signs of a hernia include painless swelling or new lump in the groin or abdomen. If you develop signs of a hernia, contact your healthcare provider but continue to perform peritoneal dialysis regularly. Treatment of a hernia generally involves surgery. (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/6/41061?source=see_link\">",
"      \"Abdominal hernias in continuous peritoneal dialysis\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H18\">",
"     <span class=\"h1\">",
"      LIVING WITH PERITONEAL DIALYSIS",
"     </span>",
"    </p>",
"    <p>",
"     Chronic kidney disease is a lifelong condition that requires lifelong treatment. Peritoneal dialysis is one option for lifelong treatment, with other options including hemodialysis and kidney transplantation. It is sometimes necessary to switch from one form of treatment to another as circumstances change.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Diet &mdash; People who undergo dialysis, both hemodialysis and peritoneal dialysis, are often required to make changes to their diet. In general, people who use peritoneal dialysis have a less restricted diet compared to those who use in-center hemodialysis. Dietary changes help to ensure that the body has an adequate, but not excessive, amount of protein and certain minerals.",
"       <br/>",
"       <br/>",
"       People who use peritoneal dialysis lose protein with every exchange, which usually means that they must eat an increased amount of protein in the diet. Protein is found in meat, milk, chicken, fish, and eggs; lower quality protein is found in some vegetables and grains. A dietitian can provide specific recommendations about how much and what type of protein is needed.",
"      </li>",
"      <li>",
"       Other changes in diet may include reducing the amount of foods eaten that contain phosphorus (found in dairy products, cheese, dried beans, liver, nuts, and chocolate) and sodium, and monitoring the amount of fluids consumed. (See",
"       <a class=\"medical medical_patient\" href=\"UTD.htm?38/61/39890?source=see_link\">",
"        \"Patient information: Low sodium diet (Beyond the Basics)\"",
"       </a>",
"       .)",
"      </li>",
"      <li>",
"       Weight gain &mdash; Weight gain can be a problem for people undergoing peritoneal dialysis because the dialysate contains a high concentration of dextrose, a type of sugar. The body absorbs some of this dextrose during the dwell, which can lead to weight gain. A dietitian can provide guidance on how to minimize weight gain by monitoring the number of calories eaten.",
"      </li>",
"      <li>",
"       Body image &mdash; The abdomen will enlarge slightly and may cause you to feel bloated when it is filled with fluid. You may need a larger size of clothing, and some people have a hard time accepting the change in their appearance. Patient support groups and websites can provide reassurance and tips for dressing. (See",
"       <a class=\"local\" href=\"#H19\">",
"        'Where to get more information'",
"       </a>",
"       below.)",
"      </li>",
"      <li>",
"       Activities and peritoneal dialysis &mdash; In general, people using peritoneal dialysis should limit physical activities when their peritoneal cavity is full (has a large volume dwell). It is still possible to exercise and participate in sports, although you should discuss your activities with your physicians.",
"      </li>",
"      <li>",
"       Time requirements &mdash; Peritoneal dialysis requires time and dedication, potentially interfering with other activities. This is especially true with CAPD, which requires the person to perform several exchanges during the daytime. Although it is possible to work and be active while using peritoneal dialysis, it may be necessary to cut back on responsibilities.",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     It is important to perform every exchange and dwell exactly as recommended. Skipping a treatment or performing a dwell for shorter or longer than recommended may increase the risk of illness and the chances of being hospitalized, and can even shorten the person's life.",
"    </p>",
"    <p>",
"     If the demands of peritoneal dialysis feel overwhelming, or if you're having trouble performing all the necessary treatments, talk to a healthcare provider.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H19\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H2287560353\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H29859791\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?15/43/16051?source=see_link\">",
"      Patient information: Peritoneal dialysis (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?27/35/28212?source=see_link\">",
"      Patient information: Chronic kidney disease (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?18/42/19107?source=see_link\">",
"      Patient information: Choosing between dialysis and kidney transplant (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?18/2/18467?source=see_link\">",
"      Patient information: Dialysis and diet (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?24/46/25315?source=see_link\">",
"      Patient information: Kidney transplant (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?12/15/12531?source=see_link\">",
"      Patient information: Planning for a kidney transplant (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?5/46/5859?source=see_link\">",
"      Patient information: Acute kidney failure (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?36/31/37363?source=see_link\">",
"      Patient information: Glomerular disease (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H29859799\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?9/26/9635?source=see_link\">",
"      Patient information: Dialysis or kidney transplantation &mdash; which is right for me? (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?39/57/40852?source=see_link\">",
"      Patient information: Hemodialysis (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?13/5/13398?source=see_link\">",
"      Patient information: Chronic kidney disease (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?34/10/34977?source=see_link\">",
"      Patient information: Constipation in adults (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?8/39/8817?source=see_link\">",
"      Patient information: High-fiber diet (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?38/61/39890?source=see_link\">",
"      Patient information: Low sodium diet (Beyond the Basics)",
"     </a>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H20\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/58/1962?source=see_link\">",
"      Adequacy of peritoneal dialysis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/35/31286?source=see_link\">",
"      Choosing a modality for chronic peritoneal dialysis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/5/22617?source=see_link\">",
"      Clinical manifestations and diagnosis of peritonitis in peritoneal dialysis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/27/8631?source=see_link\">",
"      Fungal peritonitis in continuous peritoneal dialysis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/32/4616?source=see_link\">",
"      Indications for initiation of dialysis in chronic kidney disease",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/47/36601?source=see_link\">",
"      Medical management of the dialysis patient undergoing surgery",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/11/17594?source=see_link\">",
"      Microbiology and therapy of peritonitis in continuous peritoneal dialysis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/32/41477?source=see_link\">",
"      Modalities for the diagnosis of abdominal and thoracic cavity defects in peritoneal dialysis patients",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/23/22904?source=see_link\">",
"      Noninfectious complications of continuous peritoneal dialysis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/22/7528?source=see_link\">",
"      Noninfectious complications of peritoneal dialysis catheters",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/40/26248?source=see_link\">",
"      Pathophysiology and prevention of peritonitis in peritoneal dialysis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/63/6136?source=see_link\">",
"      Placement and maintenance of the peritoneal dialysis catheter",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/50/23337?source=see_link\">",
"      Problems with solute clearance and ultrafiltration in continuous peritoneal dialysis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/60/3018?source=see_link\">",
"      Tunnel and peritoneal catheter exit site infections in continuous peritoneal dialysis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/6/41061?source=see_link\">",
"      Abdominal hernias in continuous peritoneal dialysis",
"     </a>",
"     <br/>",
"     <br/>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Library of Medicine",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/healthtopics.html\">",
"      www.nlm.nih.gov/medlineplus/healthtopics.html",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Institute of Diabetes and Digestive and Kidney Diseases",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.niddk.nih.gov/\">",
"      www.niddk.nih.gov",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Kidney Foundation",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.kidney.org/\">",
"      www.kidney.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       American Kidney Fund",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.akfinc.org/\">",
"      www.akfinc.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       American Association of Kidney Patients",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.aakp.org/\">",
"      www.aakp.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     [",
"     <a class=\"abstract\" href=\"UTD.htm?14/10/14501/abstract/1-5\">",
"      1-5",
"     </a>",
"     ]",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 24, 2012.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"UTD.htm?14/10/14501?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/10/14501/abstract/1\">",
"      Rabindranath KS, Adams J, Ali TZ, et al. Continuous ambulatory peritoneal dialysis versus automated peritoneal dialysis for end-stage renal disease. Cochrane Database Syst Rev 2007; :CD006515.",
"     </a>",
"    </li>",
"    <li>",
"     K/DOQI Clinical Practice guidelines for peritoneal dialysis adequacy. Am J Kidney Dis 2006; 47(Suppl 4):S1. Available online at www.kidney.org/Professionals/kdoqi/guideline_upHD_PD_VA/index.htm (Accessed 1/8/2009).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/10/14501/abstract/3\">",
"      Teitelbaum I, Burkart J. Peritoneal dialysis. Am J Kidney Dis 2003; 42:1082.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/10/14501/abstract/4\">",
"      Berns JS, Tokars JI. Preventing bacterial infections and antimicrobial resistance in dialysis patients. Am J Kidney Dis 2002; 40:886.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/10/14501/abstract/5\">",
"      McCormick BB, Bargman JM. Noninfectious complications of peritoneal dialysis: implications for patient and technique survival. J Am Soc Nephrol 2007; 18:3023.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f14_10_14501=[""].join("\n");
var outline_f14_10_14501=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           OVERVIEW",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           WHEN WILL I NEED DIALYSIS?",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H4\">",
"           PERITONEAL DIALYSIS CATHETER INSERTION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H5\">",
"           PERITONEAL DIALYSIS CATHETER SITE CARE",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H10\">",
"           HOW DOES PERITONEAL DIALYSIS WORK?",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H13\">",
"           PERITONEAL DIALYSIS COMPLICATIONS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H18\">",
"           LIVING WITH PERITONEAL DIALYSIS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H19\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f14_10_14502="Influenza virus vaccine (live attenuated): Pediatric drug information";
var content_f14_10_14502=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Influenza virus vaccine (live attenuated): Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?18/54/19303?source=see_link\">",
"    see \"Influenza virus vaccine (live attenuated): Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?11/43/11953?source=see_link\">",
"    see \"Influenza virus vaccine (live attenuated): Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block spa drugH1Div\" id=\"F14961380\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Special Alerts",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Influenza Virus Vaccine",
"     </span>",
"     <span class=\"collapsible-date\">",
"      2012-2013",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       The 2012-2013 influenza virus vaccine contains the same H1N1 virus as in the 2011-2012 vaccine, but different H3N2 and B viruses. The vaccine strains approved for this season in the United States are as follows: A/California/7/2009 (H1N1)-like virus, A/Victoria/361/2011 (H3N2)-like virus, and B/Wisconsin/1/2010-like virus. Because immunity to influenza virus declines over time, and because two of the three strains of the virus are different this year than last, persons should be vaccinated every year even if vaccinated during the previous season",
"      </p>",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       In addition, a variant influenza A virus (H3N2v) is currently circulating in pigs and infecting humans. Immunization with the 2012-2013 seasonal influenza vaccine is not expected to provide protection against this virus.  Symptoms of H3N2v are generally similar to those of seasonal influenza infections.  Unfortunately, standard tests used to detect influenza virus cannot differentiate between H3N2v virus from seasonal influenza A (H3N2) virus and there is a potential for false negatives with antigen detection tests. Clinicians who suspect probable H3N2v virus should contact their local or state health department for additional testing for H3N2v at a state public health laboratory. A link to recent swine exposure (within 1 week) of symptom onset should be considered a probable H3N2v case. Antiviral treatment of H3N2v influenza is the same as seasonal influenza.",
"      </p>",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       For additional information refer to the following websites:",
"      </p>",
"      <p style=\"text-indent:0em;margin-left:2em;margin-top:0em;\">",
"       FDA approves vaccines for the 2012-2013 influenza season:",
"       <a href=\"file://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm315365.htm\" target=\"_blank\">",
"        file://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm315365.htm",
"       </a>",
"      </p>",
"      <p style=\"text-indent:0em;margin-left:2em;margin-top:0em;\">",
"       CDC, Interim Information about Human Infections with H3N2v Virus:",
"       <a href=\"file://www.cdc.gov/flu/swineflu/h3n2v-clinician.htm\" target=\"_blank\">",
"        file://www.cdc.gov/flu/swineflu/h3n2v-clinician.htm",
"       </a>",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F9560232\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      FluMist&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F11239606\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      FluMist&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1047941\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Vaccine",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Vaccine, Live/Attenuated",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1047934\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?18/54/19303?source=see_link\">",
"      see \"Influenza virus vaccine (live attenuated): Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Intranasal: Administer vaccine prior to exposure to influenza. It is important to note that influenza seasons vary in their timing and duration from year to year. In general, vaccination should begin soon after the vaccine becomes available and prior to onset of influenza activity in the community; however, vaccination should continue throughout the influenza season as long as vaccine is available.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     <b>",
"      Note:",
"     </b>",
"     Children 2 to &lt;9 years who received a total of &ge;2 doses of seasonal influenza vaccine since July 1, 2010 need only 1 dose of the 2012-2013 seasonal influenza vaccine. If a child did not receive a total of &ge;2 doses of seasonal vaccine since July 1, 2010, if they have never received seasonal influenza vaccine (eg, this is their first season of vaccination), or if their vaccination status cannot be determined, they should receive 2 doses separated by &ge;4 weeks, in order to achieve satisfactory antibody response. Additional dosing considerations are provided when vaccination history is available prior to the 2010-2011 season; see current guidelines for additional information (CDC, 2012).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:0em;\">",
"     Dose frequency is per season.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children 2-8 years: 0.2 mL divided per nostril; 1 or 2 doses, dependent upon vaccination history.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children and Adolescents 9-17 years: 0.2 mL divided per nostril (1 dose)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adults 18-49 years: 0.2 mL divided per nostril (1 dose)",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F9560249\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, intranasal [spray, preservative free]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     FluMist&reg;:  (0.2 mL) [contains arginine, chicken egg protein, gelatin, gentamicin  (may have trace amounts)]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F9560334\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block prod-avail drugH1Div\" id=\"F13845071\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Product Availability",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     FluMist&reg; Quadrivalent Vaccine: FDA approved February 2012; availability anticipated for the 2013-2014 flu season. Consult prescribing information for additional information.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Seasonal quadrivalent influenza  vaccines contain two subtype A strains and two subtype B strains; trivalent influenza vaccines contain two subtype A strains and one subtype B strain.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1047944\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Intranasal: Administer 0.1 mL (half of the dose from a single sprayer) into each nostril while the recipient is in an upright position. Insert the tip of the sprayer just inside the nostril and depress the plunger to spray as rapidly as possible. Remove dose-divider clip from the sprayer to administer the second half of the dose into the other nostril. Do not administer by the I.M., SubQ, intradermal, or I.V. route.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1047937\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refrigerate upon receipt and until use at 2&deg;C to 8&deg;C (35&deg;F to 46&deg;F); do not freeze.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1047943\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Active immunization for the prevention of seasonal influenza A (subtypes H1N1 and H3N2) and B virus strains in healthy individuals (FDA approved in ages 2-49 years)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F9560333\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Influenza virus vaccine may be confused with flumazenil",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F9560240\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      All serious adverse reactions must be reported to the U.S. Department of Health and Human Services (DHHS) Vaccine Adverse Event Reporting System (VAERS) 1-800-822-7967 or online at",
"      <a href=\"https://vaers.hhs.gov/esub/index\" target=\"_blank\">",
"       https://vaers.hhs.gov/esub/index",
"      </a>",
"      .",
"     </b>",
"     In Canada, adverse reactions may be reported to local provincial/territorial health agencies or to the Vaccine Safety Section at Public Health Agency of Canada (1-866-844-0018).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Chills, fever, headache, irritability, lethargy",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain, appetite decreased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Muscle aches, tiredness/weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Otic: Otitis media",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Sinusitis, sneezing",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Cough, nasal congestion/ runny nose, wheezing",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Anaphylactic reactions, asthma exacerbations, Bell's palsy, encephalitis (vaccine associated), epistaxis, Guillain-Barr&eacute; syndrome, hypersensitivity reaction, meningitis (including eosinophilic meningitis), mitochondrial encephalomyopathy (Leigh syndrome) exacerbation, pericarditis",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1047947\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to influenza virus vaccine, chicken, egg or egg proteins (manufacturer's recommendation), gentamicin, gelatin, arginine, or any component; children or adolescents receiving aspirin or aspirin-containing therapy due to the association of Reye's syndrome with aspirin and wild-type influenza infection",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1047933\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Individuals receiving live, attenuated influenza virus vaccine intranasally should avoid close contact with immunocompromised individuals for at least 7 days. Avoid administering intranasal influenza virus vaccine during an acute phase of febrile and/or respiratory illness (postpone at least 72 hours until after the acute phase). Presence of nasal congestion may decrease delivery of the vaccine to the nasopharyngeal mucosa; postpone administration until illness resolves or use the inactivated vaccine if appropriate.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Use with caution in patients with history of Guillain-Barr&eacute; syndrome (GBS); carefully consider risks and benefits to vaccination in patients known to have experienced GBS within 6 weeks following any previous influenza vaccination. Based on limited data, the benefits of vaccination may outweigh the potential risks in persons with a history of GBS who are also at high risk for complications of influenza.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Routine prophylactic administration of acetaminophen to prevent fever due to vaccines has been shown to decrease the immune response of some vaccines; the clinical significance of this reduction in immune response has not been established (Prymula, 2009).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Allergy to eggs must be distinguished from allergy to the vaccine. Recommendations are available from the CDC regarding influenza vaccination to persons who report egg allergies; however, a prior severe allergic reaction to influenza vaccine, regardless of the component suspected, is a contraindication to vaccination. Use of trivalent inactivated influenza vaccine (TIV) is preferred over live attenuated influenza vaccine (LAIV) when considering vaccination in persons reporting an egg allergy (CDC, 2012).",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1047932\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Children &lt;2 years of age who received the live, attenuated influenza virus vaccine intranasally during clinical trials had an increased risk of hospitalization and wheezing. Because safety and efficacy information is limited, the ACIP does not recommend the use of LAIV in patients with asthma or active wheezing or in children &lt;5 years of age who have had wheezing in the past year; patients with chronic disorders of the cardiovascular (except isolated hypertension) and pulmonary systems; patients with conditions that can increase the risk for aspiration, such as neurodevelopmental disorders, spinal cord injuries, seizure disorders, or neurologic/neuromuscular disorders; pregnant women; patients requiring follow-up or hospitalization due to chronic metabolic diseases, such as diabetes, renal dysfunction, hepatic dysfunction, immunosuppression (including immunosuppression caused by medications or HIV), or hemoglobinopathies (eg, sickle cell disease); patients who have received other live vaccines within the previous 4 weeks (however, other live vaccines can be given on the same day as LAIV); residents of nursing homes and other chronic-care facilities; and in family members or close contacts of immunosuppressed persons requiring a protected environment (eg, hematopoietic stem cell transplant recipient).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Epinephrine injection must be readily available in the event of an acute anaphylactic reaction following vaccination.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299520\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F9600965\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antiviral Agents (Influenza A and B): May diminish the therapeutic effect of Influenza Virus Vaccine (Live/Attenuated). Management: Avoid anti-influenza antivirals during the period beginning 48 hours prior to and ending 2 weeks after vaccine administration.  Persons receiving these agents within 2 weeks of the live intranasal spray vaccine should receive a repeat vaccine dose.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AzaTHIOprine: May enhance the adverse/toxic effect of Vaccines (Live).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Belimumab: May enhance the adverse/toxic effect of Vaccines (Live).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Systemic): May enhance the adverse/toxic effect of Vaccines (Live).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fingolimod: May enhance the adverse/toxic effect of Vaccines (Live). Vaccinial infections may develop. Fingolimod may diminish the therapeutic effect of Vaccines (Live).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hydroxychloroquine: May enhance the adverse/toxic effect of Vaccines (Live).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Immune Globulins: May diminish the therapeutic effect of Vaccines (Live). Management: Live organism vaccination should be withheld for up to 6 months following immune globulin administration.  Live vaccine given immediately prior to immune globulin may require repeat vaccination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Immunosuppressants: May enhance the adverse/toxic effect of Vaccines (Live). Vaccinial infections may develop. Immunosuppressants may diminish the therapeutic effect of Vaccines (Live). Management: Avoid use of live organism vaccines with immunosuppressants; live-attenuated vaccines should not be given for at least 3 months after immunosuppressants.",
"     <b>",
"      Exceptions:",
"     </b>",
"     AzaTHIOprine; Beclomethasone (Oral Inhalation); Betamethasone; Budesonide (Systemic, Oral Inhalation); Corticotropin; Cortisone; Cytarabine (Liposomal); Dexamethasone (Systemic); Fludrocortisone; Fluticasone (Oral Inhalation); Hydrocortisone (Systemic); Hydroxychloroquine; Leflunomide; Mercaptopurine; Methotrexate; MethylPREDNISolone; PrednisoLONE (Systemic); PredniSONE; Triamcinolone (Systemic).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Leflunomide: May enhance the adverse/toxic effect of Vaccines (Live).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mercaptopurine: May enhance the adverse/toxic effect of Vaccines (Live).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrexate: May enhance the adverse/toxic effect of Vaccines (Live).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salicylates: Influenza Virus Vaccine (Live/Attenuated) may enhance the adverse/toxic effect of Salicylates. Specifically, Reye's syndrome may develop.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tuberculin Tests: Vaccines (Live) may diminish the diagnostic effect of Tuberculin Tests.  Management: If a parenteral live vaccine has been recently administered, a scheduled PPD skin test should not be administered for at least 4-6 weeks following the administration of the vaccine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F9600944\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F9600945\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events were not observed in animal reproduction studies. LAIV is not recommended for use during pregnancy. Influenza vaccination with the trivalent inactivated vaccine (TIV) is recommended for all women who are or will become pregnant during the influenza season and who do not otherwise have contraindications to the vaccine.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Healthy pregnant women do not need to avoid contact with persons vaccinated with LAIV and pregnant healthcare providers may administer the LAIV. The nasal vaccine contains the same strains of influenza A and B found in the injection. Information specific to the use of LAIV in pregnancy has not been located. Refer to the Influenza Virus Vaccine (Inactivated) monograph for additional information.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Healthcare providers are encouraged to refer women exposed to the influenza vaccine during pregnancy to the Vaccines and Medications in Pregnancy Surveillance System (VAMPSS) by contacting The Organization of Teratology Information Specialists (OTIS) at (877) 311-8972.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F9470206\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Monitor for &ge;15 minutes following vaccination",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1047931\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Promotes immunity to influenza virus by inducing influenza strain-specific serum antibodies",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F1047946\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: Protective antibody levels achieved &sim;2 weeks after vaccination",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: Protective antibody levels persist approximately &ge;6 months",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F10533004\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Distribution: Following nasal administration, vaccine is distributed in the nasal cavity (~90%), stomach (~3%), brain (~2%), and lung (0.4%)",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1047939\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?11/43/11953?source=see_link\">",
"      see \"Influenza virus vaccine (live attenuated): Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     If the patient sneezes after intranasal vaccine administration, the dose should not be repeated. Patients with an acute febrile illness should not receive the vaccine until symptoms improve. Report any suspected adverse effects to your physician.",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F10278555\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;margin-top:0em;display:inline\">",
"     In order to maximize vaccination rates, the ACIP recommends simultaneous administration of all age-appropriate vaccines (live or inactivated) for which a person is eligible at a single visit, unless contraindications exist. The use of combination vaccines is generally preferred over separate injections, taking into consideration provider assessment, patient preference, and potential adverse events.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     For additional information, please refer to the following website:",
"     <a href=\"file://www.cdc.gov/vaccines/vpd-vac/\" target=\"_blank\">",
"      file://www.cdc.gov/vaccines/vpd-vac/",
"     </a>",
"     .",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Academy of Pediatrics, Committee on Infectious Diseases, \"Policy Statement-Recommendations for Prevention and Control of Influenza in Children, 2011-2012,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , September 2, 2011.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/10/14502/abstract-text/21890834/pubmed\" id=\"21890834\" target=\"_blank\">",
"        21890834",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Belshe RB, Mendelman PM, Treanor J, et al, \"The Efficacy of Live Attenuated, Cold-Adapted, Trivalent, Intranasal Influenza Virus Vaccine in Children,\"",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1998, 338(20):1405-12.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/10/14502/abstract-text/9580647/pubmed\" id=\"9580647\" target=\"_blank\">",
"        9580647",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), National Center for Immunization and Respiratory Diseases, \"General Recommendations on Immunization - Recommendations of the Advisory Committee on Immunization Practices (ACIP),\"",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2011, 60(2):1-64.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/10/14502/abstract-text/21293327/pubmed\" id=\"21293327\" target=\"_blank\">",
"        21293327",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention, \"Prevention and Control of Influenza With Vaccines: Recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010,\"",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2010, 59(RR-8):1-62 . Available at",
"      <a href=\"file://www.cdc.gov/mmwr/PDF/rr/rr5908.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/mmwr/PDF/rr/rr5908.pdf",
"      </a>",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/10/14502/abstract-text/20689501/pubmed\" id=\"20689501\" target=\"_blank\">",
"        20689501",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), \"Prevention and Control of Influenza With Vaccines: Recommendations of the Advisory Committee on Immunization Practices (ACIP) &minus; United States, 2012-13 Influenza Season,\"",
"      <i>",
"       MMWR Morb Mortal Wkly Rep",
"      </i>",
"      , 2012, 61:613-8. Available at",
"      <a href=\"file://www.cdc.gov/mmwr/preview/mmwrhtml/mm6132a3.htm?s_cid=mm6132a3_w\" target=\"_blank\">",
"       file://www.cdc.gov/mmwr/preview/mmwrhtml/mm6132a3.htm?s_cid=mm6132a3_w",
"      </a>",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/10/14502/abstract-text/22895385/pubmed\" id=\"22895385\" target=\"_blank\">",
"        22895385",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Prymula R, Siegrist CA, Chlibek R, et al, \"Effect of Prophylactic Paracetamol Administration at Time of Vaccination on Febrile Reactions and Antibody Responses in Children: Two Open-Label, Randomised Controlled Trials,\"",
"      <i>",
"       Lancet",
"      </i>",
"      , 2009, 374(9698):1339-50.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/10/14502/abstract-text/19837254/pubmed\" id=\"19837254\" target=\"_blank\">",
"        19837254",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12941 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-183.166.191.243-285D26EE14-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_10_14502=[""].join("\n");
var outline_f14_10_14502=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14961380\">",
"      Special Alerts",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9560232\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11239606\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1047941\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1047934\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9560249\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9560334\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13845071\">",
"      Product Availability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1047944\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1047937\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1047943\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9560333\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9560240\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1047947\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1047933\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1047932\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299520\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9600965\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9600944\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9600945\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9470206\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1047931\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1047946\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10533004\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1047939\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10278555\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12941\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12941|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?18/54/19303?source=related_link\">",
"      Influenza virus vaccine (live attenuated): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?11/43/11953?source=related_link\">",
"      Influenza virus vaccine (live attenuated): Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f14_10_14503="Clinical manifestations of hypothyroidism";
var content_f14_10_14503=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical manifestations of hypothyroidism",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/10/14503/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/10/14503/contributors\">",
"     Martin I Surks, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/10/14503/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/10/14503/contributors\">",
"     Douglas S Ross, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/10/14503/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/10/14503/contributors\">",
"     Jean E Mulder, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?14/10/14503/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 17, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Whether hypothyroidism results from hypothalamic-pituitary disease or primary thyroid disease, symptoms and signs of the disease vary in relation to the magnitude of the thyroid hormone deficiency, and the acuteness with which the deficiency develops. Hypothyroidism is less prominent clinically and better tolerated when there is a gradual loss of thyroid function (as in most cases of primary hypothyroidism) than when it develops acutely after thyroidectomy or abrupt withdrawal of exogenous thyroid hormone.",
"   </p>",
"   <p>",
"    The typical clinical manifestations of hypothyroidism may be modified by factors such as coexisting nonthyroidal illness. Furthermore, when hypothyroidism is caused by hypothalamic-pituitary disease, the manifestations of associated endocrine deficiencies such as hypogonadism and adrenal insufficiency may mask the manifestations of hypothyroidism. Finally, when hypothyroidism follows treatment of Graves' hyperthyroidism, some manifestations of Graves' disease, such as ophthalmopathy and vitiligo, may persist throughout the patient's life.",
"   </p>",
"   <p>",
"    This topic will review the major clinical manifestations of hypothyroidism. The diagnosis and treatment of hypothyroidism, subclinical hypothyroidism, and goiter are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/7/26744?source=see_link\">",
"     \"Diagnosis of and screening for hypothyroidism\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/53/43865?source=see_link\">",
"     \"Treatment of hypothyroidism\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/48/3850?source=see_link\">",
"     \"Subclinical hypothyroidism\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/27/32185?source=see_link\">",
"     \"Diagnostic approach to and treatment of goiter in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many of the manifestations of hypothyroidism reflect one of two changes induced by lack of thyroid hormone (",
"    <a class=\"graphic graphic_table graphicRef62676 \" href=\"UTD.htm?41/41/42651\">",
"     table 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A generalized slowing of metabolic processes. This can lead to abnormalities such as fatigue, slow movement and slow speech, cold intolerance, constipation, weight gain (but not morbid obesity), delayed relaxation of deep tendon reflexes, and bradycardia.",
"     </li>",
"     <li>",
"      Accumulation of matrix glycosaminoglycans in the interstitial spaces of many tissues [",
"      <a class=\"abstract\" href=\"UTD.htm?14/10/14503/abstract/1\">",
"       1",
"      </a>",
"      ]. This can lead to coarse hair and skin, puffy facies, enlargement of the tongue, and hoarseness. These changes are often more easily recognized in young patients, and they may be attributed to aging in older patients.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Skin",
"    </span>",
"    &nbsp;&mdash;&nbsp;The skin is cool and pale in patients with hypothyroidism because of decreased blood flow. The epidermis has an atrophied cellular layer and hyperkeratosis that results in the characteristic dry roughness of the skin [",
"    <a class=\"abstract\" href=\"UTD.htm?14/10/14503/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The following skin changes may also occur:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Sweating is decreased because of decreases in calorigenesis and acinar gland secretion.",
"     </li>",
"     <li>",
"      Skin discoloration may occur. A yellowish tinge may be present if the patient has carotenemia, while hyperpigmentation may be seen when primary hypothyroidism is associated with primary adrenal failure.",
"     </li>",
"     <li>",
"      Hair may be coarse, hair loss is common, and the nails become brittle.",
"     </li>",
"     <li>",
"      Nonpitting edema (myxedema) occurs in severe hypothyroidism and may be generalized. It results from infiltration of the skin with glycosaminoglycans with associated water retention [",
"      <a class=\"abstract\" href=\"UTD.htm?14/10/14503/abstract/1\">",
"       1",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Vitiligo and alopecia areata may be present in patients with hypothyroidism after treatment of Graves' hyperthyroidism.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Eyes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Periorbital edema often presents as a manifestation of generalized nonpitting edema. In addition, as previously mentioned, Graves' ophthalmopathy may persist when hypothyroidism develops after treatment of Graves' hyperthyroidism. Thus, periorbital edema may also be a manifestation of ophthalmopathy, in which case the patient may also have variable degrees of stare, protrusion of the eyes, and extraocular muscle weakness.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Hematologic",
"    </span>",
"    &nbsp;&mdash;&nbsp;A systematic review of 36 studies reported that patients with hypothyroidism appear to be at increased risk of bleeding due to a hypothyroidism-associated hypocoagulable state [",
"    <a class=\"abstract\" href=\"UTD.htm?14/10/14503/abstract/3\">",
"     3",
"    </a>",
"    ], caused by an acquired von Willebrand's syndrome type I [",
"    <a class=\"abstract\" href=\"UTD.htm?14/10/14503/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Anemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with hypothyroidism have a decrease in red blood cell mass and a normochromic, normocytic hypoproliferative anemia [",
"    <a class=\"abstract\" href=\"UTD.htm?14/10/14503/abstract/5\">",
"     5",
"    </a>",
"    ]. Pernicious anemia occurs in 10 percent of patients with hypothyroidism caused by chronic autoimmune thyroiditis. Such patients present with a macrocytic anemia with marrow megaloblastosis. However, occasional patients without anemia may display macrocytosis without marrow megaloblastosis [",
"    <a class=\"abstract\" href=\"UTD.htm?14/10/14503/abstract/6\">",
"     6",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/14/23782?source=see_link\">",
"     \"Physiology of vitamin B12 and folate deficiency\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/16/21767?source=see_link\">",
"     \"Macrocytosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Women in the childbearing years may develop iron deficiency anemia, secondary to menorrhagia. In patients with iron deficiency anemia and hypothyroidism, combined therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/43/41656?source=see_link\">",
"     levothyroxine",
"    </a>",
"    and oral iron supplements results in correction of the anemia, which may be refractory to treatment with iron alone [",
"    <a class=\"abstract\" href=\"UTD.htm?14/10/14503/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Cardiovascular system",
"    </span>",
"    &nbsp;&mdash;&nbsp;The systemic hypometabolism that is associated with hypothyroidism results in a decrease in cardiac output that is mediated by reductions in heart rate and contractility [",
"    <a class=\"abstract\" href=\"UTD.htm?14/10/14503/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. Thyroid hormone regulation of genes coding for specific myocardial enzymes involved in myocardial contractility and relaxation is responsible for the decrease in contractility [",
"    <a class=\"abstract\" href=\"UTD.htm?14/10/14503/abstract/10\">",
"     10",
"    </a>",
"    ]. The mechanism underlying the decrease in heart rate is unknown (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/62/3046?source=see_link\">",
"     \"Cardiovascular effects of hypothyroidism\"",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Reduced cardiac output probably contributes to decreased exercise capacity and shortness of breath during exercise, two common complaints in patients with hypothyroidism. However, symptoms and signs of congestive heart failure are usually absent in patients who have no other cardiac disease. By contrast, heart failure or angina may worsen when hypothyroidism develops in patients with heart disease. In such patients, thyroxine (T4) replacement should be administered cautiously, beginning with a low initial dose (eg, 25 mcg) and then increasing in small increments every one or two months. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/53/43865?source=see_link\">",
"     \"Treatment of hypothyroidism\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other abnormalities contributing to cardiovascular disease that may occur in hypothyroid patients are:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pericardial effusion, which only rarely compromises ventricular function.",
"     </li>",
"     <li>",
"      Hypertension, because of an increase in peripheral vascular resistance. In normotensive patients, blood pressure increases are small (eg, maximal blood pressure less than",
"      <span class=\"nowrap\">",
"       150/100",
"      </span>",
"      mmHg). The blood pressure of patients with established hypertension, however, may increase further with the development of hypothyroidism.",
"     </li>",
"     <li>",
"      Hypercholesterolemia, which is caused by a decrease in the rate of cholesterol metabolism (see",
"      <a class=\"local\" href=\"#H16\">",
"       'Metabolic abnormalities'",
"      </a>",
"      below)&nbsp;[",
"      <a class=\"abstract\" href=\"UTD.htm?14/10/14503/abstract/11,12\">",
"       11,12",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Hyperhomocystemia (see",
"      <a class=\"local\" href=\"#H16\">",
"       'Metabolic abnormalities'",
"      </a>",
"      below)&nbsp;[",
"      <a class=\"abstract\" href=\"UTD.htm?14/10/14503/abstract/13\">",
"       13",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Coronary artery revascularization is occasionally necessary in patients with hypothyroidism. Studies have shown that it is safe to operate without T4 replacement [",
"    <a class=\"abstract\" href=\"UTD.htm?14/10/14503/abstract/14\">",
"     14",
"    </a>",
"    ]. T4 raises myocardial and peripheral oxygen consumption, requiring increased cardiac output and cardiac work. These changes can exacerbate established coronary artery disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/53/43865?source=see_link\">",
"     \"Treatment of hypothyroidism\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Respiratory system",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fatigue, shortness of breath on exertion, rhinitis, and decreased exercise capacity may result from impaired respiratory function, as well as cardiovascular disease. Hypoventilation occurs because of respiratory muscle weakness [",
"    <a class=\"abstract\" href=\"UTD.htm?14/10/14503/abstract/15,16\">",
"     15,16",
"    </a>",
"    ] and reduced pulmonary responses to hypoxia and hypercapnia [",
"    <a class=\"abstract\" href=\"UTD.htm?14/10/14503/abstract/17\">",
"     17",
"    </a>",
"    ]. Although respiratory muscle function is restored by T4 replacement, normalization of gas exchange may not occur, particularly in obese patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/9/23701?source=see_link\">",
"     \"Respiratory function in thyroid disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/4/40008?source=see_link\">",
"     \"Control of ventilation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Sleep apnea occurs in some patients with hypothyroidism, mostly as a result of macroglossia. Treatment of the hypothyroidism will usually reverse the sleep apnea, but some patients require treatment with continuous positive airway pressure (CPAP) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/10/14503/abstract/18\">",
"     18",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/48/38661?source=see_link\">",
"     \"Clinical manifestations and diagnosis of obesity hypoventilation syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The prevalence of hypothyroidism is high among patients with idiopathic pulmonary arterial hypertension, although hypothyroidism is not currently believed to be a risk factor for the condition [",
"    <a class=\"abstract\" href=\"UTD.htm?14/10/14503/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. The basis of the observed association of the two disorders is unclear. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/47/19193?source=see_link\">",
"     \"Overview of pulmonary hypertension in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Gastrointestinal disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;Decreased gut motility results in constipation, one of the most common complaints of patients with hypothyroidism. When euthyroid patients who already have constipation become hypothyroid, their constipation worsens [",
"    <a class=\"abstract\" href=\"UTD.htm?14/10/14503/abstract/21\">",
"     21",
"    </a>",
"    ]. In occasional patients, marked ileus may be confused with intestinal obstruction. Small intestinal bacterial overgrowth may also contribute to gastrointestinal symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?14/10/14503/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other gastrointestinal problems that can occur in hypothyroidism are:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Decreased taste sensation.",
"     </li>",
"     <li>",
"      Gastric atrophy due to the presence of antiparietal cell antibodies. Pernicious anemia occurs in 10 percent of patients with hypothyroidism caused by chronic autoimmune thyroiditis.",
"     </li>",
"     <li>",
"      Celiac disease is four times more common in hypothyroid patients compared with the general population [",
"      <a class=\"abstract\" href=\"UTD.htm?14/10/14503/abstract/23\">",
"       23",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A modest weight gain due to decreased metabolic rate and accumulation of fluid (nonpitting edema) that is rich in glycosaminoglycans is a frequent finding. However, marked obesity is not characteristic of hypothyroidism.",
"     </li>",
"     <li>",
"      Ascites is a rare finding.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Reproductive abnormalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women with hypothyroidism may have either oligo- or amenorrhea or hypermenorrhea-menorrhagia. In a study of 171 premenopausal women with hypothyroidism, 77 percent had normal cycles, 16 percent had oligo- or amenorrhea, and 7 percent had hypermenorrhea-menorrhagia; the respective frequencies in 214 normal women were 92 percent, 7 percent, and 1 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?14/10/14503/abstract/24\">",
"     24",
"    </a>",
"    ]. Among the women with hypothyroidism who had abnormal cycles, the abnormalities persisted despite T4 therapy in almost half.",
"   </p>",
"   <p>",
"    These menstrual changes result in decreased fertility. If pregnancy does occur, there is an increased likelihood for early abortion [",
"    <a class=\"abstract\" href=\"UTD.htm?14/10/14503/abstract/25\">",
"     25",
"    </a>",
"    ]. Hyperprolactinemia may occur, and is occasionally sufficiently severe to cause amenorrhea or galactorrhea [",
"    <a class=\"abstract\" href=\"UTD.htm?14/10/14503/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The serum sex hormone-binding globulin concentration may be low in hypothyroidism. This will lower serum total but not free sex hormone concentrations, a change that can be misleading in the evaluation of gonadal function. However, some men with hypothyroidism have low serum free testosterone concentrations but normal serum luteinizing hormone concentrations, suggesting a direct effect of hypothyroidism on the hypothalamus or pituitary [",
"    <a class=\"abstract\" href=\"UTD.htm?14/10/14503/abstract/27\">",
"     27",
"    </a>",
"    ]; their serum free testosterone concentrations rise with T4 treatment.",
"   </p>",
"   <p>",
"    Decreased libido, erectile dysfunction, and delayed ejaculation are found in 64 percent of hypothyroid men [",
"    <a class=\"abstract\" href=\"UTD.htm?14/10/14503/abstract/28\">",
"     28",
"    </a>",
"    ]. In one report, sperm morphology was abnormal in 64 percent of hypothyroid men before treatment and 24 percent after T4 therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?14/10/14503/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Neurological dysfunction",
"    </span>",
"    &nbsp;&mdash;&nbsp;The neurologic manifestations of hypothyroidism are both common and protean, affecting both the central and peripheral nervous system. While usually occurring in the setting of other clinical manifestations of hypothyroidism, they may be the presenting feature, and can cause significant disability. Most of these complications are partially or fully responsive to thyroid replacement. The more common disorders are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/46/36585?source=see_link\">",
"     \"Neurologic manifestations of hypothyroidism\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/26/29093?source=see_link\">",
"     \"Hypothyroid myopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Hashimoto's encephalopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The term \"Hashimoto's Encephalopathy\" has been used to describe the association of encephalopathy with autoimmune thyroiditis. A somewhat controversial disorder, Hashimoto's encephalopathy is believed to be an immune-mediated disorder rather than representing the direct effect of an altered thyroid state on the central nervous system. This topic is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/47/33527?source=see_link\">",
"     \"Hashimoto's encephalopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Myxedema coma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Myxedema coma may occur when severe hypothyroidism is complicated by trauma, infection, cold exposure, or inadvertent administration of hypnotics or opiates. The diagnosis should be suspected in comatose patients who are hypothermic, hypercapnic, and hyponatremic. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/23/8566?source=see_link\">",
"     \"Myxedema coma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Carpal tunnel",
"    </span>",
"    &nbsp;&mdash;&nbsp;Carpal tunnel syndrome is a common complication of hypothyroidism and is often reversible with thyroid hormone therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/46/36585?source=see_link&amp;anchor=H18#H18\">",
"     \"Neurologic manifestations of hypothyroidism\", section on 'Carpal tunnel syndrome'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Musculoskeletal symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Joint pains, aches, and stiffness may occur in patients with hypothyroidism, although they are not a common presentation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/15/34039?source=see_link\">",
"     \"Evaluation of the adult with polyarticular pain\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    An increased prevalence of hyperuricemia and gout has been reported in hypothyroid patients compared with the general population, probably secondary to decreased renal plasma flow and impaired glomerular filtration [",
"    <a class=\"abstract\" href=\"UTD.htm?14/10/14503/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Metabolic abnormalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of metabolic abnormalities can occur in hypothyroidism:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hyponatremia may result from a reduction in free water clearance. Hypothyroidism must be excluded in any hyponatremic patient before making the diagnosis of the syndrome of inappropriate antidiuretic hormone secretion. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/30/3562?source=see_link&amp;anchor=H88313973#H88313973\">",
"       \"Causes of hyponatremia\", section on 'Hypothyroidism'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Reversible increases in serum creatinine occur in 20 to 90 percent of hypothyroid patients [",
"      <a class=\"abstract\" href=\"UTD.htm?14/10/14503/abstract/31\">",
"       31",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/26/29093?source=see_link&amp;anchor=H5#H5\">",
"       \"Hypothyroid myopathy\", section on 'Elevation in serum creatine kinase'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      As previously mentioned, lipid clearance may be decreased, resulting in an elevation in the serum concentrations of free fatty acids and total and low-density lipoprotein cholesterol [",
"      <a class=\"abstract\" href=\"UTD.htm?14/10/14503/abstract/11,12\">",
"       11,12",
"      </a>",
"      ]. Furthermore, hypothyroidism is not an infrequent cause of hyperlipidemia in the general population. In one study of 1509 consecutive patients referred for evaluation of hyperlipidemia, 4.2 percent had hypothyroidism, approximately twice the incidence in the general population [",
"      <a class=\"abstract\" href=\"UTD.htm?14/10/14503/abstract/12\">",
"       12",
"      </a>",
"      ]. Only those patients with a serum thyrotropin (TSH) concentration above 10",
"      <span class=\"nowrap\">",
"       mU/L",
"      </span>",
"      had a significant reduction in the serum cholesterol concentration during thyroid hormone replacement. This observation suggests that minimal thyroid hormone deficiency may not adversely affect lipid metabolism, which is compatible with the inconsistent findings in patients with subclinical hypothyroidism. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/48/3850?source=see_link\">",
"       \"Subclinical hypothyroidism\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/56/28550?source=see_link\">",
"       \"Lipid abnormalities in thyroid disease\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      A variety of lipid abnormalities have been described in overt hypothyroidism. A report from the Mayo Clinic, for example, evaluated 295 patients with hypothyroidism [",
"      <a class=\"abstract\" href=\"UTD.htm?14/10/14503/abstract/11\">",
"       11",
"      </a>",
"      ]. Hypercholesterolemia was present in 56 percent, hypercholesterolemia and hypertriglyceridemia in 34 percent, and hypertriglyceridemia in 1.5 percent; only 8.5 percent had a normal lipid profile. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/56/28550?source=see_link\">",
"       \"Lipid abnormalities in thyroid disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Plasma homocysteine concentrations are increased in some hypothyroid patients, including some with recent-onset hypothyroidism, and return to normal after treatment with T4 [",
"      <a class=\"abstract\" href=\"UTD.htm?14/10/14503/abstract/13\">",
"       13",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Drug clearance",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clearance of many drugs, including antiepileptic, anticoagulant, hypnotic and opioid drugs, is decreased in hypothyroidism. Thus, drug toxicity may occur if drug dose is not reduced. In addition, drugs that are administered at effective doses in patients who are hypothyroid may become less effective during T4 replacement.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?3/54/3938?source=see_link\">",
"       \"Patient information: Hypothyroidism (underactive thyroid) (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?14/54/15203?source=see_link\">",
"       \"Patient information: Hypothyroidism (underactive thyroid) (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The symptoms and signs of hypothyroidism vary in relation to the magnitude of the thyroid hormone deficiency and the acuteness with which the deficiency develops. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Many of the manifestations of hypothyroidism reflect one of two changes induced by lack of thyroid hormone: a generalized slowing of metabolic processes and accumulation of matrix glycosaminoglycans in the interstitial spaces of many tissues (",
"      <a class=\"graphic graphic_table graphicRef62676 \" href=\"UTD.htm?41/41/42651\">",
"       table 1",
"      </a>",
"      ). Other symptoms and signs include depression, decreased hearing, diastolic hypertension, and pleural and pericardial effusions. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The clinical manifestations of central hypothyroidism are similar to those of primary hypothyroidism. When hypothyroidism is caused by hypothalamic-pituitary disease, the manifestations of associated endocrine deficiencies such as hypogonadism and adrenal insufficiency may mask the manifestations of hypothyroidism. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/6/18536?source=see_link\">",
"       \"Central hypothyroidism\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/28/41413?source=see_link\">",
"       \"Diagnosis of hypopituitarism\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A variety of metabolic abnormalities can occur in hypothyroidism, including hyponatremia, hyperlipidemia, anemia, and high serum muscle enzyme concentrations. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Metabolic abnormalities'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The clearance of many drugs, including antiepileptic, anticoagulant, hypnotic and opioid drugs, is decreased in hypothyroidism. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Drug clearance'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/10/14503/abstract/1\">",
"      Smith TJ, Bahn RS, Gorman CA. Connective tissue, glycosaminoglycans, and diseases of the thyroid. Endocr Rev 1989; 10:366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/10/14503/abstract/2\">",
"      Heymann WR. Cutaneous manifestations of thyroid disease. J Am Acad Dermatol 1992; 26:885.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/10/14503/abstract/3\">",
"      Squizzato A, Romualdi E, B&uuml;ller HR, Gerdes VE. Clinical review: Thyroid dysfunction and effects on coagulation and fibrinolysis: a systematic review. J Clin Endocrinol Metab 2007; 92:2415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/10/14503/abstract/4\">",
"      Manfredi E, van Zaane B, Gerdes VE, et al. Hypothyroidism and acquired von Willebrand's syndrome: a systematic review. Haemophilia 2008; 14:423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/10/14503/abstract/5\">",
"      Green ST, Ng JP. Hypothyroidism and anaemia. Biomed Pharmacother 1986; 40:326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/10/14503/abstract/6\">",
"      Colon-Otero G, Menke D, Hook CC. A practical approach to the differential diagnosis and evaluation of the adult patient with macrocytic anemia. Med Clin North Am 1992; 76:581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/10/14503/abstract/7\">",
"      Cinemre H, Bilir C, Gokosmanoglu F, Bahcebasi T. Hematologic effects of levothyroxine in iron-deficient subclinical hypothyroid patients: a randomized, double-blind, controlled study. J Clin Endocrinol Metab 2009; 94:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/10/14503/abstract/8\">",
"      Woeber KA. Thyrotoxicosis and the heart. N Engl J Med 1992; 327:94.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/10/14503/abstract/9\">",
"      Klein I, Ojamaa K. Thyroid hormone and the cardiovascular system: from theory to practice. J Clin Endocrinol Metab 1994; 78:1026.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/10/14503/abstract/10\">",
"      Dillmann WH. Biochemical basis of thyroid hormone action in the heart. Am J Med 1990; 88:626.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/10/14503/abstract/11\">",
"      O'Brien T, Dinneen SF, O'Brien PC, Palumbo PJ. Hyperlipidemia in patients with primary and secondary hypothyroidism. Mayo Clin Proc 1993; 68:860.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/10/14503/abstract/12\">",
"      Diekman T, Lansberg PJ, Kastelein JJ, Wiersinga WM. Prevalence and correction of hypothyroidism in a large cohort of patients referred for dyslipidemia. Arch Intern Med 1995; 155:1490.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/10/14503/abstract/13\">",
"      Hussein WI, Green R, Jacobsen DW, Faiman C. Normalization of hyperhomocysteinemia with L-thyroxine in hypothyroidism. Ann Intern Med 1999; 131:348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/10/14503/abstract/14\">",
"      Becker C. Hypothyroidism and atherosclerotic heart disease: pathogenesis, medical management, and the role of coronary artery bypass surgery. Endocr Rev 1985; 6:432.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/10/14503/abstract/15\">",
"      Laroche CM, Cairns T, Moxham J, Green M. Hypothyroidism presenting with respiratory muscle weakness. Am Rev Respir Dis 1988; 138:472.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/10/14503/abstract/16\">",
"      Siafakas NM, Salesiotou V, Filaditaki V, et al. Respiratory muscle strength in hypothyroidism. Chest 1992; 102:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/10/14503/abstract/17\">",
"      Ladenson PW, Goldenheim PD, Ridgway EC. Prediction and reversal of blunted ventilatory responsiveness in patients with hypothyroidism. Am J Med 1988; 84:877.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/10/14503/abstract/18\">",
"      Rosenow F, McCarthy V, Caruso AC. Sleep apnoea in endocrine diseases. J Sleep Res 1998; 7:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/10/14503/abstract/19\">",
"      Curnock AL, Dweik RA, Higgins BH, et al. High prevalence of hypothyroidism in patients with primary pulmonary hypertension. Am J Med Sci 1999; 318:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/10/14503/abstract/20\">",
"      Peacock AJ. Primary pulmonary hypertension. Thorax 1999; 54:1107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/10/14503/abstract/21\">",
"      Shafer RB, Prentiss RA, Bond JH. Gastrointestinal transit in thyroid disease. Gastroenterology 1984; 86:852.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/10/14503/abstract/22\">",
"      Lauritano EC, Bilotta AL, Gabrielli M, et al. Association between hypothyroidism and small intestinal bacterial overgrowth. J Clin Endocrinol Metab 2007; 92:4180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/10/14503/abstract/23\">",
"      Elfstr&ouml;m P, Montgomery SM, K&auml;mpe O, et al. Risk of thyroid disease in individuals with celiac disease. J Clin Endocrinol Metab 2008; 93:3915.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/10/14503/abstract/24\">",
"      Krassas GE, Pontikides N, Kaltsas T, et al. Disturbances of menstruation in hypothyroidism. Clin Endocrinol (Oxf) 1999; 50:655.",
"     </a>",
"    </li>",
"    <li>",
"     Burrow G. Thyroid diseases. In: Medical complications during pregnancy, 2nd, Burrow GN, Ferris TF (Eds), WB Saunders, Philadelphia 1982. p.187.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/10/14503/abstract/26\">",
"      Honbo KS, van Herle AJ, Kellett KA. Serum prolactin levels in untreated primary hypothyroidism. Am J Med 1978; 64:782.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/10/14503/abstract/27\">",
"      Donnelly P, White C. Testicular dysfunction in men with primary hypothyroidism; reversal of hypogonadotrophic hypogonadism with replacement thyroxine. Clin Endocrinol (Oxf) 2000; 52:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/10/14503/abstract/28\">",
"      Carani C, Isidori AM, Granata A, et al. Multicenter study on the prevalence of sexual symptoms in male hypo- and hyperthyroid patients. J Clin Endocrinol Metab 2005; 90:6472.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/10/14503/abstract/29\">",
"      Krassas GE, Papadopoulou F, Tziomalos K, et al. Hypothyroidism has an adverse effect on human spermatogenesis: a prospective, controlled study. Thyroid 2008; 18:1255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/10/14503/abstract/30\">",
"      Giordano N, Santacroce C, Mattii G, et al. Hyperuricemia and gout in thyroid endocrine disorders. Clin Exp Rheumatol 2001; 19:661.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/10/14503/abstract/31\">",
"      Kreisman SH, Hennessey JV. Consistent reversible elevations of serum creatinine levels in severe hypothyroidism. Arch Intern Med 1999; 159:79.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7846 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-61.234.146.186-4BCC47CC64-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_10_14503=[""].join("\n");
var outline_f14_10_14503=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H19\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Skin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Eyes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Hematologic",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Anemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Cardiovascular system",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Respiratory system",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Gastrointestinal disorders",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Reproductive abnormalities",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Neurological dysfunction",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Hashimoto's encephalopathy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Myxedema coma",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Carpal tunnel",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Musculoskeletal symptoms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Metabolic abnormalities",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Drug clearance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ENDO/7846\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/7846|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?41/41/42651\" title=\"table 1\">",
"      Symptoms and signs of hypothyroidism",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/62/3046?source=related_link\">",
"      Cardiovascular effects of hypothyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/30/3562?source=related_link\">",
"      Causes of hyponatremia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/6/18536?source=related_link\">",
"      Central hypothyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/48/38661?source=related_link\">",
"      Clinical manifestations and diagnosis of obesity hypoventilation syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/4/40008?source=related_link\">",
"      Control of ventilation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/7/26744?source=related_link\">",
"      Diagnosis of and screening for hypothyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/28/41413?source=related_link\">",
"      Diagnosis of hypopituitarism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/27/32185?source=related_link\">",
"      Diagnostic approach to and treatment of goiter in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/15/34039?source=related_link\">",
"      Evaluation of the adult with polyarticular pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/47/33527?source=related_link\">",
"      Hashimoto's encephalopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/26/29093?source=related_link\">",
"      Hypothyroid myopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/56/28550?source=related_link\">",
"      Lipid abnormalities in thyroid disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/16/21767?source=related_link\">",
"      Macrocytosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/23/8566?source=related_link\">",
"      Myxedema coma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/46/36585?source=related_link\">",
"      Neurologic manifestations of hypothyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/47/19193?source=related_link\">",
"      Overview of pulmonary hypertension in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?14/54/15203?source=related_link\">",
"      Patient information: Hypothyroidism (underactive thyroid) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?3/54/3938?source=related_link\">",
"      Patient information: Hypothyroidism (underactive thyroid) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/14/23782?source=related_link\">",
"      Physiology of vitamin B12 and folate deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/9/23701?source=related_link\">",
"      Respiratory function in thyroid disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/48/3850?source=related_link\">",
"      Subclinical hypothyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/53/43865?source=related_link\">",
"      Treatment of hypothyroidism",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f14_10_14504="Clinical manifestations and diagnosis of Zollinger-Ellison syndrome (gastrinoma)";
var content_f14_10_14504=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical manifestations and diagnosis of Zollinger-Ellison syndrome (gastrinoma)",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/10/14504/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/10/14504/contributors\">",
"     Stephen E Goldfinger, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/10/14504/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/10/14504/contributors\">",
"     David C Whitcomb, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/10/14504/contributors\">",
"     Deputy Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/10/14504/contributors\">",
"     Shilpa Grover, MD, MPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/10/14504/contributors\">",
"     Diane MF Savarese, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?14/10/14504/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 9, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;In 1955, Zollinger and Ellison described a syndrome characterized by ulceration of the upper jejunum, hypersecretion of gastric acid, and non-beta islet cell tumors of the pancreas [",
"    <a class=\"abstract\" href=\"UTD.htm?14/10/14504/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Unlike typical peptic ulcer disease, this syndrome was often progressive, persistent, and frequently life-threatening. Since then, gastrin has been identified as the humoral agent responsible for the syndrome. With current assays for serum gastrin, increasing numbers of patients are being diagnosed with the Zollinger-Ellison syndrome. Furthermore, the diagnosis is often established before development of the complications of peptic ulcer disease or spread of a malignant gastrinoma, and therapy that alters the course of the disease is almost always possible [",
"    <a class=\"abstract\" href=\"UTD.htm?14/10/14504/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The clinical manifestations and diagnosis of the Zollinger-Ellison syndrome will be reviewed here. The approach to therapy of this disorder is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/51/6968?source=see_link\">",
"     \"Management and prognosis of the Zollinger-Ellison syndrome (gastrinoma)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The epidemiology of the Zollinger-Ellison syndrome (ZES) is incompletely understood. It was initially estimated that the incidence in the United States ranged from 0.1 to 1 percent of patients with peptic ulcer disease [",
"    <a class=\"abstract\" href=\"UTD.htm?14/10/14504/abstract/4\">",
"     4",
"    </a>",
"    ]. However, this may be an underestimation because patients with undiagnosed ZES often have symptoms similar to those caused by typical peptic ulcer disease related to H. pylori infection or nonsteroidal antiinflammatory drugs. These symptoms may be controlled by standard doses of an antisecretory drug, and the patients may not be tested for hypergastrinemia [",
"    <a class=\"abstract\" href=\"UTD.htm?14/10/14504/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most patients are diagnosed between the ages of 20 and 50, but patients as young as 7 and as old as 90 have been identified. The male to female ratio ranges between 1.5:1 and 2:1 [",
"    <a class=\"abstract\" href=\"UTD.htm?14/10/14504/abstract/5\">",
"     5",
"    </a>",
"    ]. Gastrinomas can be either sporadic or associated with multiple endocrine neoplasia type 1. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/14/43240?source=see_link\">",
"     \"Multiple endocrine neoplasia type 1: Clinical manifestations and diagnosis\"",
"    </a>",
"    .) Approximately 80 percent of patients have the sporadic form [",
"    <a class=\"abstract\" href=\"UTD.htm?14/10/14504/abstract/6\">",
"     6",
"    </a>",
"    ], although somatic (acquired) mutations in the MEN1 gene are observed commonly in sporadic gastrinomas (",
"    <a class=\"graphic graphic_table graphicRef53057 \" href=\"UTD.htm?19/40/20108\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/10/14504/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CLASSIFICATION, NOMENCLATURE, AND HISTOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gastrinomas are derived from multipotential stem cells of endodermal origin. Known as enteroendocrine cells, they arise mainly in the pancreas, but also in the small intestine. Tumors that arise from these cells are considered neuroendocrine tumors (NETs).",
"   </p>",
"   <p>",
"    The World Health Organization (WHO) classifies neuroendocrine tumors arising within the digestive system into two broad categories, based upon the extent to which they resemble their normal nonneoplastic counterparts (",
"    <a class=\"graphic graphic_table graphicRef60365 \" href=\"UTD.htm?17/14/17644\">",
"     table 2",
"    </a>",
"    ) (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/40/6794?source=see_link&amp;anchor=H2474956#H2474956\">",
"     \"Pathology, classification, and grading of neuroendocrine tumors arising in the digestive system\", section on '2010 WHO classification'",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/10/14504/abstract/8\">",
"     8",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Well differentiated neuroendocrine tumors, which are further separated, according to proliferative rate, into low-grade (G1) and intermediate grade (G2) subgroups.",
"     </li>",
"     <li>",
"      Poorly differentiated neuroendocrine carcinomas, all of which are high-grade (G3). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/43/22201?source=see_link&amp;anchor=H1176454#H1176454\">",
"       \"Pathology of lung malignancies\", section on 'Neuroendocrine tumors'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Histologically, most gastrinomas are well differentiated NETs with few mitoses, and a histologic appearance that is similar to that of other pancreatic neuroendocrine tumors. The cells are arranged in a solid, trabecular, gyriform, or glandular pattern, with fairly uniform nuclei, salt-and-pepper chromatin, and finely granular cytoplasm. As with other pancreatic NETs, the degree of malignancy cannot be predicted by morphologic appearance alone.",
"   </p>",
"   <p>",
"    The cells produce abundant neurosecretory granules, as reflected in the strong and diffuse immunohistochemical expression of neuroendocrine markers such as synaptophysin and chromogranin. Gastrin is the predominant peptide within the secretory granules of gastrinoma cells, but other neuroendocrine peptides such as vasoactive intestinal peptide and glucagon can sometimes be identified as well.",
"   </p>",
"   <p>",
"    The designation of the tumor as a gastrinoma is based upon the presence of a clinical syndrome that results from tumor production of gastrin, and not by its morphologic appearance or the presence of gastrin in the secretory granules. If a tumor stains for gastrin but does not produce symptoms of the Zollinger-Ellison syndrome, it should not be considered a gastrinoma. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/40/6794?source=see_link&amp;anchor=H799428#H799428\">",
"     \"Pathology, classification, and grading of neuroendocrine tumors arising in the digestive system\", section on 'Functionality and nomenclature'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As many as 70 percent of gastrinomas form in the duodenum; the remainder, with rare exception, arise in the pancreas or less often (approximately 10 percent) in lymph nodes adjacent to the pancreas [",
"    <a class=\"abstract\" href=\"UTD.htm?14/10/14504/abstract/9\">",
"     9",
"    </a>",
"    ]. Duodenal gastrinomas tend to be quite small and are often multiple. They have less malignant potential than the solitary, sporadic pancreatic gastrinomas.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Excessive gastrin secretion from a gastrinoma results in high gastric acid output for two reasons (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/30/29160?source=see_link\">",
"     \"Physiology of gastric acid secretion\"",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/10/14504/abstract/5\">",
"     5",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Gastrin has trophic action on parietal cells and histamine-secreting enterochromaffin-like (ECL) cells (",
"      <a class=\"graphic graphic_picture graphicRef78549 \" href=\"UTD.htm?40/38/41577\">",
"       picture 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Gastrin stimulates parietal cells largely via the release of histamine.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Over 90 percent of patients with the Zollinger-Ellison syndrome (ZES) develop peptic ulcers (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef57632 \" href=\"UTD.htm?0/25/404\">",
"     image 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/10/14504/abstract/10\">",
"     10",
"    </a>",
"    ]. Patients with this syndrome, like those with sporadic peptic ulcer disease, often present with solitary ulcers less than 1 cm in diameter. Most (75 percent) are in the first portion of the duodenum, 14 percent in the distal duodenum, and 11 percent in the jejunum [",
"    <a class=\"abstract\" href=\"UTD.htm?14/10/14504/abstract/11\">",
"     11",
"    </a>",
"    ]. The ulcers recur much more often than in patients with sporadic ulcer disease.",
"   </p>",
"   <p>",
"    Diarrhea can also be a prominent feature of ZES. The factors that cause diarrhea include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The high rate of gastric acid secretion, resulting in a volume load that cannot be fully reabsorbed by the small intestine and colon.",
"     </li>",
"     <li>",
"      The excess acid secretion, which exceeds the neutralizing capacity of pancreatic bicarbonate secretion. The exceptionally low pH of the intestinal contents inactivates pancreatic digestive enzymes, interferes with the emulsification of fat by bile acids, and damages intestinal epithelial cells and villi. Thus, both maldigestion and malabsorption may result in steatorrhea [",
"      <a class=\"abstract\" href=\"UTD.htm?14/10/14504/abstract/5\">",
"       5",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The extremely high serum gastrin concentrations may inhibit absorption of sodium and water by the small intestine, thereby adding a secretory component to the diarrhea [",
"      <a class=\"abstract\" href=\"UTD.htm?14/10/14504/abstract/5\">",
"       5",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Metastatic disease is evident at the time of diagnosis in approximately one-third of patients with a gastrinoma [",
"    <a class=\"abstract\" href=\"UTD.htm?14/10/14504/abstract/12\">",
"     12",
"    </a>",
"    ]. The liver is the most common site of spread; bone metastases, primarily to the axial skeleton, also occur, but only in those with hepatic metastases [",
"    <a class=\"abstract\" href=\"UTD.htm?14/10/14504/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Investigators at the National Institutes of Health collated the clinical presentations of 261 patients with ZES who were seen during a 25-year period (",
"    <a class=\"graphic graphic_figure graphicRef82168 \" href=\"UTD.htm?32/37/33374\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/10/14504/abstract/14\">",
"     14",
"    </a>",
"    ]. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The mean age of symptom onset was 41 years while the mean delay between symptom onset and diagnosis was 5.2 years.",
"     </li>",
"     <li>",
"      Abdominal pain (75 percent) and diarrhea (73 percent) were the most frequent initial complaints.",
"     </li>",
"     <li>",
"      Heartburn and weight loss were reported by 44 and 17 percent of patients, respectively, and initial presentation was with gastrointestinal bleeding in 25 percent.",
"     </li>",
"     <li>",
"      A history of nephrocalcinosis or renal colic was more common among MEN1 subjects compared to those with sporadic tumors.",
"     </li>",
"     <li>",
"      Prominent gastric folds were apparent at endoscopy in 94 percent of patients whereas stricture of the pylorus, duodenum, or esophagus was observed in fewer than 10 percent.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The introduction of potent antisecretory therapy during the study period had no effect on the profile of presenting symptoms or delay in diagnosis. However, these drugs were associated with a dramatic reduction in surgery designed to reduce gastric acid secretion. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/51/6968?source=see_link&amp;anchor=H3#H3\">",
"     \"Management and prognosis of the Zollinger-Ellison syndrome (gastrinoma)\", section on 'Proton pump inhibitors'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Only a small number of patients with peptic ulcer disease have the Zollinger-Ellison syndrome (ZES). Its presence should be suspected in patients with findings suggestive of acid hypersecretion (eg, multiple or refractory ulcers, or ulcer location distal to the duodenum), diarrhea, or a personal or family history of multiple endocrine neoplasia type 1 (",
"    <a class=\"graphic graphic_table graphicRef50291 \" href=\"UTD.htm?3/52/3916\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/10/14504/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There have been three time-honored tests for the diagnosis of ZES:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Fasting serum gastrin concentration",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/49/28435?source=see_link\">",
"       Secretin",
"      </a>",
"      stimulation test",
"     </li>",
"     <li>",
"      Gastric acid secretion studies",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Of these, only the fasting serum gastrin concentration and the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/49/28435?source=see_link\">",
"     secretin",
"    </a>",
"    stimulation test are used routinely. Several other tests have also been described that may still have an adjunctive role, particularly when secretin is unavailable.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Serum gastrin concentration",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fasting serum gastrin should be measured in any patient suspected of having the ZES. The upper limit of normal for serum gastrin is 110",
"    <span class=\"nowrap\">",
"     pg/mL.",
"    </span>",
"    In the presence of gastric acid (ie, a gastric pH below 5.0), a serum gastrin value greater than 1000",
"    <span class=\"nowrap\">",
"     pg/mL",
"    </span>",
"    (475",
"    <span class=\"nowrap\">",
"     pmol/L)",
"    </span>",
"    is virtually diagnostic of the disorder. Measurement of gastric pH on a single specimen is important to exclude secondary hypergastrinemia due to achlorhydria (eg, in patients with pernicious anemia or atrophic gastritis) since the serum gastrin level can easily exceed 1000",
"    <span class=\"nowrap\">",
"     pg/mL",
"    </span>",
"    in these circumstances.",
"   </p>",
"   <p>",
"    Higher levels are more likely with pancreatic (compared with duodenal) tumors, larger tumor size, and with metastatic disease [",
"    <a class=\"abstract\" href=\"UTD.htm?14/10/14504/abstract/5\">",
"     5",
"    </a>",
"    ]. However, about two-thirds of patients with the ZES have serum gastrin concentrations less than 10 times the upper limit of normal (generally between 150 and 1000",
"    <span class=\"nowrap\">",
"     pg/mL",
"    </span>",
"    (71 and 475",
"    <span class=\"nowrap\">",
"     pmol/L))",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?14/10/14504/abstract/5\">",
"     5",
"    </a>",
"    ]. This degree of hypergastrinemia is nonspecific and can also be present in patients with normal or slightly increased gastric acid secretion, including patients with renal insufficiency, massive small bowel resection, G-cell hyperplasia, gastric outlet obstruction, and retained gastric antrum, and in patients receiving potent antisecretory drugs.",
"   </p>",
"   <p>",
"    Falsely low serum gastrin levels in patients with ZES syndrome may be reported by commercial immunoassay kits in current use [",
"    <a class=\"abstract\" href=\"UTD.htm?14/10/14504/abstract/16\">",
"     16",
"    </a>",
"    ]. Falsely low serum gastrin levels result because gastrinomas often secrete a variety of bioactive progastrin molecules (G-17, G-71, G-52, G-34, G-14), but many of the assays detect only the gastrin-17 molecule. False negatives are most likely to occur at relatively low gastrin concentrations, with most assays accurately detecting patients with ZES whose serum gastrin concentrations are greater than 400",
"    <span class=\"nowrap\">",
"     pmol/L",
"    </span>",
"    (845",
"    <span class=\"nowrap\">",
"     pg/mL).",
"    </span>",
"    In one study that looked at 12 different commercial assay kits, four of the kits returned falsely low results in 20 to 80 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?14/10/14504/abstract/16\">",
"     16",
"    </a>",
"    ]. Falsely high serum gastrin levels can also be reported by commercial immunoassays. Thus, if the clinical suspicion for a gastrinoma is high, additional testing should be obtained (eg, determining a serum chromogranin A level or obtaining an imaging study). (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Serum chromogranin A'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H11\">",
"     'Tumor localization and staging'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Secretin stimulation test",
"    </span>",
"    &nbsp;&mdash;&nbsp;The",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/49/28435?source=see_link\">",
"     secretin",
"    </a>",
"    stimulation test can differentiate patients with gastrinomas from those with the many other causes of hypergastrinemia, and should be performed in every patient suspected to have the ZES who has a nondiagnostic fasting serum gastrin concentration. For unknown reasons, secretin stimulates the release of gastrin by gastrinoma cells, and therefore most patients with these tumors have a dramatic rise in serum gastrin in response to a secretin infusion. In contrast, normal gastric G cells are inhibited by secretin, and therefore serum gastrin concentrations do not rise in patients with other causes of hypergastrinemia.",
"   </p>",
"   <p>",
"    The",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/49/28435?source=see_link\">",
"     secretin",
"    </a>",
"    stimulation test is performed by administering 0.4 &micro;g of secretin per kg body weight (RepliGen Corporation, Waltham, MA) intravenously over one minute; a baseline serum gastrin is measured twice before the secretin is administered and classically 2, 5, 10, 15, and 20 minutes later (",
"    <a class=\"graphic graphic_table graphicRef64937 \" href=\"UTD.htm?3/8/3212\">",
"     table 4",
"    </a>",
"    ). Several criteria have been proposed to define a positive test; one of the most commonly used is a rise in serum gastrin by 200",
"    <span class=\"nowrap\">",
"     pg/mL",
"    </span>",
"    (95",
"    <span class=\"nowrap\">",
"     pmol/L)",
"    </span>",
"    or more [",
"    <a class=\"abstract\" href=\"UTD.htm?14/10/14504/abstract/17\">",
"     17",
"    </a>",
"    ]. The peak serum gastrin is usually seen by 10 minutes (",
"    <a class=\"graphic graphic_figure graphicRef66223 \" href=\"UTD.htm?14/53/15197\">",
"     figure 2",
"    </a>",
"    ), which has led some investigators to question whether the last two measurements are necessary.",
"   </p>",
"   <p>",
"    The following test characteristics were described in a large series from the National Institutes of Health involving patients ZES underwent provocative testing using",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/49/28435?source=see_link\">",
"     secretin",
"    </a>",
"    , using an intravenous bolus (2",
"    <span class=\"nowrap\">",
"     U/kg",
"    </span>",
"    body weight ) of Secretin-Kabi (Ferring AB, Malmo, Sweden), with fasting serum gastrin levels measured at -15, -5, 0, 2, 5, 10, 20, and 30 minutes [",
"    <a class=\"abstract\" href=\"UTD.htm?14/10/14504/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Using a rise of &ge;200",
"      <span class=\"nowrap\">",
"       pg/mL",
"      </span>",
"      as the cutoff sensitivity and specificity were 83 and 100 percent, respectively.",
"     </li>",
"     <li>",
"      Using a rise of &ge;50 percent from baseline as the cutoff, the sensitivity and specificity were 86 and 93 percent, respectively.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The authors concluded that the optimal cutoff was a rise of &ge;120",
"    <span class=\"nowrap\">",
"     pg/mL,",
"    </span>",
"    which was associated with the highest sensitivity and specificity (94 and 100 percent, respectively). The investigators used a",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/49/28435?source=see_link\">",
"     secretin",
"    </a>",
"    preparation that is no longer used commonly but results are probably applicable to the secretin from RepliGen as well.",
"   </p>",
"   <p>",
"    The standard",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/49/28435?source=see_link\">",
"     secretin",
"    </a>",
"    test (from which the reference standards were derived) was performed with patients off antacids and anticholinergics for at least 12 hours; H2 antagonists and proton pump inhibitors were not available at that time. However, patients with severe ZES can develop complications (such as acute bleeding and perforation) if acid suppression is discontinued [",
"    <a class=\"abstract\" href=\"UTD.htm?14/10/14504/abstract/19\">",
"     19",
"    </a>",
"    ]. Thus, discontinuation of acid suppression should be performed cautiously. While the accuracy of the test in patients taking a PPI has not been well established, some authorities suggest that PPIs do not interfere with the interpretation of the secretin stimulation test and that PPIs do not need to be discontinued, especially considering the above [",
"    <a class=\"abstract\" href=\"UTD.htm?14/10/14504/abstract/19\">",
"     19",
"    </a>",
"    ]. We suggest a PPI be discontinued for one week.",
"   </p>",
"   <p>",
"    In countries in which",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/49/28435?source=see_link\">",
"     secretin",
"    </a>",
"    is not available, provocation with glucagon has been reported but experience is limited [",
"    <a class=\"abstract\" href=\"UTD.htm?14/10/14504/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Gastric acid secretion studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gastric acid secretion studies, which were pivotal in establishing the diagnosis of ZES at an earlier time, are no longer performed in most major medical centers, although they may still have an ancillary role [",
"    <a class=\"abstract\" href=\"UTD.htm?14/10/14504/abstract/21\">",
"     21",
"    </a>",
"    ]. Other diagnostic modalities discussed above have generally replaced this approach, which can be technically difficult to perform.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Serum chromogranin A",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serum chromogranin A (CGA) is a general marker for well-differentiated neuroendocrine tumors that does not differentiate between the various tumor subtypes [",
"    <a class=\"abstract\" href=\"UTD.htm?14/10/14504/abstract/22\">",
"     22",
"    </a>",
"    ]. Nevertheless, it is elevated in most patients with gastrinomas, and the level of elevation tends to correlate with tumor volume [",
"    <a class=\"abstract\" href=\"UTD.htm?14/10/14504/abstract/23\">",
"     23",
"    </a>",
"    ]. However, in contrast to other neuroendocrine tumors, very high levels of CGA can be seen in gastrinomas without liver metastases [",
"    <a class=\"abstract\" href=\"UTD.htm?14/10/14504/abstract/24\">",
"     24",
"    </a>",
"    ]. Elevated CGA levels are present in a number of other conditions (",
"    <a class=\"graphic graphic_table graphicRef73287 \" href=\"UTD.htm?40/9/41116\">",
"     table 5",
"    </a>",
"    ), and specificity depends on the cutoff value. In particular, very high serum concentrations of chromogranin A can be caused by proton pump inhibitor therapy, which is frequently used in patients with dyspepsia [",
"    <a class=\"abstract\" href=\"UTD.htm?14/10/14504/abstract/25,26\">",
"     25,26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Measurement of serum CGA is less sensitive and specific than measurement of serum gastrin, but it may be used as a confirmatory test in difficult cases. CGA levels are usually normal or near normal in patients with high gastrin levels secondary to pernicious anemia and enterochromaffin-like cell (ie, type I) carcinoids [",
"    <a class=\"abstract\" href=\"UTD.htm?14/10/14504/abstract/27\">",
"     27",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/60/969?source=see_link&amp;anchor=H8#H8\">",
"     \"Clinical characteristics of carcinoid tumors\", section on 'Stomach'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Calcium infusion study",
"    </span>",
"    &nbsp;&mdash;&nbsp;The calcium infusion study (selective arterial stimulation with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/11/18616?source=see_link\">",
"     calcium gluconate",
"    </a>",
"    followed by venous sampling) is considerably less sensitive and specific compared to the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/49/28435?source=see_link\">",
"     secretin",
"    </a>",
"    stimulation test for diagnostic purposes and more cumbersome to perform [",
"    <a class=\"abstract\" href=\"UTD.htm?14/10/14504/abstract/18\">",
"     18",
"    </a>",
"    ]. However, it may be positive in patients with ZES who have a negative secretin stimulation test. As a result, it is usually reserved for patients with gastric acid hypersecretion in whom there is a strong clinical suspicion of gastrinoma despite a negative secretin test [",
"    <a class=\"abstract\" href=\"UTD.htm?14/10/14504/abstract/18\">",
"     18",
"    </a>",
"    ], and for tumor localization in patients with a radiographically occult gastrinoma.",
"   </p>",
"   <p>",
"    The test is performed by infusing",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/11/18616?source=see_link\">",
"     calcium gluconate",
"    </a>",
"    (5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    body weight per hour for three hours) and determining serum gastrin and calcium levels every 30 minutes. Infusion is associated with an increase in serum gastrin and calcium levels in patients with gastrinoma. Positive responses are usually observed between 120 and 180 minutes [",
"    <a class=\"abstract\" href=\"UTD.htm?14/10/14504/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The following test characteristics were described in one of the largest published series and review of the literature [",
"    <a class=\"abstract\" href=\"UTD.htm?14/10/14504/abstract/18\">",
"     18",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Using a change in calcium of &ge;395",
"      <span class=\"nowrap\">",
"       pg/mL",
"      </span>",
"      as a cutoff, sensitivity ranged from 54 to 62 percent and specificity was 100 percent.",
"     </li>",
"     <li>",
"      Using a change in calcium of &ge;50 percent as the cutoff, the sensitivity and specificity were 78 and 83 percent, respectively.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     TUMOR LOCALIZATION AND STAGING",
"    </span>",
"    &nbsp;&mdash;&nbsp;After the diagnosis of the Zollinger-Ellison syndrome (ZES) is made, the gastrinoma must be located and staged. The only exception is in patients in whom the decision has been made to treat medically, as for example, in the MEN1 syndrome. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/51/6968?source=see_link\">",
"     \"Management and prognosis of the Zollinger-Ellison syndrome (gastrinoma)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/61/38871?source=see_link\">",
"     \"Multiple endocrine neoplasia type 1: Treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The major modalities for tumor identification are:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cross sectional imaging with helical, contrast-enhanced triple phase computed tomography (CT) and magnetic resonance imaging (MRI) (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/57/18330?source=see_link&amp;anchor=H12145107#H12145107\">",
"       \"Classification, epidemiology, clinical presentation, localization, and staging of pancreatic neuroendocrine tumors (islet-cell tumors)\", section on 'Computed tomography'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/57/18330?source=see_link&amp;anchor=H12145114#H12145114\">",
"       \"Classification, epidemiology, clinical presentation, localization, and staging of pancreatic neuroendocrine tumors (islet-cell tumors)\", section on 'Magnetic resonance imaging'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Endoscopic ultrasound is especially valuable in imaging subcentimeter pancreatic neuroendocrine tumors, and duodenal gastrinomas; in addition, it permits fine needle aspiration for histological identification. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/57/18330?source=see_link&amp;anchor=H12145121#H12145121\">",
"       \"Classification, epidemiology, clinical presentation, localization, and staging of pancreatic neuroendocrine tumors (islet-cell tumors)\", section on 'Endoscopic ultrasonography'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Somatostatin receptor scintigraphy (SRS) with 111-Indium-penetreotide (OctreoScan) which is most accurate with the addition of single photon emission computed tomography (SPECT) to planar imaging. In older studies, the sensitivity of SRS compared favorably with other imaging modalities for gastrinomas. In one series, for example, SRS detected primary gastrinomas at a rate of 58 percent, a sensitivity equal to that of other imaging studies such as ultrasonography, CT, MRI, and angiography combined [",
"      <a class=\"abstract\" href=\"UTD.htm?14/10/14504/abstract/29\">",
"       29",
"      </a>",
"      ]. In another, SRS was superior to CT scanning for localizing gastrinomas [",
"      <a class=\"abstract\" href=\"UTD.htm?14/10/14504/abstract/30\">",
"       30",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      However, technological advancements in CT and MRI over the past several decades have led some to question whether SRS is still a necessary component of the staging workup for gastroenteropancreatic neuroendocrine tumors. Nevertheless, there is still a place for SRS in the evaluation of a patient with a gastrinoma. Routine use of SRS as an adjunct for tumor staging is justified if the finding of extraabdominal metastases would change patient management and the treatment plan. In addition to anatomical information, SRS offers functional information on levels of somatostatin-receptor expression; this can help in the selection of appropriate candidates with advanced disease for somatostatin-based therapies. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/57/18330?source=see_link&amp;anchor=H12145128#H12145128\">",
"       \"Classification, epidemiology, clinical presentation, localization, and staging of pancreatic neuroendocrine tumors (islet-cell tumors)\", section on 'Somatostatin-receptor scintigraphy (OctreoScan)'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    When strong clinical suspicion persists despite negative results, other techniques that can be used to localize the tumor include angiography and selective arterial stimulation and venous sampling with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/11/18616?source=see_link\">",
"     calcium gluconate",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?14/10/14504/abstract/31\">",
"     31",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Calcium infusion study'",
"    </a>",
"    above.) Sometimes tumor localization can only be achieved at laparotomy, by direct palpation, duodenal transillumination, or intraoperative ultrasound. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/57/18330?source=see_link&amp;anchor=H12145142#H12145142\">",
"     \"Classification, epidemiology, clinical presentation, localization, and staging of pancreatic neuroendocrine tumors (islet-cell tumors)\", section on 'Intraoperative localization techniques'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Staging system",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pancreatic endocrine tumors such as gastrinomas are included in the combined American Joint Committee on Cancer",
"    <span class=\"nowrap\">",
"     (AJCC)/International",
"    </span>",
"    Union Against Cancer (UICC) TNM (tumor-node-metastasis) staging system for pancreatic tumors (",
"    <a class=\"graphic graphic_table graphicRef62155 \" href=\"UTD.htm?42/32/43532\">",
"     table 6",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/10/14504/abstract/32\">",
"     32",
"    </a>",
"    ]. Five and ten-year survival rates for patients undergoing resection for a pancreatic neuroendocrine tumor (either an islet cell or carcinoid tumor), stratified by stage at presentation are presented in the following table (",
"    <a class=\"graphic graphic_table graphicRef80523 \" href=\"UTD.htm?4/42/4780\">",
"     table 7",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/10/14504/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Zollinger-Ellison syndrome is characterized by ulceration of the upper jejunum, hypersecretion of gastric acid, and non-beta islet cell tumors of the pancreas. Gastrin has been identified as the humoral agent responsible for the syndrome, and a neuroendocrine tumor, a gastrinoma, is responsible for production of gastrin. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Over 90 percent of patients with the ZES develop peptic ulcers (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef57632 \" href=\"UTD.htm?0/25/404\">",
"       image 1",
"      </a>",
"      ). Patients with this syndrome, like those with sporadic peptic ulcer disease, often present with solitary ulcers less than 1 cm in diameter. Most (75 percent) are in the first portion of the duodenum, 14 percent in the distal duodenum, and 11 percent in the jejunum. The ulcers recur much more often than in patients with sporadic ulcer disease. Diarrhea can also be a prominent feature of ZES. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There are three tests for the diagnosis of ZES: fasting serum gastrin concentration,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/49/28435?source=see_link\">",
"       secretin",
"      </a>",
"      stimulation test, and gastric acid secretion studies. Of these, only the fasting serum gastrin concentration and the secretin stimulation test are used routinely. Several other tests have also been described that may still have an adjunctive role, particularly when secretin is unavailable (",
"      <a class=\"graphic graphic_algorithm graphicRef64792 \" href=\"UTD.htm?27/35/28223\">",
"       algorithm 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      After the diagnosis of the ZES is made, the gastrinoma must be located. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Tumor localization and staging'",
"      </a>",
"      above.) The only exception is in patients in whom the decision has been made to treat medically, as for example patients with known widespread metastases or those who are poor surgical candidates. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/51/6968?source=see_link\">",
"       \"Management and prognosis of the Zollinger-Ellison syndrome (gastrinoma)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/61/38871?source=see_link\">",
"       \"Multiple endocrine neoplasia type 1: Treatment\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/10/14504/abstract/1\">",
"      ZOLLINGER RM, ELLISON EH. Primary peptic ulcerations of the jejunum associated with islet cell tumors of the pancreas. Ann Surg 1955; 142:709.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/10/14504/abstract/2\">",
"      Ellison EC, Johnson JA. The Zollinger-Ellison syndrome: a comprehensive review of historical, scientific, and clinical considerations. Curr Probl Surg 2009; 46:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/10/14504/abstract/3\">",
"      Metz DC, Pisegna JR, Fishbeyn VA, et al. Control of gastric acid hypersecretion in the management of patients with Zollinger-Ellison syndrome. World J Surg 1993; 17:468.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/10/14504/abstract/4\">",
"      Isenberg JI, Walsh JH, Grossman MI. Zollinger-Ellison syndrome. Gastroenterology 1973; 65:140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/10/14504/abstract/5\">",
"      Berna MJ, Hoffmann KM, Serrano J, et al. Serum gastrin in Zollinger-Ellison syndrome: I. Prospective study of fasting serum gastrin in 309 patients from the National Institutes of Health and comparison with 2229 cases from the literature. Medicine (Baltimore) 2006; 85:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/10/14504/abstract/6\">",
"      Norton JA. Neuroendocrine tumors of the pancreas and duodenum. Curr Probl Surg 1994; 31:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/10/14504/abstract/7\">",
"      Zhuang Z, Vortmeyer AO, Pack S, et al. Somatic mutations of the MEN1 tumor suppressor gene in sporadic gastrinomas and insulinomas. Cancer Res 1997; 57:4682.",
"     </a>",
"    </li>",
"    <li>",
"     Rindi G, Arnold R, Bosman FT, et al. Nomenclature and classification of neuroendocrine neoplasms of the digestive system. In: WHO Classification of Tumours of the Digestive System, 4th ed, Bosman TF, Carneiro F, Hruban RH, Theise ND (Eds), International Agency for Research on cancer (IARC), Lyon 2010. p.13.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/10/14504/abstract/9\">",
"      Norton JA, Alexander HR, Fraker DL, et al. Possible primary lymph node gastrinoma: occurrence, natural history, and predictive factors: a prospective study. Ann Surg 2003; 237:650.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/10/14504/abstract/10\">",
"      Deveney CW, Deveney KE. Zollinger-Ellison syndrome (gastrinoma). Current diagnosis and treatment. Surg Clin North Am 1987; 67:411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/10/14504/abstract/11\">",
"      Meko JB, Norton JA. Management of patients with Zollinger-Ellison syndrome. Annu Rev Med 1995; 46:395.",
"     </a>",
"    </li>",
"    <li>",
"     Jensen RT, Gardner JD. Gastrinoma. In: The Pancreas: Biology, Pathobiology and Disease, 2nd ed, Go VL, DiMagno EP, Gardner JD, et al (Eds), Raven Press, New York 1993. p.947.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/10/14504/abstract/13\">",
"      Gibril F, Doppman JL, Reynolds JC, et al. Bone metastases in patients with gastrinomas: a prospective study of bone scanning, somatostatin receptor scanning, and magnetic resonance image in their detection, frequency, location, and effect of their detection on management. J Clin Oncol 1998; 16:1040.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/10/14504/abstract/14\">",
"      Roy PK, Venzon DJ, Shojamanesh H, et al. Zollinger-Ellison syndrome. Clinical presentation in 261 patients. Medicine (Baltimore) 2000; 79:379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/10/14504/abstract/15\">",
"      Orloff SL, Debas HT. Advances in the management of patients with Zollinger-Ellison syndrome. Surg Clin North Am 1995; 75:511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/10/14504/abstract/16\">",
"      Rehfeld JF, Gingras MH, Bardram L, et al. The Zollinger-Ellison syndrome and mismeasurement of gastrin. Gastroenterology 2011; 140:1444.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/10/14504/abstract/17\">",
"      McGuigan JE, Wolfe MM. Secretin injection test in the diagnosis of gastrinoma. Gastroenterology 1980; 79:1324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/10/14504/abstract/18\">",
"      Berna MJ, Hoffmann KM, Long SH, et al. Serum gastrin in Zollinger-Ellison syndrome: II. Prospective study of gastrin provocative testing in 293 patients from the National Institutes of Health and comparison with 537 cases from the literature. evaluation of diagnostic criteria, proposal of new criteria, and correlations with clinical and tumoral features. Medicine (Baltimore) 2006; 85:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/10/14504/abstract/19\">",
"      D&eacute;sir B, Poitras P. Oral pantoprazole for acid suppression in the treatment of patients with Zollinger-Ellison syndrome. Can J Gastroenterol 2001; 15:795.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/10/14504/abstract/20\">",
"      Shibata C, Funayama Y, Fukushima K, et al. The glucagon provocative test for the diagnosis and treatment of Zollinger-Ellison syndrome. J Gastrointest Surg 2008; 12:344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/10/14504/abstract/21\">",
"      Roy PK, Venzon DJ, Feigenbaum KM, et al. Gastric secretion in Zollinger-Ellison syndrome. Correlation with clinical expression, tumor extent and role in diagnosis--a prospective NIH study of 235 patients and a review of 984 cases in the literature. Medicine (Baltimore) 2001; 80:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/10/14504/abstract/22\">",
"      Modlin IM, Gustafsson BI, Moss SF, et al. Chromogranin A--biological function and clinical utility in neuro endocrine tumor disease. Ann Surg Oncol 2010; 17:2427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/10/14504/abstract/23\">",
"      Nobels FR, Kwekkeboom DJ, Coopmans W, et al. Chromogranin A as serum marker for neuroendocrine neoplasia: comparison with neuron-specific enolase and the alpha-subunit of glycoprotein hormones. J Clin Endocrinol Metab 1997; 82:2622.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/10/14504/abstract/24\">",
"      Tomassetti P, Migliori M, Simoni P, et al. Diagnostic value of plasma chromogranin A in neuroendocrine tumours. Eur J Gastroenterol Hepatol 2001; 13:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/10/14504/abstract/25\">",
"      Sanduleanu S, Stridsberg M, Jonkers D, et al. Serum gastrin and chromogranin A during medium- and long-term acid suppressive therapy: a case-control study. Aliment Pharmacol Ther 1999; 13:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/10/14504/abstract/26\">",
"      Giusti M, Sidoti M, Augeri C, et al. Effect of short-term treatment with low dosages of the proton-pump inhibitor omeprazole on serum chromogranin A levels in man. Eur J Endocrinol 2004; 150:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/10/14504/abstract/27\">",
"      Hirschowitz BI, Worthington J, Mohnen J, Haber M. Chromogranin A in patients with acid hypersecretion and/or hypergastrinaemia. Aliment Pharmacol Ther 2007; 26:869.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/10/14504/abstract/28\">",
"      Frucht H, Howard JM, Slaff JI, et al. Secretin and calcium provocative tests in the Zollinger-Ellison syndrome. A prospective study. Ann Intern Med 1989; 111:713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/10/14504/abstract/29\">",
"      Gibril F, Reynolds JC, Doppman JL, et al. Somatostatin receptor scintigraphy: its sensitivity compared with that of other imaging methods in detecting primary and metastatic gastrinomas. A prospective study. Ann Intern Med 1996; 125:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/10/14504/abstract/30\">",
"      Schirmer WJ, Melvin WS, Rush RM, et al. Indium-111-pentetreotide scanning versus conventional imaging techniques for the localization of gastrinoma. Surgery 1995; 118:1105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/10/14504/abstract/31\">",
"      Thom AK, Norton JA, Doppman JL, et al. Prospective study of the use of intraarterial secretin injection and portal venous sampling to localize duodenal gastrinomas. Surgery 1992; 112:1002.",
"     </a>",
"    </li>",
"    <li>",
"     AJCC (American Joint Committee on Cancer) Cancer Staging Manual, 7th ed, Edge SB, Byrd DR, Compton CC, et al (Eds), Springer, New York  Vol 2010, p.241.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/10/14504/abstract/33\">",
"      Bilimoria KY, Bentrem DJ, Merkow RP, et al. Application of the pancreatic adenocarcinoma staging system to pancreatic neuroendocrine tumors. J Am Coll Surg 2007; 205:558.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2627 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-200.131.240.2-8C269A7C77-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_10_14504=[""].join("\n");
var outline_f14_10_14504=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H13\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CLASSIFICATION, NOMENCLATURE, AND HISTOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Serum gastrin concentration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Secretin stimulation test",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Gastric acid secretion studies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Serum chromogranin A",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Calcium infusion study",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      TUMOR LOCALIZATION AND STAGING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Staging system",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/2627\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/2627|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?27/35/28223\" title=\"algorithm 1\">",
"      Zollinger-Ellison syndrome algorithm",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/2627|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?0/25/404\" title=\"diagnostic image 1\">",
"      Zollinger Ellison syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/2627|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?32/37/33374\" title=\"figure 1\">",
"      Symptoms in ZES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?14/53/15197\" title=\"figure 2\">",
"      Secretin test for gastrinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/2627|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?40/38/41577\" title=\"picture 1\">",
"      Zollinger Ellison Light",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/2627|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?19/40/20108\" title=\"table 1\">",
"      MEN syndromes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?17/14/17644\" title=\"table 2\">",
"      Nomenclature and classification for neuroendocrine tumors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?3/52/3916\" title=\"table 3\">",
"      Conditions associated with ZES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?3/8/3212\" title=\"table 4\">",
"      Secretin stimulation test",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?40/9/41116\" title=\"table 5\">",
"      Conditions associated with elevated chromogranin A",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?42/32/43532\" title=\"table 6\">",
"      TNM panc endo exo CA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?4/42/4780\" title=\"table 7\">",
"      Survival rates following resection of a pancreatic neuroendocrine tumor",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/57/18330?source=related_link\">",
"      Classification, epidemiology, clinical presentation, localization, and staging of pancreatic neuroendocrine tumors (islet-cell tumors)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/60/969?source=related_link\">",
"      Clinical characteristics of carcinoid tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/51/6968?source=related_link\">",
"      Management and prognosis of the Zollinger-Ellison syndrome (gastrinoma)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/14/43240?source=related_link\">",
"      Multiple endocrine neoplasia type 1: Clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/61/38871?source=related_link\">",
"      Multiple endocrine neoplasia type 1: Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/43/22201?source=related_link\">",
"      Pathology of lung malignancies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/40/6794?source=related_link\">",
"      Pathology, classification, and grading of neuroendocrine tumors arising in the digestive system",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/30/29160?source=related_link\">",
"      Physiology of gastric acid secretion",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f14_10_14505="Neurological examination of the newborn";
var content_f14_10_14505=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Neurological examination of the newborn",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/10/14505/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/10/14505/contributors\">",
"     Suresh Kotagal, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/10/14505/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/10/14505/contributors\">",
"     Joseph A Garcia-Prats, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/10/14505/contributors\">",
"     Douglas R Nordli, Jr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/10/14505/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/10/14505/contributors\">",
"     Melanie S Kim, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?14/10/14505/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 10, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;A comprehensive neurologic assessment should be performed in any newborn suspected to have a neurologic abnormality either based upon history (eg, perinatal asphyxia) or a physical finding detected during the routine neonatal assessment. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/21/24922?source=see_link&amp;anchor=H47#H47\">",
"     \"Assessment of the newborn infant\", section on 'Neurologic examination'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There have been a number of publications that describe the newborn neurologic examination [",
"    <a class=\"abstract\" href=\"UTD.htm?14/10/14505/abstract/1-15\">",
"     1-15",
"    </a>",
"    ]. The discussion on the neonatal neurologic assessment presented here is based upon a review of the literature and the experience of the author. Other aspects of the routine assessment of the newborn are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/21/24922?source=see_link\">",
"     \"Assessment of the newborn infant\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     OVERVIEW",
"    </span>",
"    &nbsp;&mdash;&nbsp;The goals of the neurologic examination are to assist in localization of the disturbance, establish a diagnosis, and to some extent, predict the long-term outcome [",
"    <a class=\"abstract\" href=\"UTD.htm?14/10/14505/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The following factors may alter the results of the neurologic examination and, therefore, must be taken into consideration:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Conceptional age (CA) of the infant &mdash; The normal neurologic examination changes with maturation. In particular, passive tone and posture vary with gestational age and are used by the Ballard score to assign gestational age (",
"      <a class=\"graphic graphic_figure graphicRef78670 \" href=\"UTD.htm?25/63/26615\">",
"       figure 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef58241 \" href=\"UTD.htm?30/43/31421\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/35/22068?source=see_link&amp;anchor=H8#H8\">",
"       \"Postnatal assessment of gestational age\", section on 'New Ballard score'",
"      </a>",
"      and",
"      <a class=\"local\" href=\"#H16\">",
"       'Passive tone/posture'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Level of alertness &mdash; The neurologic examination varies dependent upon the level of alertness of the infant. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Level of alertness'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Experience of the clinician &mdash; Many neonatal neurologic maneuvers are dependent upon the skill of the examiner (eg, elicitation of deep tendon reflexes).",
"     </li>",
"     <li>",
"      Serial examinations are sometimes necessary to reliably establish the neurologic finding.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The neurologic examination includes the following components:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      General assessment, including determining the vital signs, level of alertness, and examination of the skin, head, and spine",
"     </li>",
"     <li>",
"      Motor function",
"     </li>",
"     <li>",
"      Cranial nerves",
"     </li>",
"     <li>",
"      Reflexes (deep tendon, superficial, and developmental)",
"     </li>",
"     <li>",
"      Sensory examination",
"     </li>",
"     <li>",
"      Behavioral assessment",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     GENERAL EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Key components of the general examination that are important in a neonatal neurologic evaluation include vital signs, gestational age (",
"    <a class=\"graphic graphic_figure graphicRef78670 \" href=\"UTD.htm?25/63/26615\">",
"     figure 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef58241 \" href=\"UTD.htm?30/43/31421\">",
"     table 1",
"    </a>",
"    ), determination of whether the infant's birth weight is appropriate for gestation, thorough examination of the head and spine, and identification of dysmorphic features that suggest a congenital anomaly or inborn errors of metabolism.",
"   </p>",
"   <p>",
"    Other components of the general newborn assessment are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/21/24922?source=see_link\">",
"     \"Assessment of the newborn infant\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Observation",
"    </span>",
"    &nbsp;&mdash;&nbsp;A brief period of observation before handling the infant is recommended to determine the level of alertness, the presence of involuntary movements [",
"    <a class=\"abstract\" href=\"UTD.htm?14/10/14505/abstract/11\">",
"     11",
"    </a>",
"    ], posture, and respiratory rate. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Passive tone/posture'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Level of alertness",
"    </span>",
"    &nbsp;&mdash;&nbsp;The neurologic examination varies depending upon the following five levels of alertness (state).",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Quiet sleep (also referred to as nonrapid eye movement sleep)",
"     </li>",
"     <li>",
"      Active sleep (also referred to as rapid eye movement sleep)",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       Awake/drowsy",
"      </span>",
"      (eyes open without gross movements)",
"     </li>",
"     <li>",
"      Alert",
"     </li>",
"     <li>",
"      Crying",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    As an example, muscle tone is diminished during active sleep compared to quiet sleep. It increases in the alert infant, and is greatest in the hungry, crying infant.",
"   </p>",
"   <p>",
"    The optimal time for assessment is when the infant is quiet and awake, which is typically after feeding and before the infant has fallen back to sleep. In very premature infants (gestational age before 28 weeks), it is often difficult to differentiate among the various states [",
"    <a class=\"abstract\" href=\"UTD.htm?14/10/14505/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An abnormal level of alertness is one of the most commonly observed neurologic deficits in the neonate [",
"    <a class=\"abstract\" href=\"UTD.htm?14/10/14505/abstract/14\">",
"     14",
"    </a>",
"    ]. An altered level of alertness is defined as a diminished or absent response to arousal maneuvers (ie, persistent and gentle shaking, perioral stimulation, pinching, shining a light, or ringing a bell).",
"   </p>",
"   <p>",
"    The following classification of altered alertness states for infants greater than 28 and 30 weeks gestation is based upon the neonatal response to arousal maneuvers and a more noxious stimulus, such as sternal rub or pressure on the supraorbital nerve [",
"    <a class=\"abstract\" href=\"UTD.htm?14/10/14505/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Normal &mdash; The infant appears awake, and has normal arousal and noxious stimuli responses.",
"     </li>",
"     <li>",
"      Mild stupor (lethargic) &mdash; The infant appears sleepy with slightly diminished arousal and noxious stimuli responses.",
"     </li>",
"     <li>",
"      Moderate stupor &mdash; The infant is unresponsive with moderately diminished arousal and noxious stimuli responses.",
"     </li>",
"     <li>",
"      Deep stupor &mdash; The infant is unresponsive with an absent arousal response and a markedly diminished reaction to noxious stimuli.",
"     </li>",
"     <li>",
"      Coma &mdash; The infant is unresponsive with absent arousal and noxious stimuli.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Altered levels of alertness are seen in infants with cortical dysfunction. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/24/2442?source=see_link\">",
"     \"Clinical features, diagnosis, and treatment of neonatal encephalopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Head",
"    </span>",
"    &nbsp;&mdash;&nbsp;The examination includes measuring its size, noting the skull shape, presence of abnormal hair patterns, scalp defects, and unusual lesions or protuberances. Additional evaluation includes auscultation for bruits and transillumination. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/21/24922?source=see_link&amp;anchor=H11#H11\">",
"     \"Assessment of the newborn infant\", section on 'Head'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Head size",
"    </span>",
"    &nbsp;&mdash;&nbsp;The fronto-occipital head circumference (FOC) should be measured at its maximum using a cloth tape. The tape should be positioned in the front just above the nasion (ie, bridge of the nose where the frontal and nasal bones of the skull meet), and in the back, across the external occipital protuberance (",
"    <a class=\"graphic graphic_picture graphicRef70799 \" href=\"UTD.htm?35/54/36707\">",
"     picture 1",
"    </a>",
"    ). At 40 weeks gestation, the average FOC is 35 cm (10th to 90th percentile, 33 to 37 cm).",
"   </p>",
"   <p>",
"    Microcephaly, defined as a FOC more than 2 standard deviations (SD) below the mean (&lt;3rd percentile), is usually due to a genetic abnormality or toxic, metabolic, or infectious insult that affects brain development (",
"    <a class=\"graphic graphic_table graphicRef61045 \" href=\"UTD.htm?24/5/24669\">",
"     table 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef75479 \" href=\"UTD.htm?16/2/16429\">",
"     table 3",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/51/36665?source=see_link&amp;anchor=H10#H10\">",
"     \"Etiology and evaluation of microcephaly in infants and children\", section on 'Etiology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In contrast, macrocephaly is defined as a FOC greater than 2 SD above the mean (&gt;97th percentile). Macrocephaly is caused by an increase in size of any of the components of the cranium, such as the brain parenchyma, cerebrospinal fluid, blood, or bone, or can be attributable to increased intracranial pressure (",
"    <a class=\"graphic graphic_table graphicRef65812 \" href=\"UTD.htm?6/50/6957\">",
"     table 4",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/54/3946?source=see_link&amp;anchor=H6#H6\">",
"     \"Etiology and evaluation of macrocephaly in infants and children\", section on 'Etiology'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Fontanel",
"    </span>",
"    &nbsp;&mdash;&nbsp;The fontanels should be palpated, preferably with the infant in the sitting position. The following findings may be associated with a specific neurologic condition.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Anterior fontanel tends to be small in infants with microcephaly, and enlarged in those with hydrocephalus, megalencephaly, hypothyroidism, or peroxisomal disorders, such as cerebro-hepato-renal syndrome.",
"     </li>",
"     <li>",
"      A tense and bulging fontanel in an infant who is placed in the sitting position and is not crying may be an indication of raised intracranial pressure, which may be present in patients with a subdural hematoma, bacterial meningitis, or cerebral edema. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/47/22265?source=see_link&amp;anchor=H15#H15\">",
"       \"Neonatal birth injuries\", section on 'Subdural hemorrhage'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/43/24246?source=see_link\">",
"       \"Neurologic complications of bacterial meningitis in the neonate\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Sutures",
"    </span>",
"    &nbsp;&mdash;&nbsp;The principal sutures of the skull (sagittal, coronal, lambdoid, and metopic) should be palpated. Passage through the birth canal may result in molding, a temporary asymmetry of the skull caused by overlapping or overriding of the sutures. However, an asymmetric skull that persists for longer than two to three days after birth, or a persistent palpable ridge along the suture line is abnormal, and might suggest craniosynostosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/37/10841?source=see_link&amp;anchor=H5#H5\">",
"     \"Overview of craniosynostosis\", section on 'Categorization of cranial deformities'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Scalp swelling",
"    </span>",
"    &nbsp;&mdash;&nbsp;Edema or bleeding into various compartments within the scalp and skull may be due to injuries that occur during delivery, particularly vacuum assisted deliveries. These injuries include caput succedaneum, cephalohematoma, and subgaleal hematoma, and are discussed separately (",
"    <a class=\"graphic graphic_figure graphicRef53176 \" href=\"UTD.htm?15/3/15411\">",
"     figure 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/47/22265?source=see_link&amp;anchor=H7#H7\">",
"     \"Neonatal birth injuries\", section on 'Extracranial injuries'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Auscultation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Auscultation of the head may detect a venous hum, which is a benign finding. However, an asymmetric systolic-diastolic bruit that is heard over the eyeballs and anterior fontanel may indicate the presence of an arteriovenous malformation, which involves the vein of Galen. This finding is best heard by using the bell of the stethoscope. It also may also be associated with high output cardiac failure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Transillumination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Transillumination of the head is performed by placing a bright light with a darkened rim on to the scalp surface in a darkened room. The normal zone of transillumination is generally 1 to 2 cm from the rim of light, and is somewhat larger over the frontal than the parieto-occipital regions. Increased transillumination is suggestive of a fluid-filled, intracranial lesion, such as hydrocephalus, hydranencephaly, or porencephalic cyst.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Spine",
"    </span>",
"    &nbsp;&mdash;&nbsp;The spine is inspected and palpated to detect abnormalities, such as a neural tube defect. Myelomeningocele is a readily apparent neurulation defect that is most often localized to the lumbar region, and less frequently at the thoracic or cervical level. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/62/33767?source=see_link\">",
"     \"Pathophysiology and clinical manifestations of myelomeningocele (spina bifida)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The gluteal folds should be separated to determine presence of a sacrococcygeal cleft or dimple, tuft of hair, hemangioma (",
"    <a class=\"graphic graphic_picture graphicRef72298 \" href=\"UTD.htm?17/3/17471\">",
"     picture 2",
"    </a>",
"    ), or discoloration may indicate an underlying postneurulation defect, such as tethered cord syndrome or diastematomyelia (split cord). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/21/24922?source=see_link&amp;anchor=H44#H44\">",
"     \"Assessment of the newborn infant\", section on 'Trunk and spine'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Associated findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following findings may be associated with a congenital disorder with neurologic abnormalities:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hypopigmented skin patches may be associated with tuberous sclerosis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/38/34410?source=see_link\">",
"       \"Tuberous sclerosis complex: Genetics, clinical features, and diagnosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Facial hemangioma involving the ophthalmic and maxillary divisions of the trigeminal nerve distribution is suggestive of the Sturge Weber syndrome. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/39/4727?source=see_link\">",
"       \"Sturge-Weber syndrome\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The combined findings of petechiae and hepatosplenomegaly are suggestive of congenital cytomegaloviral infection. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/51/36664?source=see_link&amp;anchor=H4#H4\">",
"       \"Cytomegalovirus infection and disease in newborns, infants, children and adolescents\", section on 'Congenital infection'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Congenital brain anomalies may accompany infants with dysmorphic facial features, such as hypotelorism, hypertelorism, low set ears, narrow palpebral fissures, and cleft lip",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      palate. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/0/23562?source=see_link\">",
"       \"Congenital cytogenetic abnormalities\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/57/3991?source=see_link\">",
"       \"Primary (congenital) encephalocele\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Atrophy or hypoplasia of the orbicularis oris muscle that accompanies congenital myopathies confers an inverted U-shape appearance of the upper lip. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/6/13417?source=see_link\">",
"       \"Congenital myopathies\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Arthrogryposis (contractures around multiple joints) may be associated with congenital myasthenia gravis, myopathy, or anterior horn cell disease. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/9/8344?source=see_link&amp;anchor=H11#H11\">",
"       \"Spinal muscular atrophy\", section on 'Arthrogryposis multiplex congenita'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     MOTOR FUNCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;This is based upon evaluation of passive tone and posture, and active muscle activity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Passive tone/posture",
"    </span>",
"    &nbsp;&mdash;&nbsp;Passive tone is generally assessed by observing the resting neonatal posture, and may be measured by the resistance to passive movement of the limbs. The normal resting posture and passive tone of the neonate varies with conceptional age (CA) (",
"    <a class=\"graphic graphic_figure graphicRef78670 \" href=\"UTD.htm?25/63/26615\">",
"     figure 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef58241 \" href=\"UTD.htm?30/43/31421\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?14/10/14505/abstract/1,15\">",
"     1,15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The normal resting posture is elevated with the head placed in midline. It should be symmetric in all four extremities and varies with CA as follows (",
"    <a class=\"graphic graphic_figure graphicRef78670 \" href=\"UTD.htm?25/63/26615\">",
"     figure 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      &le;28 weeks CA &mdash; All the infant's limbs are passively extended",
"     </li>",
"     <li>",
"      32 weeks CA &mdash; Slight flexion starting at the knee, then the hip with extended upper extremities",
"     </li>",
"     <li>",
"      34 weeks CA &mdash; Increasing flexion of the knee and hip with extended upper extremities",
"     </li>",
"     <li>",
"      36 weeks CA &mdash; Weak flexion of all four extremities",
"     </li>",
"     <li>",
"      40 weeks CA (term infant) &mdash; Strong flexion of all four extremities",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Passive tone can be measured in a supine infant starting at 28 weeks CA by using the following passive maneuvers (",
"    <a class=\"graphic graphic_figure graphicRef78670 \" href=\"UTD.htm?25/63/26615\">",
"     figure 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?14/10/14505/abstract/1,3\">",
"     1,3",
"    </a>",
"    ]. During these manipulations, the head should remain in the midline position.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Popliteal angle &mdash; At 28 weeks CA, extension of the lower extremity at the knee (while the hips are still in contact with the bed) is about 150 degrees (popliteal angle), whereas in the 40 week CA term infant, the range of the popliteal angle diminishes to 80 degrees.",
"     </li>",
"     <li>",
"      Scarf sign &mdash; The scarf sign measures the range of shoulder adduction. At 28 weeks CA, it is possible to adduct the shoulder and bring the elbow to touch the opposite shoulder, whereas by 40 weeks CA, passive adduction decreases so that the elbow only reaches midline.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Active muscle function",
"    </span>",
"    &nbsp;&mdash;&nbsp;By 32 to 34 weeks gestation, infants should exhibit symmetric, smooth, and spontaneous movements in all extremities. Persistent asymmetry may indicate weakness of the side that is less active. As an example, the affected upper limb is generally immobile in infants with a brachial plexus lesion. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/53/2906?source=see_link&amp;anchor=H32#H32\">",
"     \"Brachial plexus syndromes\", section on 'Congenital brachial plexus palsy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In most normal term infants, small amplitude, choreo-athetoid movements of the hands are seen. Common normal findings during active sleep include fragmentary myoclonus that migrates from one limb to another, facial twitches, and irregular respiratory rate. Although jitteriness or tremulousness can occur in normal awake infants, sustained tremulousness beyond the fourth day of life may be a marker of cortical dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?14/10/14505/abstract/4\">",
"     4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/40/18058?source=see_link&amp;anchor=H32#H32\">",
"     \"Hyperkinetic movement disorders in children\", section on 'Benign neonatal sleep myoclonus'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Active motor tone and strength can be measured in the axial and appendicular musculature by the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Stepping response can be obtained in infants born &ge;32 weeks CA by holding the infant in a vertical position with",
"      <span class=\"nowrap\">",
"       his/her",
"      </span>",
"      feet in contact with a flat surface [",
"      <a class=\"abstract\" href=\"UTD.htm?14/10/14505/abstract/15\">",
"       15",
"      </a>",
"      ]. This initiates a slow alternate stepping action of flexion and extension of the legs (",
"      <a class=\"graphic graphic_figure graphicRef66214 \" href=\"UTD.htm?30/52/31552\">",
"       figure 3",
"      </a>",
"      ).",
"      <br/>",
"      <br/>",
"      Vertical suspension measures the strength of the neonate's shoulder girdle. The examiner holds the infant in an upright position by placing the hands under the arms and around the chest with feet unsupported (",
"      <a class=\"graphic graphic_figure graphicRef56025 \" href=\"UTD.htm?29/46/30434\">",
"       figure 4",
"      </a>",
"      ). Vertical suspension is also helpful in evaluating for subtle increases in muscle tone in the lower extremities. In the presence of lower extremity hypertonicity, there may be adduction at the hips combined with hyperextension at the knees and ankles. The lower extremities may appear to cross over each other (scissoring posture).",
"     </li>",
"     <li>",
"      Head control &mdash; By 40 weeks CA, the infant has sufficient neck and truncal strength to maintain the head in line with the trunk for one to two seconds while being pulled from a supine to sitting position (",
"      <a class=\"graphic graphic_figure graphicRef79753 \" href=\"UTD.htm?41/45/42707\">",
"       figure 5",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Ventral suspension measures the strength of the infant's trunk and neck. The infant is held in a suspended prone position in the air by placing a hand under the chest. A normal term infant will keep",
"      <span class=\"nowrap\">",
"       his/her",
"      </span>",
"      head in the horizontal plan momentarily with flexion of both the upper and lower extremities (",
"      <a class=\"graphic graphic_figure graphicRef65156 \" href=\"UTD.htm?28/38/29282\">",
"       figure 6",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Abnormal motor exam",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypotonia (decrease muscle tone) is the most common motor abnormality. When associated with weakness and absent tendon reflexes, it suggests the likelihood of a disorder of the anterior horn cells of the spinal cord or the peripheral nerves or muscle (the motor unit). When hypotonia is associated with relative preservation of mobility and with tendon reflexes that are brisk or exaggerated, it is likely that hypotonia is of the central nervous system origin, such as seen in an infant with Down syndrome. Of note, it is difficult to identify a motor abnormality in premature infants with gestational ages below 28 to 30 weeks because of their premature tone, posture, and motility.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Hypotonia",
"    </span>",
"    &nbsp;&mdash;&nbsp;The hypotonic term infant lies supine in a frog-like position with the hips abducted and the limbs abnormally extended [",
"    <a class=\"abstract\" href=\"UTD.htm?14/10/14505/abstract/6\">",
"     6",
"    </a>",
"    ]. Spontaneous activity is decreased. Decreased muscle tone can also be recognized when the following are observed:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Vertical suspension &mdash; Decreased tone of the shoulder girdle allows the infant to slip through the examiner's hands and the legs are extended (",
"      <a class=\"graphic graphic_figure graphicRef56025 \" href=\"UTD.htm?29/46/30434\">",
"       figure 4",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Ventral suspension &mdash; The infant appears limp with the extended limbs and the head drooping (",
"      <a class=\"graphic graphic_figure graphicRef65156 \" href=\"UTD.htm?28/38/29282\">",
"       figure 6",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Head control &mdash; The head lags behind as the infant is pulled from the supine to sitting position and continues to lag when the sitting position is reached (",
"      <a class=\"graphic graphic_figure graphicRef79753 \" href=\"UTD.htm?41/45/42707\">",
"       figure 5",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Neonatal hypotonia is caused by a variety of conditions that affect the central nervous system (brain or spinal cord), peripheral nervous system, or skeletal muscles (",
"    <a class=\"graphic graphic_table graphicRef66572 \" href=\"UTD.htm?27/44/28365\">",
"     table 5",
"    </a>",
"    ). These disorders and the approach to an infant with hypotonia are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/48/11015?source=see_link\">",
"     \"Overview of peripheral nerve and muscle disorders causing hypotonia in the newborn\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/13/34004?source=see_link\">",
"     \"Approach to the infant with hypotonia and weakness\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Hypertonia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypertonia is less common than hypotonia. It is associated with dysfunction of the pyramidal or extrapyramidal systems. Spasticity is a form of hypertonia that accompanies pyramidal tract dysfunction. It is characterized by an abnormal lengthening-shortening reaction of the muscle that is most apparent in the distal portion of extremities. On passive movement of the limb, a \"clasp knife\" type of resistance is felt. Rigidity is associated with increased resistance to movement throughout the range of motion of the joint. It may be proximal or distal, and has the feel of bending a \"lead pipe\" or a \"cog wheel\". Sometimes it is difficult to determine whether the newborn hypertonia is due to spasticity or rigidity. Congenital brain anomalies and hypoxic-ischemic lesions are the most common etiologies of hypertonia.",
"   </p>",
"   <p>",
"    Opisthotonus (ie, persistent arching of the neck and trunk) is caused by decreased cerebral cortical inhibition of the labyrinthine-brainstem-spinal cord motor projections that mediate extension of the trunk and proximal extremities. It is associated with moderate to severe acute bilirubin encephalopathy or a severe, diffuse disturbance of cortical function. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/63/25593?source=see_link\">",
"     \"Clinical manifestations of unconjugated hyperbilirubinemia in term and late preterm infants\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/0/23562?source=see_link\">",
"     \"Congenital cytogenetic abnormalities\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     CRANIAL NERVES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     CN I and XI",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although a response to peppermint smell in the form of alerting or stereotyped sucking can be elicited as early as 32 weeks CA, smell (I) is rarely tested in the neonate [",
"    <a class=\"abstract\" href=\"UTD.htm?14/10/14505/abstract/17\">",
"     17",
"    </a>",
"    ]. Cranial nerve (CN) XI is also rarely tested because it is difficult to assess the function of the sternocleidomastoid muscle in the newborn.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Cranial nerve II",
"    </span>",
"    &nbsp;&mdash;&nbsp;Visual responses mature with CA [",
"    <a class=\"abstract\" href=\"UTD.htm?14/10/14505/abstract/14\">",
"     14",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      At 26 weeks CA, infants consistently blink to light.",
"     </li>",
"     <li>",
"      At 32 weeks CA, infants begin to show signs of fixation.",
"     </li>",
"     <li>",
"      At 34 weeks CA, most infants can track a fluffy ball of red wool.",
"     </li>",
"     <li>",
"      At 37 weeks CA, infants will turn their eyes towards a soft light.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A response to an opticokinetic stimulus is present in the majority of infants by 36 weeks CA and can be observed by using commercially available drums or with tapes made of alternating black and white stripes.",
"   </p>",
"   <p>",
"    It is difficult to directly examine the optic fundi in the newborn because of the small pupil size. Indirect ophthalmoscopy can be requested dependent upon the clinical setting.",
"   </p>",
"   <p>",
"    Intact cranial nerves II and III are necessary for a pupillary light response, which is consistently present by 35 weeks gestation [",
"    <a class=\"abstract\" href=\"UTD.htm?14/10/14505/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     CN III, IV, and VI",
"    </span>",
"    &nbsp;&mdash;&nbsp;Extraocular movements can be evaluated by observation of spontaneous eye movements or by the use of the Doll's eye phenomenon, which assesses the vestibuloocular response (VOR).",
"   </p>",
"   <p>",
"    The Doll's eye maneuver test can be performed as early as 25 weeks CA [",
"    <a class=\"abstract\" href=\"UTD.htm?14/10/14505/abstract/14\">",
"     14",
"    </a>",
"    ]. The test entails moving the head and neck from side to side, which leads to eye deviation to the opposite side. The conjugate deviation of the eyes in the opposite direction demonstrates intact eye adduction (III) and abduction (VI). Another method to demonstrate VOR is for the examiner to spin in one direction while holding the infant upright and supporting the neck. The eyes should deviate in the opposite direction to the spin. The neck can be flexed and extended in a similar manner to the doll's test to produce vertical eye movements (IV).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Abnormal eye movements",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following abnormal eye movements may be associated with neurologic problems:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Spontaneous, horizontal, unidirectional, jerky eye movements may be associated with a seizure originating in the opposite frontal lobe.",
"     </li>",
"     <li>",
"      Tonic horizontal deviation of the eyes to one side suggests a destructive central nervous system (CNS) lesion in the hemisphere, towards which the eyes are deviated.",
"     </li>",
"     <li>",
"      Tonic downward gaze deviation may indicate raised intracranial pressure due to pressure in the pretectal region of the brainstem.",
"     </li>",
"     <li>",
"      Skew eye deviation, in which the eyes are at different horizontal planes, suggest metabolic brainstem dysfunction. It is most commonly observed after hypoxic ischemic encephalopathy.",
"     </li>",
"     <li>",
"      A unilaterally dilated and poorly reactive pupil in a comatose patient is a marker for ipsilateral uncal herniation.",
"     </li>",
"     <li>",
"      A unilaterally constricted pupil on the side of a flaccid, immobile upper extremity may indicate pupillary sympathetic paralysis due to brachial nerve injury involving the C8-T1 nerve roots (ie, partial Horner's syndrome). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/32/32262?source=see_link\">",
"       \"Horner's syndrome\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Cranial nerve V",
"    </span>",
"    &nbsp;&mdash;&nbsp;The response to tactile stimuli, such as tissue paper or pinprick, over the face assesses cranial nerve V. This includes the corneal reflex in which gentle, tactile stimulation of the cornea with a tissue paper results in an ipsilateral and consensual blink response.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Cranial nerve VII",
"    </span>",
"    &nbsp;&mdash;&nbsp;The normal newborn is able to close both eyelids during vigorous crying. In the presence of a peripheral VII nerve lesion, the eyelid may not close, and the nasolabial furrow may be less prominent on the affected side. In addition, sucking may be less vigorous with drooling of saliva or milk from the affected side.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Cranial nerve VIII",
"    </span>",
"    &nbsp;&mdash;&nbsp;By 28 weeks gestation, the infant startles or blinks to a sudden loud noise [",
"    <a class=\"abstract\" href=\"UTD.htm?14/10/14505/abstract/14\">",
"     14",
"    </a>",
"    ]. During quiet wakefulness, term infants respond to the sound of a bell, rattle, hand clap, or voice by a startle response or an increase in their state of alertness. The consistent absence of a response does not signify hearing loss but does indicate that audiometry should be performed. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/19/44344?source=see_link\">",
"     \"Evaluation of hearing impairment in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Sucking/swallowing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Muscle function for sucking and swallowing is mediated through branches of cranial nerves V, VII, IX, X, and XII. Sucking patterns that are similar to term infants begin to appear around 33 and 34 weeks gestation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/4/21576?source=see_link\">",
"     \"Sucking and swallowing disorders in the newborn\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h3\">",
"     CNs IX and X",
"    </span>",
"    &nbsp;&mdash;&nbsp;Impairment of cranial nerves IX and X is associated with difficulty in swallowing, diminished soft palatal movements, and a weak or absent gag reflex.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Cranial nerve XII",
"    </span>",
"    &nbsp;&mdash;&nbsp;The tongue is innervated by cranial nerve XII. Atrophy and fasciculations of the tongue (slow undulating movement of the surface of the tongue) suggest degeneration of the hypoglossal nucleus, which is seen in patients with type I (infantile) spinal muscular atrophy. Deviation of the tongue to one side usually implies ipsilateral XII nerve palsy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/9/8344?source=see_link\">",
"     \"Spinal muscular atrophy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h1\">",
"     REFLEXES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Testing of reflexes provides information on the integrity of the central and peripheral nervous system.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Tendon",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the newborn, tendon reflexes may be difficult to obtain and interpret. The assessment is most useful when the reflexes are consistently absent or asymmetric. As with all parts of the neurologic examination, the information should be interpreted in the context of other findings. As an example, the absence of a biceps reflex is likely not significant when the infant has a normal resting posture and symmetrical spontaneous movement.",
"   </p>",
"   <p>",
"    The following tendon reflexes can be elicited in the newborn infant generally after 33 weeks gestation. An examiner's finger that is placed over the tendon to be tested can be lightly struck with a percussion hammer to elicit the reflex.",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Jaw &mdash; Tapping the chin with the mouth slightly open leads to slight jaw closure.",
"     </li>",
"     <li>",
"      Biceps &mdash; With the elbow flexed, tapping the biceps tendon in the antecubital fossa leads to flexion at the elbow.",
"     </li>",
"     <li>",
"      Brachioradialis (supinator) &mdash; Tapping above the wrist on the radial aspect of the forearm leads to flexion at the elbow.",
"     </li>",
"     <li>",
"      Knee (patellar) &mdash; Tapping the quadriceps tendon below the patella leads to extension of the knee.",
"     </li>",
"     <li>",
"      Ankle (Achilles) &mdash; With the knee in the flexed position, tapping the Achilles tendon leads to flexion at the ankle.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In the newborn, it is difficult to elicit the triceps reflex because of strong flexion of the elbows in the normal neonatal resting posture.",
"   </p>",
"   <p>",
"    Lower motor neuron lesions are generally associated with diminished to absent tendon reflex responses, while upper motor neuron lesions elicit exaggerated responses. Altitudinal dissociation in the amplitude of the tendon reflexes is helpful in determining the level of a spinal cord lesion. An intact jaw jerk combined with absent biceps, brachioradialis, knee, and ankle reflexes in a flaccid immobile infant suggests a cervical spinal cord lesion. Similarly, the combination of normal jaw, biceps, and supinator reflexes with an absent patellar response may indicate a thoracic or lumbar spinal cord lesion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h2\">",
"     Superficial",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following superficial reflexes can be elicited in the newborn:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Abdominal reflexes in each of the four quadrants of the abdomen are elicited by gentle stroking in an axial to peripheral direction, resulting in contraction of the abdominal wall. The absence of response may be consistent with an ipsilateral pyramidal tract lesion.",
"     </li>",
"     <li>",
"      In males, the cremasteric reflex can be demonstrated by stroking the inner thigh area in an anterior to posterior direction, which results in ipsilateral scrotal retraction and testicular rise due to contraction of the scrotal dartos muscle. The lack of response or an asymmetrical response may be consistent with a corticospinal tract abnormality.",
"     </li>",
"     <li>",
"      Anal wink reflex is elicited by gentle stroking of the perianal region, which results in contraction of the perianal muscle. The absence of may be consistent compatible with a spinal cord lesion.",
"     </li>",
"     <li>",
"      Corneal reflex (see",
"      <a class=\"local\" href=\"#H26\">",
"       'Cranial nerve V'",
"      </a>",
"      above).",
"     </li>",
"     <li>",
"      In the newborn infant, an extensor plantar response (Babinski) may be normally elicited in a term infant when the plantar surface of the foot is stroked with a pointed but not sharp object. However, an extensor plantar response may be indicative of corticospinal tract lesions, if it is consistent and persistent on one side, and there is a plantar flexor response on the contralateral side.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h2\">",
"     Developmental",
"    </span>",
"    &nbsp;&mdash;&nbsp;Developmental reflexes, also called primitive reflexes, are mediated at the brainstem or spinal cord level and are generally present at birth (",
"    <a class=\"graphic graphic_table graphicRef58453 \" href=\"UTD.htm?26/3/26684\">",
"     table 6",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/10/14505/abstract/15,18-22\">",
"     15,18-22",
"    </a>",
"    ]. They resolve in a fairly set time course with maturation of descending, inhibitory projections from the cerebral cortex. These reflexes may persist or reappear later in life in the presence of degenerative disorders.",
"   </p>",
"   <p>",
"    The developmental reflexes include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Moro reflex &mdash; Moro reflex is elicited by the sudden dropping of the infant's head in relation to the trunk. It results in abduction and extension of the infant's arms and opening of the hands, followed by flexion (",
"      <a class=\"graphic graphic_figure graphicRef68117 \" href=\"UTD.htm?12/15/12530\">",
"       figure 7",
"      </a>",
"      ). It is present starting at 32 weeks gestation, well-established by 37 weeks gestation, and disappears by three to six months of age [",
"      <a class=\"abstract\" href=\"UTD.htm?14/10/14505/abstract/14\">",
"       14",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Stepping reflex is obtained by holding the infant in a vertical position with the feet in contact with a flat surface [",
"      <a class=\"abstract\" href=\"UTD.htm?14/10/14505/abstract/15\">",
"       15",
"      </a>",
"      ]. This initiates a slow alternate stepping action of flexion and extension of the legs (",
"      <a class=\"graphic graphic_figure graphicRef66214 \" href=\"UTD.htm?30/52/31552\">",
"       figure 3",
"      </a>",
"      ). It is present starting at 32 weeks gestation and disappears by one to two months of age [",
"      <a class=\"abstract\" href=\"UTD.htm?14/10/14505/abstract/14\">",
"       14",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Grasp reflexes (palmar and plantar) are well established by 32 weeks of age [",
"      <a class=\"abstract\" href=\"UTD.htm?14/10/14505/abstract/14\">",
"       14",
"      </a>",
"      ] and disappear by three months of age (",
"      <a class=\"graphic graphic_figure graphicRef74355 \" href=\"UTD.htm?10/8/10383\">",
"       figure 8",
"      </a>",
"      ). The absence of the plantar grasp reflex in the term newborn has been reported to be associated with an increased risk of developing cerebral palsy [",
"      <a class=\"abstract\" href=\"UTD.htm?14/10/14505/abstract/23\">",
"       23",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Asymmetrical tonic neck reflex (ATNR) is characterized by extension of the upper and lower extremities on the side to which the head and neck is turned with flexion of the contralateral upper extremity (fencing posture) (",
"      <a class=\"graphic graphic_figure graphicRef75985 \" href=\"UTD.htm?16/44/17088\">",
"       figure 9",
"      </a>",
"      ). This reflex is due to decreased inhibition of the labyrinthine-brainstem-spinal cord pathway that subserves limb extension. ATNR that is seen as a resting posture rather than being elicited is never normal. ATNR appears at 35 weeks gestation, is well-established by one month postnatal age, and disappears by three to four months of age in a term infant [",
"      <a class=\"abstract\" href=\"UTD.htm?14/10/14505/abstract/14\">",
"       14",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Galant reflex (trunk incurvation) is obtained by placing the baby in ventral suspension and then stroking the paravertebral region from the thorax to the lumbar area. This will elicit movement of the infant's trunk and hips towards the side of the stimulus.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h1\">",
"     SENSORY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The neonatal assessment of sensation is challenging because it is difficult to accurately determine an infant's response to sensory stimuli. As a result, sensory assessment is limited or not generally performed as part of the neonatal neurologic examination.",
"   </p>",
"   <p>",
"    Perioral tactile sensation can be evaluated by the rooting response in which gentle stroking of the cheek results in the infant turning towards the stimulus with an open mouth ready to latch onto the object [",
"    <a class=\"abstract\" href=\"UTD.htm?14/10/14505/abstract/20\">",
"     20",
"    </a>",
"    ]. In a patient with a spinal cord lesion, there may be loss of pinprick sensation on the trunk or neck, below the level of the lesion. This is probably the one situation in the newborn where testing sensation with a pinprick provides useful information. Otherwise, testing in the newborn with pinpricks provides little useful information.",
"   </p>",
"   <p>",
"    Assessment of pain is also difficult in the newborn and is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/7/31863?source=see_link\">",
"     \"Assessment of neonatal pain\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h1\">",
"     BEHAVIORAL EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Evaluation of neonatal behavior assesses higher cortical function. Several behavioral neonatal assessment tools have been developed, including the Neonatal Behavioral Assessment Scale (NBAS). The NBAS includes 27 behavioral responses and 20 reflex items, and takes about 20 minutes to administer [",
"    <a class=\"abstract\" href=\"UTD.htm?14/10/14505/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The following two key elements from the NBAS are incorporated into the neurological examination:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Consolability &mdash; Consolability is easiest to assess in a crying infant. A number of techniques are used to try to calm the infant within 15 seconds. They include infant sucking on a pacifier or the examiner's finger, holding, rocking, placing a hand on the infant's belly, restraining one or both arms of the infant, soothing by voice, or a combination of a soothing voice and the examiner's face approaching the infant. Infants with brain injury are more difficult to console than a normal infant.",
"     </li>",
"     <li>",
"      Habituation &mdash; Habituation is a marker of cortical inhibitory function and measures the infant's ability to learn to diminish their response to repetitive stimuli. The use of repeating light or auditory stimuli are used to test for habituation. The shining of a soft light initially elicits a blinking response that diminishes in intensity over the first four to five trials, and afterwards ceases with subsequent trials. Similarly, auditory stimuli, such as hand claps, elicit a startle response to the first four or five stimuli, and after which there is little to no response. The lack of habituation is compatible with cortical dysfunction, which may be present in an infant with prenatal substance abuse exposure.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38\">",
"    <span class=\"h1\">",
"     INTERPRETATION AND PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The newborn neurologic examination has some limitations in its specificity and its ability to predict long-term outcome, in part due to the number of factors that can affect the results of the newborn neurologic examination.",
"   </p>",
"   <p>",
"    Nevertheless, abnormal neurologic findings can be useful in guiding care and predicting outcome in the following manner:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      It can define the site and extent of injury, which guides the choice of further management decisions. As an example, the neurologic examination is an important component in making the diagnosis of encephalopathy and determining its severity. The severity of encephalopathy guides management decisions, including the use of hypothermia. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/24/2442?source=see_link\">",
"       \"Clinical features, diagnosis, and treatment of neonatal encephalopathy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Persistent neurologic dysfunction is associated with an increased risk of permanent disability. As an example, preterm infants with abnormal neurologic examination at the time of discharge compared to those with a normal examination have an increased risk of long-term motor impairment (eg, cerebral palsy) [",
"      <a class=\"abstract\" href=\"UTD.htm?14/10/14505/abstract/24,25\">",
"       24,25",
"      </a>",
"      ]. The risk of cerebral palsy increases in infants with persistent marked hypotonia, weak cry, poor sucking, and decreased level of activity. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/50/41768?source=see_link\">",
"       \"Epidemiology and etiology of cerebral palsy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Persistent asymmetric findings often are associated with an underlying abnormality, and should be further evaluated.",
"     </li>",
"     <li>",
"      Composites of neurologic findings appear to be better predictors of outcome than isolated neurologic findings. As an example, the Prechtl test, which is based upon classifying neurologic abnormalities into five neurologic syndromes, is reported to be a good predictor of neurological outcome at two years of age [",
"      <a class=\"abstract\" href=\"UTD.htm?14/10/14505/abstract/4,26\">",
"       4,26",
"      </a>",
"      ]. Results of testing performed at corrected term age are divided into normal (none of the syndromes), abnormal (presence of one or more syndromes), or suspect examinations (some symptoms of a syndrome). In one study of preterm infants (gestational age &lt;30 weeks), the group with an abnormal Prechtl test was most likely to have abnormal Bayley Mental and Psychomotor Developmental Index scores at 24 months corrected age, followed by those with suspect results, and the normal group was least likely to have an abnormal Bayley scores [",
"      <a class=\"abstract\" href=\"UTD.htm?14/10/14505/abstract/26\">",
"       26",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H39\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A comprehensive neurologic assessment should be performed in any neonate that is suspected to have a neurologic abnormality either based upon history (eg, perinatal asphyxia) or a finding during routine neonatal assessment. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/21/24922?source=see_link\">",
"     \"Assessment of the newborn infant\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Findings on the neurologic examination vary with gestational age and the infant's level of alertness. Serial examinations are sometimes necessary to reliably confirm a neurologic finding. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Overview'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H5\">",
"     'Level of alertness'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The newborn neurologic examination can be useful in guiding care and predicting outcome. However, there are limitations in its specificity and prognostic ability, partly due to the number of factors that affect the results of the examination. (See",
"    <a class=\"local\" href=\"#H38\">",
"     'Interpretation and prognosis'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The neurologic examination includes the following components:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      General assessment includes the vital signs, determination of the conceptional age (CA) of the infant and whether the infant's birth weight is appropriate for CA, a thorough examination of the head and spine, and identification of abnormalities suggestive of an underlying congenital disorder with associated neurologic problems. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'General evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Motor function assessment is based upon evaluation of passive tone and posture, and active motor activity. Hypotonia is the most commonly identified motor abnormality, and is due to a variety of neurologic and muscular disorders (",
"      <a class=\"graphic graphic_table graphicRef61045 \" href=\"UTD.htm?24/5/24669\">",
"       table 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Motor function'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Cranial nerve (CN) development varies with CA. In general, CNs I and XI are not tested in the neonates. The assessment of extraocular movements (CNs III, IV, VI) is based upon observation of spontaneous eye movements or the infant's response to the Doll's eyes test. Observation of the infant's sucking and swallowing assesses CNs V, VII, IX, X, and XII. Impaired gag reflex and decreased movement of the soft palate suggest dysfunction of cranial nerves IX or X. Fasciculations over the tongue are seen with degeneration of the hypoglossal (cranial nerve XII) nucleus.",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Cranial nerves'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Reflex examination provides information on the integrity of the central and peripheral nervous system, and includes evaluation of deep tendon, superficial, and developmental (also referred to as primitive) reflexes. Developmental reflexes (eg, Moro, stepping, grasp, and asymmetrical tonic neck reflex) require coordination of multiple muscles and nerves (",
"      <a class=\"graphic graphic_figure graphicRef68117 \" href=\"UTD.htm?12/15/12530\">",
"       figure 7",
"      </a>",
"      and",
"      <a class=\"graphic graphic_figure graphicRef66214 \" href=\"UTD.htm?30/52/31552\">",
"       figure 3",
"      </a>",
"      and",
"      <a class=\"graphic graphic_figure graphicRef74355 \" href=\"UTD.htm?10/8/10383\">",
"       figure 8",
"      </a>",
"      and",
"      <a class=\"graphic graphic_figure graphicRef75985 \" href=\"UTD.htm?16/44/17088\">",
"       figure 9",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H32\">",
"       'Reflexes'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Sensory &mdash; Sensory assessment is not generally performed as part of neonatal neurologic examination because it is difficult to accurately determine an infant's response to sensory stimuli. (See",
"      <a class=\"local\" href=\"#H36\">",
"       'Sensory'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Behavioral &mdash; Evaluation of neonatal behavior including consolability and habituation assesses higher cortical functions. (See",
"      <a class=\"local\" href=\"#H37\">",
"       'Behavioral evaluation'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/10/14505/abstract/1\">",
"      Amiel-Tison C. Neurological evaluation of the maturity of newborn infants. Arch Dis Child 1968; 43:89.",
"     </a>",
"    </li>",
"    <li>",
"     Brazelton, T, Nugent, K. Neonatal Behavior Assessment Scale, 3rd ed, Mac Keith Press, London 1995.",
"    </li>",
"    <li>",
"     Dubowitz, LMS, Dubowitz, V, Mercuri, E. The neurological assessment of the preterm and full-term infant, 2nd ed, Mac Keith Press, London 1999.",
"    </li>",
"    <li>",
"     Prechtl, H. The neurological examination of the full term infant, 2nd ed, London 1977.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/10/14505/abstract/5\">",
"      Sheridan-Pereira M, Ellison PH, Helgeson V. The construction of a scored neonatal neurological examination for assessment of neurological integrity in full-term neonates. J Dev Behav Pediatr 1991; 12:25.",
"     </a>",
"    </li>",
"    <li>",
"     Als, H, Lester, B, Tronic,k E, Brazelton, TB. Manual for the assessment of preterm infants' behavior (APIB). In: Theory and Research in Behavioral Pediatrics, Fitzgerald, H, Lster, B, Yogman, M (Eds), Plenum Press, New York p. 65.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/10/14505/abstract/7\">",
"      Morgan AM, Koch V, Lee V, Aldag J. Neonatal neurobehavioral examination. A new instrument for quantitative analysis of neonatal neurological status. Phys Ther 1988; 68:1352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/10/14505/abstract/8\">",
"      Campbell, S, Osten, E, Kolobe, T, Fisher, AG. Development of the test of infant motor performance. Physical and Medical Rehabilitation Clinics. 1993; 4:541.",
"     </a>",
"    </li>",
"    <li>",
"     Prechtl, H. The neurological examination of the full term newborn infant. Clinics in Developmental Medicine, No. 63, Spastics International Medical Publications, London 1977.",
"    </li>",
"    <li>",
"     Kroner, A, Thom, VA. Neurobehavioral assessment of the preterm infant, The Psychological Corporation, New York 1991.",
"    </li>",
"    <li>",
"     Swaiman, KF. Neurological examination of the term and preterm infant. In Pediatric Neurology. In: Principles and Practice, 4th ed, Swaiman, KF, Ashwal, S, Ferriero, DM (Eds), Mosby Elsevier, Philadelphia 2006. p.47.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/10/14505/abstract/12\">",
"      Paine, RS. Neurological examination of infants and children. Pediatr Clin North Am 1960; 7:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/10/14505/abstract/13\">",
"      Majnemer A, Mazer B. Neurologic evaluation of the newborn infant: definition and psychometric properties. Dev Med Child Neurol 1998; 40:708.",
"     </a>",
"    </li>",
"    <li>",
"     Volpe JJ. The neurological examination: normal and abnormal features. In: Neurology of the newborn, Saunders/Elseviar, Philadelphia 2008. p.121.",
"    </li>",
"    <li>",
"     Larsen, PD, Stensass, SS. PediNeurologic Exam. University of Utah School of Medicine, 2005, file://library.med.utah.edu/pedineurologicexam.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/10/14505/abstract/16\">",
"      Bax M. Neurological examination of the newborn. Dev Med Child Neurol 1998; 40:651.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/10/14505/abstract/17\">",
"      Sarnat HB. Olfactory reflexes in the newborn infant. J Pediatr 1978; 92:624.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/10/14505/abstract/18\">",
"      Shevell M. The tripartite origins of the tonic neck reflex: Gesell, Gerstmann, and Magnus. Neurology 2009; 72:850.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/10/14505/abstract/19\">",
"      Zafeiriou DI. Primitive reflexes and postural reactions in the neurodevelopmental examination. Pediatr Neurol 2004; 31:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/10/14505/abstract/20\">",
"      Sheppard JJ, Mysak ED. Ontogeny of infantile oral reflexes and emerging chewing. Child Dev 1984; 55:831.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/10/14505/abstract/21\">",
"      Allen MC, Capute AJ. The evolution of primitive reflexes in extremely premature infants. Pediatr Res 1986; 20:1284.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/10/14505/abstract/22\">",
"      Capute AJ, Palmer FB, Shapiro BK, et al. Primitive reflex profile: a quantitation of primitive reflexes in infancy. Dev Med Child Neurol 1984; 26:375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/10/14505/abstract/23\">",
"      Futagi Y, Suzuki Y, Goto M. Clinical significance of plantar grasp response in infants. Pediatr Neurol 1999; 20:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/10/14505/abstract/24\">",
"      Nelson KB, Ellenberg JH. Neonatal signs as predictors of cerebral palsy. Pediatrics 1979; 64:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/10/14505/abstract/25\">",
"      Allen MC, Capute AJ. Neonatal neurodevelopmental examination as a predictor of neuromotor outcome in premature infants. Pediatrics 1989; 83:498.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/10/14505/abstract/26\">",
"      Maas YG, Mirmiran M, Hart AA, et al. Predictive value of neonatal neurological tests for developmental outcome of preterm infants. J Pediatr 2000; 137:100.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5036 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-217.16.9.173-04C97D187A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_10_14505=[""].join("\n");
var outline_f14_10_14505=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H39\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      OVERVIEW",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      GENERAL EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Observation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Level of alertness",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Head",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Head size",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Fontanel",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Sutures",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Scalp swelling",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Auscultation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Transillumination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Spine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Associated findings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      MOTOR FUNCTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Passive tone/posture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Active muscle function",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Abnormal motor exam",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Hypotonia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Hypertonia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      CRANIAL NERVES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      CN I and XI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Cranial nerve II",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      CN III, IV, and VI",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Abnormal eye movements",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Cranial nerve V",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Cranial nerve VII",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Cranial nerve VIII",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Sucking/swallowing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      - CNs IX and X",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Cranial nerve XII",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      REFLEXES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Tendon",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      Superficial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      Developmental",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      SENSORY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      BEHAVIORAL EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H38\">",
"      INTERPRETATION AND PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H39\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/5036\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5036|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?25/63/26615\" title=\"figure 1\">",
"      New Ballard Score 1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?15/3/15411\" title=\"figure 2\">",
"      Neonatal extracranial and intracranial birth injuries",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?30/52/31552\" title=\"figure 3\">",
"      Stepping response",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?29/46/30434\" title=\"figure 4\">",
"      Neonatal vertical suspension",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?41/45/42707\" title=\"figure 5\">",
"      Head control",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?28/38/29282\" title=\"figure 6\">",
"      Ventral suspension",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?12/15/12530\" title=\"figure 7\">",
"      Moro reflex",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?10/8/10383\" title=\"figure 8\">",
"      Plantar grasp",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?16/44/17088\" title=\"figure 9\">",
"      Infant asymmetric tonic neck reflex",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5036|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?35/54/36707\" title=\"picture 1\">",
"      Head circumference measure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?17/3/17471\" title=\"picture 2\">",
"      Lumbosacral hemangioma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5036|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?30/43/31421\" title=\"table 1\">",
"      New Ballard Score 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?24/5/24669\" title=\"table 2\">",
"      Syndromic microcephaly",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/2/16429\" title=\"table 3\">",
"      Etiology of microcephaly",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?6/50/6957\" title=\"table 4\">",
"      Etiology of macrocephaly",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?27/44/28365\" title=\"table 5\">",
"      Newborn neuromuscular disorders",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?26/3/26684\" title=\"table 6\">",
"      Developmental reflexes",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/13/34004?source=related_link\">",
"      Approach to the infant with hypotonia and weakness",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/7/31863?source=related_link\">",
"      Assessment of neonatal pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/21/24922?source=related_link\">",
"      Assessment of the newborn infant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/53/2906?source=related_link\">",
"      Brachial plexus syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/24/2442?source=related_link\">",
"      Clinical features, diagnosis, and treatment of neonatal encephalopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/63/25593?source=related_link\">",
"      Clinical manifestations of unconjugated hyperbilirubinemia in term and late preterm infants",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/0/23562?source=related_link\">",
"      Congenital cytogenetic abnormalities",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/6/13417?source=related_link\">",
"      Congenital myopathies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/51/36664?source=related_link\">",
"      Cytomegalovirus infection and disease in newborns, infants, children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/50/41768?source=related_link\">",
"      Epidemiology and etiology of cerebral palsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/54/3946?source=related_link\">",
"      Etiology and evaluation of macrocephaly in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/51/36665?source=related_link\">",
"      Etiology and evaluation of microcephaly in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/19/44344?source=related_link\">",
"      Evaluation of hearing impairment in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/32/32262?source=related_link\">",
"      Horner's syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/40/18058?source=related_link\">",
"      Hyperkinetic movement disorders in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/47/22265?source=related_link\">",
"      Neonatal birth injuries",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/43/24246?source=related_link\">",
"      Neurologic complications of bacterial meningitis in the neonate",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/37/10841?source=related_link\">",
"      Overview of craniosynostosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/48/11015?source=related_link\">",
"      Overview of peripheral nerve and muscle disorders causing hypotonia in the newborn",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/62/33767?source=related_link\">",
"      Pathophysiology and clinical manifestations of myelomeningocele (spina bifida)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/35/22068?source=related_link\">",
"      Postnatal assessment of gestational age",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/57/3991?source=related_link\">",
"      Primary (congenital) encephalocele",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/9/8344?source=related_link\">",
"      Spinal muscular atrophy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/39/4727?source=related_link\">",
"      Sturge-Weber syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/4/21576?source=related_link\">",
"      Sucking and swallowing disorders in the newborn",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/38/34410?source=related_link\">",
"      Tuberous sclerosis complex: Genetics, clinical features, and diagnosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f14_10_14506="Hepatic encephalopathy: Pathogenesis";
var content_f14_10_14506=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"6\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Hepatic encephalopathy: Pathogenesis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/10/14506/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/10/14506/contributors\">",
"     Peter Ferenci, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/10/14506/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/10/14506/contributors\">",
"     Bruce A Runyon, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/10/14506/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/10/14506/contributors\">",
"     Anne C Travis, MD, MSc, FACG",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?14/10/14506/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 20, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hepatic encephalopathy (HE) or portosystemic encephalopathy (PSE) is a reversible syndrome of impaired brain function occurring in patients with advanced liver failure. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/22/34153?source=see_link\">",
"     \"Clinical manifestations and diagnosis of hepatic encephalopathy\"",
"    </a>",
"    .) However, HE is not a single clinical entity. It may reflect either a reversible metabolic encephalopathy, brain atrophy, brain edema, or any combination of these conditions. The mechanisms causing brain dysfunction in liver failure are still unknown. In advanced coma, the effects of brain swelling, impaired cerebral perfusion, and reversible impairment of neurotransmitter systems cannot be distinguished. Furthermore, these events overlap, at least in models of acute liver failure.",
"   </p>",
"   <p>",
"    Data on cerebral function in HE are usually derived from animal studies since brains of patients with HE cannot be studied with neurochemical or neurophysiologic methods. It is beyond the scope of this review to discuss each of the animal models in detail, but it must be appreciated that they may not accurately reflect human disease.",
"   </p>",
"   <p>",
"    The metabolic factors that contribute to the development of HE will be reviewed here [",
"    <a class=\"abstract\" href=\"UTD.htm?14/10/14506/abstract/1\">",
"     1",
"    </a>",
"    ]. Ammonia is clearly implicated; in addition, there may be a role for inhibitory neurotransmission through gamma-aminobutyric acid (GABA) receptors in the central nervous system (CNS) and changes in central neurotransmitters and circulating amino acids. These hypotheses are not mutually exclusive, and multiple factors may be present at the same time. Currently available therapies for hepatic encephalopathy are based upon these hypotheses. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/15/4346?source=see_link\">",
"     \"Hepatic encephalopathy in adults: Treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    These factors are directly related to liver failure (eg, decreased metabolism of ammonia). In addition, concurrent disorders can contribute to the development of HE. These include (",
"    <a class=\"graphic graphic_table graphicRef50440 \" href=\"UTD.htm?0/34/556\">",
"     table 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Decreased oxygen delivery, which can result from a variety of factors including gastrointestinal bleeding, sepsis, the effects of cytokines or compounds released from necrotic liver tissue [",
"      <a class=\"abstract\" href=\"UTD.htm?14/10/14506/abstract/2\">",
"       2",
"      </a>",
"      ]. In particular, proinflammatory cytokines may have a pivotal role in impairing several brain functions [",
"      <a class=\"abstract\" href=\"UTD.htm?14/10/14506/abstract/3,4\">",
"       3,4",
"      </a>",
"      ]. The effects of hypotension on cerebral perfusion may be magnified in liver failure because of an associated impairment in the autoregulation of cerebral blood flow [",
"      <a class=\"abstract\" href=\"UTD.htm?14/10/14506/abstract/5,6\">",
"       5,6",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Functional and structural changes in cerebral function independent of the liver failure as in alcoholics, intravenous drug users, and patients with Wilson's disease.",
"     </li>",
"     <li>",
"      Creation of a portosystemic shunt to treat portal hypertension, as with a transjugular intrahepatic portosystemic shunt, precipitates HE in approximately 30 percent of patients. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/5/15448?source=see_link\">",
"       \"Complications of transjugular intrahepatic portosystemic shunts\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Other events which can precipitate HE such as the administration of sedatives, hypokalemia, and hyponatremia. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/12/17608?source=see_link\">",
"       \"Hyponatremia in patients with cirrhosis\"",
"      </a>",
"      .) The effect of hypokalemia is thought to be mediated by potassium movement out of the cells to replenish extracellular stores [",
"      <a class=\"abstract\" href=\"UTD.htm?14/10/14506/abstract/7\">",
"       7",
"      </a>",
"      ]. Electroneutrality is maintained in part by the movement of extracellular hydrogen into the cells; the ensuing intracellular acidosis in renal tubular cells increases the production of ammonia [",
"      <a class=\"abstract\" href=\"UTD.htm?14/10/14506/abstract/8\">",
"       8",
"      </a>",
"      ]. The often concurrent metabolic alkalosis may contribute by promoting the conversion of ammonium (NH4+), a charged particle which cannot cross the blood-brain barrier, into ammonia (NH3) which can enter the brain [",
"      <a class=\"abstract\" href=\"UTD.htm?14/10/14506/abstract/8\">",
"       8",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     NEUROTOXINS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Ammonia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ammonia is the best characterized neurotoxin that precipitates HE. The gastrointestinal tract is the primary source of ammonia, which enters the circulation via the portal vein. Ammonia is produced by enterocytes from glutamine and by colonic bacterial catabolism of nitrogenous sources, such as ingested protein and secreted urea. Another source of ammonia may be urea digested by H. pylori in the stomach [",
"    <a class=\"abstract\" href=\"UTD.htm?14/10/14506/abstract/9\">",
"     9",
"    </a>",
"    ], although the role of H. pylori in HE is unclear [",
"    <a class=\"abstract\" href=\"UTD.htm?14/10/14506/abstract/10\">",
"     10",
"    </a>",
"    ]. The intact liver clears almost all of the portal vein ammonia, converting it into glutamine and preventing entry into the systemic circulation. However, glutamine is metabolized in mitochondria yielding glutamate and ammonia, and glutamine-derived ammonia may interfere with mitochondrial function leading to astrocyte dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?14/10/14506/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The increase in blood ammonia in advanced liver disease is a consequence of impaired liver function and of shunting of blood around the liver. Muscle wasting, a common occurrence in these patients, also may contribute since muscle is an important site for extrahepatic ammonia removal.",
"   </p>",
"   <p>",
"    The arterial concentration of ammonia is increased in about 90 percent of patients with HE. Proof of the pathogenetic role of ammonia in HE has come from the efficacy of therapies aimed to lower plasma ammonia in improving HE (",
"    <a class=\"graphic graphic_table graphicRef64629 \" href=\"UTD.htm?18/9/18589\">",
"     table 2",
"    </a>",
"    ). Ammonia interferes with brain function at several sites, each of which can contribute to the development of encephalopathy. In addition, other toxins, such as mercaptans or short-chain fatty acids (C4 to C8), may potentiate ammonia toxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?14/10/14506/abstract/12\">",
"     12",
"    </a>",
"    ]. However, studies using positron emission tomography have illustrated that cerebral ammonia metabolism is not the only causal factor related to the development of hepatic encephalopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?14/10/14506/abstract/13\">",
"     13",
"    </a>",
"    ]. Some of the other factors that have been implicated will be described below. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/22/34153?source=see_link&amp;anchor=H15#H15\">",
"     \"Clinical manifestations and diagnosis of hepatic encephalopathy\", section on 'Magnetic resonance spectroscopy and positron emission tomography'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Impaired blood to brain transport of amino acids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hyperammonemia may increase the cerebral uptake of neutral amino acids by enhancing the activity of the L-amino acid transporter at the blood-brain barrier. This effect may be the consequence of the brain to blood transport of glutamine, which is formed in excess for ammonia removal [",
"    <a class=\"abstract\" href=\"UTD.htm?14/10/14506/abstract/14\">",
"     14",
"    </a>",
"    ]. Consistent with this hypothesis is the observation that transport of tryptophan into the brain is increased by ammonia infusions [",
"    <a class=\"abstract\" href=\"UTD.htm?14/10/14506/abstract/15\">",
"     15",
"    </a>",
"    ]. The ensuing elevation in the cerebral concentration of neutral amino acids tyrosine, phenylalanine, and tryptophan may affect the synthesis of the neurotransmitters dopamine, norepinephrine, and serotonin [",
"    <a class=\"abstract\" href=\"UTD.htm?14/10/14506/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Increase in intracellular osmolarity in astrocytes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Brain edema has been observed in acute hyperammonemia [",
"    <a class=\"abstract\" href=\"UTD.htm?14/10/14506/abstract/17\">",
"     17",
"    </a>",
"    ], in animal models of hepatic encephalopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?14/10/14506/abstract/18\">",
"     18",
"    </a>",
"    ] and in patients with cirrhosis and HE [",
"    <a class=\"abstract\" href=\"UTD.htm?14/10/14506/abstract/19\">",
"     19",
"    </a>",
"    ]. One possible explanation for brain edema is an increase in intracellular osmolarity resulting from the metabolism of ammonia in astrocytes to form glutamine. Inhibition of glutamine synthetase prevents brain swelling in rats infused with ammonia [",
"    <a class=\"abstract\" href=\"UTD.htm?14/10/14506/abstract/20\">",
"     20",
"    </a>",
"    ] and inhibits cellular swelling in cultures of astrocytes incubated with ammonia. In other experiments, portacaval shunted rats, but not control rats, developed encephalopathy associated with a significant increase in intracranial pressure after infusions with ammonium acetate [",
"    <a class=\"abstract\" href=\"UTD.htm?14/10/14506/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. Both groups had similar elevations in blood and brain ammonia concentrations, but brain and cerebrospinal fluid (CSF) concentrations of glutamine and aromatic amino acids were higher in the portacaval shunted rats.",
"   </p>",
"   <p>",
"    These data are supported by in vivo measurements in cirrhotic patients in which proton magnetic resonance spectroscopy of the brain showed depletion of myoinositol (a sign of increased osmolarity) and increased glutamine&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?14/10/14506/abstract/22\">",
"     22",
"    </a>",
"    ]. Thus, as mentioned above with TIPS insertion, portosystemic shunting adds an essential contribution to the pathogenesis of encephalopathy.",
"   </p>",
"   <p>",
"    Some studies have implicated a role of ammonia-induced oxidative stress and changes in mitochondrial permeability in inducing cell swelling. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Oxidative stress'",
"    </a>",
"    below.) Furthermore, oxidative stress activates mitogen-activated protein kinases (MAPKs), which may lead to astrocyte swelling [",
"    <a class=\"abstract\" href=\"UTD.htm?14/10/14506/abstract/23\">",
"     23",
"    </a>",
"    ]. One protein strongly implicated is the water channel protein aquaporin-4 (AQP-4), which is abundantly expressed in astrocytes. Several observations support a potential role of AQP-4 in brain edema in in-vivo models of HE and in ammonia-induced cell swelling in cultured astrocytes [",
"    <a class=\"abstract\" href=\"UTD.htm?14/10/14506/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition to cell swelling, vasodilatation may contribute to the increase in intracranial pressure in acute liver failure. Ammonia induced glutamate release and impaired glutamate clearance may elevate extracellular glutamate levels and cause overstimulation of NMDA (N-methyl-D-aspartate) receptors. NMDA receptor activation triggers nitric oxide synthetase (n-NOS) via a calmodulin mediated mechanism. NOS catalyzed synthesis of nitric oxide (NO) produces vasodilatation [",
"    <a class=\"abstract\" href=\"UTD.htm?14/10/14506/abstract/25\">",
"     25",
"    </a>",
"    ]. Thus, ammonia-induced cerebral water accumulation (probably due to astrocyte swelling) triggers cerebral hyperemia [",
"    <a class=\"abstract\" href=\"UTD.htm?14/10/14506/abstract/26\">",
"     26",
"    </a>",
"    ]. The detrimental effects of the inhibition of NOS on HE in acute liver failure [",
"    <a class=\"abstract\" href=\"UTD.htm?14/10/14506/abstract/27\">",
"     27",
"    </a>",
"    ] are consistent with this hypothesis. In contrast, mild hypothermia may be effective in the prevention of brain edema in experimental acute liver failure by reducing blood-brain transfer of ammonia",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    reduction of extracellular brain glutamate concentrations [",
"    <a class=\"abstract\" href=\"UTD.htm?14/10/14506/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Swelling of astrocytes may be a key event in the development of HE [",
"    <a class=\"abstract\" href=\"UTD.htm?14/10/14506/abstract/29\">",
"     29",
"    </a>",
"    ]. It has been assumed that one major pathogenetic effect in the development of HE in chronic liver disease is an increase in astrocyte hydration without clinically overt increase in intracranial pressure, but sufficient to trigger multiple alterations of astrocyte function. Such changes in cell size interfere with various basic cell functions [",
"    <a class=\"abstract\" href=\"UTD.htm?14/10/14506/abstract/30\">",
"     30",
"    </a>",
"    ] and may also lead to brain edema.",
"   </p>",
"   <p>",
"    Glutamine is not just an osmolyte. Much of the newly synthesized glutamine in astrocytes is transported from the cytoplasm into mitochondria via a histidine-sensitive glutamine carrier and is metabolized by phosphate-activated glutaminase (PAG), yielding glutamate and ammonia. The generation of ammonia by PAG in the relatively small mitochondrial compartment may reach extremely high levels leading to the induction of the mitochondrial permeability transition (MPT) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/10/14506/abstract/31\">",
"     31",
"    </a>",
"    ], production of free radicals and potentially to oxidative damage of mitochondrial constituents. MPT is a calcium-dependent process associated with a collapse of the inner mitochondrial membrane potential due to the opening of the permeability transition pore. Thus, glutamine acts like a \"Trojan horse\" serving as a carrier of ammonia into mitochondria [",
"    <a class=\"abstract\" href=\"UTD.htm?14/10/14506/abstract/11\">",
"     11",
"    </a>",
"    ]. The glutamine-derived ammonia within mitochondria leads to the phenomena known to bring about astrocyte dysfunction, including cell swelling.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Altered neuronal electric activity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ammonia directly affects neuronal electric activity by inhibiting the generation of both excitatory and inhibitory postsynaptic potentials [",
"    <a class=\"abstract\" href=\"UTD.htm?14/10/14506/abstract/32-34\">",
"     32-34",
"    </a>",
"    ]. The effects of ammonia on glutamatergic neurotransmission and on altered brain energy metabolism [",
"    <a class=\"abstract\" href=\"UTD.htm?14/10/14506/abstract/35,36\">",
"     35,36",
"    </a>",
"    ] will be discussed below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Oxidative stress",
"    </span>",
"    &nbsp;&mdash;&nbsp;Oxidative stress has a major role in cerebral ammonia toxicity and the pathogenesis of hepatic encephalopathy. Ammonia induces rapid RNA oxidation in cultured rat astrocytes, mouse brain slices, and rat brain in vivo [",
"    <a class=\"abstract\" href=\"UTD.htm?14/10/14506/abstract/37\">",
"     37",
"    </a>",
"    ]. Ammonia-induced RNA oxidation in cultured astrocytes may modulate the N-methyl-D-aspartic acid (NMDA) receptor activation [",
"    <a class=\"abstract\" href=\"UTD.htm?14/10/14506/abstract/38\">",
"     38",
"    </a>",
"    ]. Because hypo-osmolarity, tumor necrosis factor alpha (TNF-alpha), and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/46/16105?source=see_link\">",
"     diazepam",
"    </a>",
"    increase RNA oxidation in cultured astrocytes, it is conceivable that the action of different HE-precipitating factors converges at the level of RNA oxidation. The messenger RNA (mRNA) coding for the",
"    <span class=\"nowrap\">",
"     glutamate/aspartate",
"    </span>",
"    transporter (GLAST) and 18S-rRNA have been identified among the oxidized RNA species. Oxidized RNA species may participate in postsynaptic protein synthesis, which is a biochemical substrate for learning and memory consolidation [",
"    <a class=\"abstract\" href=\"UTD.htm?14/10/14506/abstract/37\">",
"     37",
"    </a>",
"    ]. In one study, oxidative stress markers in the brain of patients with cirrhosis with severe HE included elevated levels of protein tyrosine-nitrated proteins, heat shock protein-27, and 8-hydroxyguanosine as a marker for RNA oxidation [",
"    <a class=\"abstract\" href=\"UTD.htm?14/10/14506/abstract/39\">",
"     39",
"    </a>",
"    ]. Glutamine synthetase activity was decreased while protein expression of the",
"    <span class=\"nowrap\">",
"     glutamate/aspartate",
"    </span>",
"    cotransporter was up-regulated",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Oxindole",
"    </span>",
"    &nbsp;&mdash;&nbsp;Oxindole is a tryptophan metabolite formed by gut bacteria (via indol) that can cause sedation, muscle weakness, hypotension, and coma. It appears to be produced in the intestine and cleared by the liver, which is similar to ammonia [",
"    <a class=\"abstract\" href=\"UTD.htm?14/10/14506/abstract/40\">",
"     40",
"    </a>",
"    ]. Cerebral concentrations of oxindole are increased 200-fold in rats with acute liver failure, an effect that was partially reversed by oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/57/14229?source=see_link\">",
"     neomycin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?14/10/14506/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a study in humans, indole levels were significantly higher in patients with overt HE and higher in patients with cirrhosis compared with controls [",
"    <a class=\"abstract\" href=\"UTD.htm?14/10/14506/abstract/42\">",
"     42",
"    </a>",
"    ]. In another report, indole and ammonia levels increased after placement of a TIPS [",
"    <a class=\"abstract\" href=\"UTD.htm?14/10/14506/abstract/40\">",
"     40",
"    </a>",
"    ]. Psychometric performance deteriorated in four patients, all of whom had higher indole plasma concentrations compared with patients whose psychometric performance remained stable.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     IMPAIRMENT OF NEUROTRANSMISSION",
"    </span>",
"    &nbsp;&mdash;&nbsp;HE is characterized by biochemical alterations in functions associated with neural membranes, such as the changes in the uptake of neurotransmitters, in enzyme activities, and the expression of neurotransmitter receptors. A possible common pathway for these changes may be alterations in membrane properties in HE. Gross alterations in cerebral cortical membrane lipid composition (including a decrease in cholesterol, phosphatidylserine, sphingomyelin, mono- and polyunsaturated fatty acids) and the annular membrane fluidity were documented in rats with TAA-induced HE [",
"    <a class=\"abstract\" href=\"UTD.htm?14/10/14506/abstract/43,44\">",
"     43,44",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     GABA-benzodiazepine neurotransmitter system",
"    </span>",
"    &nbsp;&mdash;&nbsp;A role has been proposed for increased tone of the inhibitory GABAA-benzodiazepine neurotransmitter system in the development of HE. As an example, visual evoked potentials in rabbits with HE are similar to those induced in normal animals by drugs acting through the GABAA-benzodiazepine receptor complex [",
"    <a class=\"abstract\" href=\"UTD.htm?14/10/14506/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Neurochemical studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple studies have examined the GABAA-benzodiazepine neurotransmitter system in liver failure. In contrast to initial reports of an increase in GABA and benzodiazepine receptors on cortical membranes [",
"    <a class=\"abstract\" href=\"UTD.htm?14/10/14506/abstract/46\">",
"     46",
"    </a>",
"    ], subsequent studies yielded conflicting results [",
"    <a class=\"abstract\" href=\"UTD.htm?14/10/14506/abstract/47\">",
"     47",
"    </a>",
"    ]. In most studies, GABA and benzodiazepine receptors and cerebral GABA concentrations are not changed in HE [",
"    <a class=\"abstract\" href=\"UTD.htm?14/10/14506/abstract/48,49\">",
"     48,49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An increasing body of evidence supports the notion that activation of the astrocytic 18-kDa translocator protein (formerly referred to as the peripheral-type benzodiazepine receptors (PTBR)) contributes to the pathogenesis of the central nervous system symptoms of HE. Binding site densities for the PTBR ligand [3H-PK11195] are increased in autopsied brain tissue from PSE patients as well as in the brains of animals with experimental chronic liver failure. In the case of the animal studies, increased PTBR sites resulted from increased PTBR gene expression. This increase may be due to exposure to ammonia or manganese. Activation of PTBR results in increased cholesterol uptake and increased synthesis in brain of neurosteroids, some of which have potent positive allosteric modulator properties on the GABA-A receptor system. Accumulation of such substances in the brain in chronic liver failure could contribute to the development of HE [",
"    <a class=\"abstract\" href=\"UTD.htm?14/10/14506/abstract/50\">",
"     50",
"    </a>",
"    ]. Downregulation of PTBR reduced cell swelling and prevented the ammonia-induced decline of the cyclosporin A-sensitive mitochondrial inner membrane potential. These findings highlight the important role of the PTBR in the mechanism of ammonia neurotoxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?14/10/14506/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Neurobehavioral studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rats with liver failure are more sensitive to the sedative effects of benzodiazepines than normal rats [",
"    <a class=\"abstract\" href=\"UTD.htm?14/10/14506/abstract/52\">",
"     52",
"    </a>",
"    ]. Furthermore, administration of antagonists of the GABAA-benzodiazepine receptor complex to animals with fulminant hepatic failure and HE has led to a transient clinical improvement which was associated with a normalization of abnormal visual evoked potentials [",
"    <a class=\"abstract\" href=\"UTD.htm?14/10/14506/abstract/53,54\">",
"     53,54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Antagonists with partial inverse agonistic properties appear to be most effective for the amelioration of HE [",
"    <a class=\"abstract\" href=\"UTD.htm?14/10/14506/abstract/55,56\">",
"     55,56",
"    </a>",
"    ]. However, the beneficial effects of these agonists do not necessarily imply overactivity of the GABAA-benzodiazepine neurotransmitter system. An alternative explanation is an imbalance of excitatory and inhibitory neurotransmission.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Electrophysiologic studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Single cell recordings from Purkinje neurons have revealed increased sensitivity in HE to the inhibitory effects of benzodiazepine agonists, a finding consistent with activation of the GABAA-benzodiazepine neurotransmitter system in HE [",
"    <a class=\"abstract\" href=\"UTD.htm?14/10/14506/abstract/57\">",
"     57",
"    </a>",
"    ]. In contrast, neuronal firing action was augmented in cerebella of rabbits with HE but not of control rabbits when",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/6/41062?source=see_link\">",
"     flumazenil",
"    </a>",
"    or other benzodiazepine antagonists were added to the perfusion medium [",
"    <a class=\"abstract\" href=\"UTD.htm?14/10/14506/abstract/57\">",
"     57",
"    </a>",
"    ]. This observation is compatible with displacement from the GABAA-benzodiazepine receptor of a benzodiazepine-like ligand not present in normal brains.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Endogenous benzodiazepines",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endogenous benzodiazepines involved in the activation of the GABAA-ergic neurotransmission have been isolated, characterized, and positively identified by gas chromatography-mass spectroscopy as benzodiazepines in brain, sera, and CSF of experimental animals and humans with acute liver failure due to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    toxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?14/10/14506/abstract/58,59\">",
"     58,59",
"    </a>",
"    ]. The brain concentration of these substances correlated closely with the degree of neurologic impairment in an animal model of HE [",
"    <a class=\"abstract\" href=\"UTD.htm?14/10/14506/abstract/60\">",
"     60",
"    </a>",
"    ]. In these drug-free animals, the presence of benzodiazepines (including",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/46/16105?source=see_link\">",
"     diazepam",
"    </a>",
"    and desmethyldiazepam) cannot be explained by exogenous benzodiazepine administration, which could occur in humans. However, the use of benzodiazepines prior to HE was carefully excluded in human studies [",
"    <a class=\"abstract\" href=\"UTD.htm?14/10/14506/abstract/59\">",
"     59",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Neurosteroids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neurosteroids are metabolites of progesterone and are endogenous neuroactive compounds. Allopregnanolone and tetrahydrodeoxycorticosterone are potent selective positive allosteric modulators of the GABA-A receptor complex. Administration of these steroids induces behavioral effects that include sedation, a property consistent with enhancement of the neuronal inhibition characteristic of HE. In one report, allopregnanolone and pregnenolone (a neurosteroid precursor) concentrations were increased in the brains of hepatic coma patients [",
"    <a class=\"abstract\" href=\"UTD.htm?14/10/14506/abstract/61\">",
"     61",
"    </a>",
"    ]. Concentrations of allopregnanolone comparable to those observed in hepatic coma brains are pathophysiologically relevant and correlated with the magnitude of induction of [3H] muscimol binding. Increased brain concentrations of pregnenolone and consecutively of allopregnanolone could be peripheral in origin. Both allopregnanolone and its precursors cross the blood brain barrier and pregnenolone and progesterone are metabolized by the liver. TGR5 (Gpbar-1) is a novel neurosteroid receptor in the brain that may be involved in the pathogenesis of HE [",
"    <a class=\"abstract\" href=\"UTD.htm?14/10/14506/abstract/62\">",
"     62",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Glutamatergic neurotransmission",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is increasing evidence that alterations of glutamatergic function are implicated in the pathogenesis of central nervous system consequences of acute liver failure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Neurochemical studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Total brain glutamate levels are decreased in various models of HE and in patients dying from chronic liver failure [",
"    <a class=\"abstract\" href=\"UTD.htm?14/10/14506/abstract/63\">",
"     63",
"    </a>",
"    ]. NMR-spectroscopy in hyperammonemic rats and in rats with acute liver failure following liver ischemia confirmed the reduced concentration of glutamate in vivo [",
"    <a class=\"abstract\" href=\"UTD.htm?14/10/14506/abstract/64\">",
"     64",
"    </a>",
"    ]. This decrease in glutamate is presumably due to glutamine formation during the process of ammonia detoxification. It is not known whether a similar change occurs in neuronal glutamate.",
"   </p>",
"   <p>",
"    In contrast, extracellular glutamate concentrations are elevated in HE [",
"    <a class=\"abstract\" href=\"UTD.htm?14/10/14506/abstract/65,66\">",
"     65,66",
"    </a>",
"    ]. This effect may be due to excessive release of glutamate from neurons depolarized by ammonia or to impaired reuptake by neurons or glial cells [",
"    <a class=\"abstract\" href=\"UTD.htm?14/10/14506/abstract/49,67\">",
"     49,67",
"    </a>",
"    ]. Astrocytes may be involved in these derangements since ammonia can impair the ability of these cells to take up glutamate. Reduced capacity of astrocytes to reuptake neuronally-released glutamate and the ensuing compromise in neuron-astrocytic trafficking of glutamate could contribute to the pathogenesis of HE. This effect may result from diminished expression of GLT (glutamate transporter)-1 mRNA [",
"    <a class=\"abstract\" href=\"UTD.htm?14/10/14506/abstract/68-70\">",
"     68-70",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Receptor binding studies in some experimental animals with acute liver failure suggested that glutamatergic neurotransmission may be altered in HE [",
"    <a class=\"abstract\" href=\"UTD.htm?14/10/14506/abstract/71\">",
"     71",
"    </a>",
"    ]. However, this finding has not been found in other models [",
"    <a class=\"abstract\" href=\"UTD.htm?14/10/14506/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Glutamate receptors",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are three major subtypes of glutamate receptors, defined according to their coupling to ion channels and their affinity to certain ligands:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      NMDA (N-methyl-D-aspartate)",
"     </li>",
"     <li>",
"      Non NMDA &mdash; AMPA (amino-3-hydroxy-5-methyl-4-isoxazol propionic acid) and kainate",
"     </li>",
"     <li>",
"      Metabotropic glutamate receptor",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In one study of liver failure induced by ischemia, a selective loss of up to 60 percent of binding sites for the kainate- and AMPA-receptor ligands was observed at coma stages of HE in the cerebral cortex, the hippocampus, the hypothalamus, and cerebellum [",
"    <a class=\"abstract\" href=\"UTD.htm?14/10/14506/abstract/72\">",
"     72",
"    </a>",
"    ]. NMDA-receptors were within normal limits. In contrast, other models of acute liver failure have noted increased NMDA-displaceable glutamate binding in the cerebral cortex and hippocampus [",
"    <a class=\"abstract\" href=\"UTD.htm?14/10/14506/abstract/73,74\">",
"     73,74",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The selective loss of AMPA sites is consistent with the inhibition of AMPA-mediated neuronal depolarization resulting from exposure of hippocampal neurons to millimolar concentrations of ammonia [",
"    <a class=\"abstract\" href=\"UTD.htm?14/10/14506/abstract/75\">",
"     75",
"    </a>",
"    ]. NMDA sites are uniquely neuronal, whereas kainate and AMPA sites are localized on both neurons and astrocytes. Thus, the selective loss of non-NMDA sites in acute liver failure may reflect astrocytic changes. Because astrocytic glutamate receptors are implicated in potassium and neurotransmitter reuptake, alterations in their density could result in altered neuronal excitability and could contribute to the neurologic dysfunction characteristic of HE in acute liver failure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Neurobehavioral studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/16/24837?source=see_link\">",
"     Memantine",
"    </a>",
"    is a noncompetitive NMDA-receptor antagonist. In portacaval shunted rats infused with ammonia and rats with acute hepatic failure due to liver ischemia, memantine improved clinical grading, EEG activity, and the increases in CSF glutamate concentrations, intracranial pressure, and brain water content [",
"    <a class=\"abstract\" href=\"UTD.htm?14/10/14506/abstract/76\">",
"     76",
"    </a>",
"    ]. Memantine had no effect on ammonia concentrations in either model. In another study, different NMDA receptor antagonists, acting on different sites of NMDA receptors, prevented death in mice induced by injection of ammonium acetate [",
"    <a class=\"abstract\" href=\"UTD.htm?14/10/14506/abstract/77\">",
"     77",
"    </a>",
"    ]. These results suggest that NMDA-receptor activation might be involved in the encephalopathy in these settings [",
"    <a class=\"abstract\" href=\"UTD.htm?14/10/14506/abstract/76\">",
"     76",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H129432728\">",
"    <span class=\"h3\">",
"     Genetic studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Certain patients appear to be predisposed to hepatic encephalopathy to a greater degree than others with similarly advanced liver disease. The reasons for these differences in susceptibility are incompletely understood. One study suggested that variation in the glutaminase gene may in part be responsible [",
"    <a class=\"abstract\" href=\"UTD.htm?14/10/14506/abstract/78\">",
"     78",
"    </a>",
"    ]. Patients who had a variant of the promoter region of the glutaminase gene that was associated with increased enzyme activity appeared to have an increased risk of hepatic encephalopathy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Catecholamines",
"    </span>",
"    &nbsp;&mdash;&nbsp;Altered concentrations of catecholamines in HE have been linked to altered amino acid metabolism. In chronic liver failure, the plasma and brain concentrations of aromatic amino acids (AAAs; phenylalanine, tryptophan, and tyrosine) are increased, while those of the branched-chain amino acids (BCAAs) valine, leucine, and isoleucine are reduced. Since these amino acids share a common carrier at the blood-brain barrier, decreased BCAA concentrations in the blood may result in increased transport of AAA into the brain [",
"    <a class=\"abstract\" href=\"UTD.htm?14/10/14506/abstract/79\">",
"     79",
"    </a>",
"    ]. A low molar ratio of plasma BCAA to AAA is a consistent finding in patients with cirrhosis and HE, but also occurs in patients without HE [",
"    <a class=\"abstract\" href=\"UTD.htm?14/10/14506/abstract/80,81\">",
"     80,81",
"    </a>",
"    ]. This ratio closely correlates with indices of liver function, with a decreased ratio implying poor hepatocellular function [",
"    <a class=\"abstract\" href=\"UTD.htm?14/10/14506/abstract/81\">",
"     81",
"    </a>",
"    ]. Thus, it appears unlikely that changes in the plasma concentrations of neutral amino acids contribute to the development of HE.",
"   </p>",
"   <p>",
"    Tyrosine-3-hydroxylase is the key enzyme for the synthesis of catecholaminergic neurotransmitters, and high concentrations of phenylalanine in the brain may inhibit the enzyme. In addition, other amines such as tyramine, octopamine, and phenylethanolamine are synthesized from tyrosine by alternative metabolic pathways. These false neurotransmitters may compete with the normal catecholamine neurotransmitters (eg, dopamine) for the same receptor site [",
"    <a class=\"abstract\" href=\"UTD.htm?14/10/14506/abstract/79\">",
"     79",
"    </a>",
"    ]. However, no experimental or clinical studies investigating the false neurotransmitter hypothesis have been published since the 1990s. In addition, cerebral dopamine concentrations in HE are usually within the normal range in both experimental animals and in humans with HE [",
"    <a class=\"abstract\" href=\"UTD.htm?14/10/14506/abstract/82\">",
"     82",
"    </a>",
"    ], and depletion of brain dopamine in rats does not result in the induction of coma [",
"    <a class=\"abstract\" href=\"UTD.htm?14/10/14506/abstract/83\">",
"     83",
"    </a>",
"    ]. Thus, there is no firm evidence that impaired dopaminergic neurotransmission contributes to any appreciable extent to HE.",
"   </p>",
"   <p>",
"    However, some of the extrapyramidal symptoms in patients with cirrhosis may be due to altered dopaminergic function, which is closely related to accumulation of manganese in basal ganglia [",
"    <a class=\"abstract\" href=\"UTD.htm?14/10/14506/abstract/84\">",
"     84",
"    </a>",
"    ]. Manganese appears to normalize low striatal levels of dopamine. Thus, manganese accumulation in basal ganglia [",
"    <a class=\"abstract\" href=\"UTD.htm?14/10/14506/abstract/85,86\">",
"     85,86",
"    </a>",
"    ] may represent an attempt of the brain to correct dopamine deficiency in liver disease.",
"   </p>",
"   <p>",
"    Finally, another fairly consistent finding in animal models of acute or chronic liver failure is a reduced norepinephrine (noradrenaline) concentration in the brain. The decreased brain norepinephrine content is due to overactivity of noradrenergic neurotransmission, possibly induced by hyperammonemia [",
"    <a class=\"abstract\" href=\"UTD.htm?14/10/14506/abstract/87\">",
"     87",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Serotonin",
"    </span>",
"    &nbsp;&mdash;&nbsp;A two to fourfold increase in cerebral concentration of the serotonin metabolite 5-hydroxyindoleacetic acid is the most consistent neurochemical finding in HE [",
"    <a class=\"abstract\" href=\"UTD.htm?14/10/14506/abstract/87,88\">",
"     87,88",
"    </a>",
"    ]. In addition, HE is associated with alterations in the number of 5HT1A and 5HT2 receptors [",
"    <a class=\"abstract\" href=\"UTD.htm?14/10/14506/abstract/89\">",
"     89",
"    </a>",
"    ] and increased activity of both MAOA and MAOB (enzymes catabolizing 5-HT) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/10/14506/abstract/90\">",
"     90",
"    </a>",
"    ]. These findings suggest an increased serotonin turnover rate in HE, but do not necessarily imply an overactivity of this neurotransmitter system. Although increased neocortical serotonin output has been described in some animal models of HE [",
"    <a class=\"abstract\" href=\"UTD.htm?14/10/14506/abstract/91,92\">",
"     91,92",
"    </a>",
"    ], studies using serotonin agonists or antagonists on the evolution of HE in rats with thioacetamide-induced liver failure do not support a pathogenetic role for increased serotoninergic tone in HE [",
"    <a class=\"abstract\" href=\"UTD.htm?14/10/14506/abstract/93\">",
"     93",
"    </a>",
"    ]; to the contrary, the amount of biologically active serotonin at the synaptic cleft may be reduced [",
"    <a class=\"abstract\" href=\"UTD.htm?14/10/14506/abstract/94\">",
"     94",
"    </a>",
"    ]. Serotonin transporters are decreased in various brain regions of rats with acute liver failure [",
"    <a class=\"abstract\" href=\"UTD.htm?14/10/14506/abstract/95\">",
"     95",
"    </a>",
"    ]. The loss of transporter binding sites is accompanied by significant increases of L-tryptophan, serotonin, and 5-HIAA concentrations in extracellular fluid.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Histamine",
"    </span>",
"    &nbsp;&mdash;&nbsp;The binding properties and the regional densities of histamine H1 receptors in the brains of rats with portacaval anastomosis suggested that this neurotransmitter system is also affected in liver failure. Autopsied brain tissue from cirrhotic patients with HE displayed a higher density and a lower affinity of histamine H1 receptors compared with control human frontal cortex [",
"    <a class=\"abstract\" href=\"UTD.htm?14/10/14506/abstract/96\">",
"     96",
"    </a>",
"    ]. Binding was highest in the parietal and temporal cortices and lowest in caudate-putamen. A selective increase in H1 receptor density was also observed in parietal and insular cortices of patients with HE. The central histaminergic system is implicated in the control of arousal and circadian rhythmicity. A selective up-regulation of brain H1 could contribute to the neuropsychiatric symptoms characteristic of human HE, and may be amenable to treatment with selective histamine H1 receptor antagonists.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Melatonin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sleep disturbances are common in patients with subclinical HE [",
"    <a class=\"abstract\" href=\"UTD.htm?14/10/14506/abstract/97\">",
"     97",
"    </a>",
"    ] and may be due to a centrally mediated alteration of circadian rhythm [",
"    <a class=\"abstract\" href=\"UTD.htm?14/10/14506/abstract/98\">",
"     98",
"    </a>",
"    ]. The 24-hour rhythm of melatonin, which is considered to be the output signal of the biological \"clock,\" is considerably altered in patients with cirrhosis [",
"    <a class=\"abstract\" href=\"UTD.htm?14/10/14506/abstract/98\">",
"     98",
"    </a>",
"    ]. The onset of the rise in plasma levels of melatonin and the melatonin peak during the night are displaced to later hours. Furthermore, plasma melatonin levels are significantly higher during daylight hours, at a time when melatonin is normally very low or absent. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/46/13034?source=see_link\">",
"     \"Physiology and clinical use of melatonin\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     ALTERATION OF THE BLOOD-BRAIN BARRIER",
"    </span>",
"    &nbsp;&mdash;&nbsp;The brain uptake of various tracer substances is increased in several animal models of acute liver failure [",
"    <a class=\"abstract\" href=\"UTD.htm?14/10/14506/abstract/99\">",
"     99",
"    </a>",
"    ]. The reason for this nonspecific increase in blood-brain barrier permeability is unknown. Regardless of the mechanism, this change can lead to exposure of the brain to a variety of neurotoxic substances circulating in the blood and may result in brain edema.",
"   </p>",
"   <p>",
"    Blood-brain permeability was unchanged in a study of patients with chronic liver disease without HE [",
"    <a class=\"abstract\" href=\"UTD.htm?14/10/14506/abstract/100\">",
"     100",
"    </a>",
"    ]. By contrast, specific changes in blood-brain barrier transport have been demonstrated in patients with HE [",
"    <a class=\"abstract\" href=\"UTD.htm?14/10/14506/abstract/101\">",
"     101",
"    </a>",
"    ]. Of particular interest are changes of amino acid transport into the brain. Amino acids such as tyrosine, phenylalanine, and tryptophan are precursors of the neurotransmitters dopamine, norepinephrine, and serotonin, while other amino acids, such as glutamate, aspartate, taurine, and glycine, are neurotransmitters themselves. Alterations in specific transport systems seem to be important in chronic HE.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     ALTERED BRAIN ENERGY METABOLISM",
"    </span>",
"    &nbsp;&mdash;&nbsp;Undisturbed energy supply and energy metabolism is a prerequisite for normal brain function. Glucose is the most important cerebral energy fuel and hypoglycemia can occur in the terminal stages of liver failure due to impaired hepatic gluconeogenesis. However, the administration of glucose is not sufficient to normalize brain function in HE.",
"   </p>",
"   <p>",
"    Several studies have addressed cerebral glucose utilization in HE. A report which evaluated regional cerebral glucose metabolism in rats with a portacaval shunt found a 5 to 34 percent decrease in cerebral glucose utilization in the 38 brain areas examined [",
"    <a class=\"abstract\" href=\"UTD.htm?14/10/14506/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The depression in cerebral glucose metabolism is due in part to hyperammonemia. This effect seems to begin with increased synthesis of glutamine [",
"    <a class=\"abstract\" href=\"UTD.htm?14/10/14506/abstract/102,103\">",
"     102,103",
"    </a>",
"    ]. Ammonia itself is without effect at concentrations less than 1",
"    <span class=\"nowrap\">",
"     &micro;mol/mL",
"    </span>",
"    if it is not converted into glutamine. A study evaluating the impact of ammonia on cerebral metabolism relied on measurement of the oxygen metabolism rate (CMRO(2)) by (15)O-oxygen positron emission tomography (PET) and of cerebral blood flow (CBF) by (15)O-water PET [",
"    <a class=\"abstract\" href=\"UTD.htm?14/10/14506/abstract/104\">",
"     104",
"    </a>",
"    ]. There were no differences between patients with cirrhosis without HE and healthy subjects, but both measures were significantly reduced in patients with cirrhosis with HE throughout the brain. CMRO(2) and CBF correlated negatively with arterial ammonia concentration. These observations suggested that the primary event in the pathogenesis of HE was the inhibition of cerebral energy metabolism by increased blood ammonia. Hyperammonemia may also reduce brain ATP levels, indicating a marked impairment of brain energy metabolism [",
"    <a class=\"abstract\" href=\"UTD.htm?14/10/14506/abstract/105\">",
"     105",
"    </a>",
"    ]. However, this abnormality was found only in patients with severe disease who had already developed multi-organ failure and may therefore be unrelated to the evolution of HE.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     SYSTEMIC RESPONSE TO INFECTIONS AND NEUROINFLAMMATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infection is a well-known precipitant of hepatic encephalopathy, but the mechanisms involved are incompletely understood [",
"    <a class=\"abstract\" href=\"UTD.htm?14/10/14506/abstract/4\">",
"     4",
"    </a>",
"    ]. Patients with cirrhosis are known to be functionally immunosuppressed and prone to develop infections [",
"    <a class=\"abstract\" href=\"UTD.htm?14/10/14506/abstract/106\">",
"     106",
"    </a>",
"    ]. Whether infections themselves or the inflammatory response exacerbate HE is unclear.",
"   </p>",
"   <p>",
"    The systemic inflammatory response syndrome (SIRS) results from the release and circulation of proinflammatory cytokines and mediators. Sepsis-associated encephalopathy is characterized by changes in mental status and motor activity, ranging from delirium to coma [",
"    <a class=\"abstract\" href=\"UTD.htm?14/10/14506/abstract/107\">",
"     107",
"    </a>",
"    ]. Up to one-third of patients with sepsis have a reduced level of consciousness, which is an independent prognostic factor for increased mortality. Possible causes of brain dysfunction include alterations in cerebral blood flow, brain metabolites, and the release of inflammatory mediators; importantly, these processes occur without the direct infection of brain tissue [",
"    <a class=\"abstract\" href=\"UTD.htm?14/10/14506/abstract/108\">",
"     108",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    During an episode of sepsis, cytokines (15 to 20 kDa) cannot diffuse across the blood-brain barrier and are therefore unable to have a direct effect. Nevertheless, the peripheral immune system can signal the brain to elicit a response through the expression of proinflammatory cytokines, both in the periphery and in the brain. Brain signaling may occur through direct transport of the cytokine across the blood-brain barrier [",
"    <a class=\"abstract\" href=\"UTD.htm?14/10/14506/abstract/109\">",
"     109",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The circumventricular organs (which are positioned around the margin of the brain's ventricular system) express components of innate and adaptive immune systems and are located close to neuroendocrine nuclei. Activated endothelial cells, microglial cells, and astrocytes produce repertoire variety of cytokines in response to inflammation and release of various mediators into the brain, resulting in the intracerebral synthesis of NO and prostanoids. Cytokines also influence the permeability of the blood-brain barrier [",
"    <a class=\"abstract\" href=\"UTD.htm?14/10/14506/abstract/110\">",
"     110",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In patients with cirrhosis, SIRS may exacerbate the symptoms of HE, both in patients with minimal and overt HE [",
"    <a class=\"abstract\" href=\"UTD.htm?14/10/14506/abstract/111,112\">",
"     111,112",
"    </a>",
"    ]. The presence and severity of minimal HE in patients with cirrhosis are independent of the severity of liver disease and plasma ammonia concentration, but markers of systemic inflammation are significantly higher in those with minimal HE compared with those without [",
"    <a class=\"abstract\" href=\"UTD.htm?14/10/14506/abstract/31\">",
"     31",
"    </a>",
"    ]. In one report, increasing grades of HE were associated with SIRS and neutrophilia, but not arterial ammonia concentration [",
"    <a class=\"abstract\" href=\"UTD.htm?14/10/14506/abstract/113\">",
"     113",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Another potential factor inciting an inflammatory response is bacterial translocation of organisms from the gut, which results in chronic endotoxemia [",
"    <a class=\"abstract\" href=\"UTD.htm?14/10/14506/abstract/113\">",
"     113",
"    </a>",
"    ]. Bacterial translocation may activate proinflammatory",
"    <span class=\"nowrap\">",
"     cytokines/chemokines",
"    </span>",
"    and neutrophils through Toll-like and chemokine receptors [",
"    <a class=\"abstract\" href=\"UTD.htm?14/10/14506/abstract/114\">",
"     114",
"    </a>",
"    ]. In support of this hypothesis are studies in rats with endotoxin-induced chronic neuroinflammation or with portocaval shunts [",
"    <a class=\"abstract\" href=\"UTD.htm?14/10/14506/abstract/3\">",
"     3",
"    </a>",
"    ]. Learning and memory deficits were reversed by the glutamatergic antagonist",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/16/24837?source=see_link\">",
"     memantine",
"    </a>",
"    and by the nonsteroidal anti-inflammatory drug",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/38/15978?source=see_link\">",
"     ibuprofen",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?14/10/14506/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Experimental evidence points to a synergistic relationship of inflammation and infection with ammonia, both at the level of the brain and at the level of neutrophils [",
"    <a class=\"abstract\" href=\"UTD.htm?14/10/14506/abstract/113,115,116\">",
"     113,115,116",
"    </a>",
"    ]. Some reports suggest that hyperammonemia may cause neuroinflammation [",
"    <a class=\"abstract\" href=\"UTD.htm?14/10/14506/abstract/116\">",
"     116",
"    </a>",
"    ]. In vitro ammonia impairs neutrophil chemotaxis, phagocytosis, degranulation, and stimulated oxidative burst, resulting in swelling of certain cells, including neutrophils and possibly astrocytes [",
"    <a class=\"abstract\" href=\"UTD.htm?14/10/14506/abstract/117\">",
"     117",
"    </a>",
"    ]. Impaired phagocytosis may augment the impaired immune response to bacterial antigens. A similar reduction in phagocytosis following induction of hyponatremia, which is a well-known stimulus for cell swelling, supports neutrophil swelling as a potential mechanism to explain this neutrophil dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?14/10/14506/abstract/118\">",
"     118",
"    </a>",
"    ]. Similar observations have been made in patients with liver disease. The effects of hyponatremia and ammonia were additive, causing more pronounced neutrophil swelling and phagocytic dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?14/10/14506/abstract/117\">",
"     117",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These observations potentially have therapeutic implications. Potential therapeutic strategies might include antibiotics, the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/13/23767?source=see_link\">",
"     granulocyte colony-stimulating factor",
"    </a>",
"    , antagonist of proinflammatory cytokines or their receptors, antioxidants, nonsteroidal anti-inflammatory drugs, and hypothermia [",
"    <a class=\"abstract\" href=\"UTD.htm?14/10/14506/abstract/28,117,119\">",
"     28,117,119",
"    </a>",
"    ]. Modulation of intestinal microbiota by probiotics is an emerging strategy to reduce the bacterial translocation of LPS and other bacterial activators of TLRs. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/15/4346?source=see_link\">",
"     \"Hepatic encephalopathy in adults: Treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18224960\">",
"    <span class=\"h1\">",
"     BACTERIAL OVERGROWTH",
"    </span>",
"    &nbsp;&mdash;&nbsp;Small bowel bacterial overgrowth has been hypothesized to contribute to minimal hepatic encephalopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?14/10/14506/abstract/120\">",
"     120",
"    </a>",
"    ]. However, more studies are needed to clarify the validity and implications of the association.",
"   </p>",
"   <p>",
"    Gut bacterial microbiome analysis is a valuable new approach to study the pathogenesis of various diseases. The gut microbiome was studied by multitag pyrosequencing of stool of patients with cirrhosis and age-matched controls. Patients with cirrhosis had significantly fewer autochthonous and more pathogenic genera than controls [",
"    <a class=\"abstract\" href=\"UTD.htm?14/10/14506/abstract/121\">",
"     121",
"    </a>",
"    ]. This was especially true for patients with HE. Patients with cirrhosis had more Enterobacteriaceae, Alcaligenaceae, and Fusobacteriaceae and fewer Ruminococcaceae and Lachnospiraceae than controls. In the patients with cirrhosis, Alcaligenaceae and Porphyromonadaceae were positively associated with cognitive impairment. Fusobacteriaceae, Veillonellaceae, and Enterobacteriaceae were positively associated with markers of inflammation, and Ruminococcaceae was negatively associated.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/34/33316?source=see_link\">",
"     Lactulose",
"    </a>",
"    withdrawal did not change the microbiome significantly [",
"    <a class=\"abstract\" href=\"UTD.htm?14/10/14506/abstract/122\">",
"     122",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, \"The Basics\" and \"Beyond the Basics.\" The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on \"patient info\" and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?7/40/7810?source=see_link\">",
"       \"Patient information: Hepatic encephalopathy (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The various hypotheses of the pathogenesis of hepatic encephalopathy (HE) are not mutually exclusive. It seems likely that many of the described abnormalities may be present at the same time and may ultimately be responsible for the development of HE. The synergistic action of ammonia with other toxins may account for many of the abnormalities occurring in liver failure, such as the changes in blood-to-brain transport of neurotransmitter precursors, the metabolism of amino acid neurotransmitters, and cerebral glucose oxidation. These changes may lead to activation of inhibitory (GABA, serotonin) and impairment of excitatory (glutamate, catecholamines) neurotransmitter systems, resulting in enhanced neural inhibition. Sepsis, neuroinflammation, and alterations in gut flora appear to be additional factors in the development of altered brain function in advanced liver disease.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/10/14506/abstract/1\">",
"      Ferenci P. Brain dysfunction in fulminant hepatic failure. J Hepatol 1994; 21:487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/10/14506/abstract/2\">",
"      Saija A, Princi P, Lanza M, et al. Systemic cytokine administration can affect blood-brain barrier permeability in the rat. Life Sci 1995; 56:775.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/10/14506/abstract/3\">",
"      Cauli O, Rodrigo R, Piedrafita B, et al. Inflammation and hepatic encephalopathy: ibuprofen restores learning ability in rats with portacaval shunts. Hepatology 2007; 46:514.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/10/14506/abstract/4\">",
"      O'Beirne JP, Chouhan M, Hughes RD. The role of infection and inflammation in the pathogenesis of hepatic encephalopathy and cerebral edema in acute liver failure. Nat Clin Pract Gastroenterol Hepatol 2006; 3:118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/10/14506/abstract/5\">",
"      Strauss G, Hansen BA, Kirkegaard P, et al. Liver function, cerebral blood flow autoregulation, and hepatic encephalopathy in fulminant hepatic failure. Hepatology 1997; 25:837.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/10/14506/abstract/6\">",
"      Larsen FS, Knudsen GM, Hansen BA. Pathophysiological changes in cerebral circulation, oxidative metabolism and blood-brain barrier in patients with acute liver failure. Tailored cerebral oxygen utilization. J Hepatol 1997; 27:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/10/14506/abstract/7\">",
"      Artz SA, Paes IC, Faloon WW. Hypokalemia-induced hepatic coma in cirrhosis. Occurrence despite neomycin therapy. Gastroenterology 1966; 51:1046.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/10/14506/abstract/8\">",
"      Gabduzda GJ, Hall PW 3rd. Relation of potassium depletion to renal ammonium metabolism and hepatic coma. Medicine (Baltimore) 1966; 45:481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/10/14506/abstract/9\">",
"      Suto H, Azuma T, Ito S, et al. Helicobacter pylori infection induces hyperammonaemia in Mongolian gerbils with liver cirrhosis. Gut 2001; 48:605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/10/14506/abstract/10\">",
"      Blei AT. Helicobacter pylori, harmful to the brain? Gut 2001; 48:590.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/10/14506/abstract/11\">",
"      Albrecht J, Norenberg MD. Glutamine: a Trojan horse in ammonia neurotoxicity. Hepatology 2006; 44:788.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/10/14506/abstract/12\">",
"      Zieve L, Doizaki WM, Zieve J. Synergism between mercaptans and ammonia or fatty acids in the production of coma: a possible role for mercaptans in the pathogenesis of hepatic coma. J Lab Clin Med 1974; 83:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/10/14506/abstract/13\">",
"      Weissenborn K, Ahl B, Fischer-Wasels D, et al. Correlations between magnetic resonance spectroscopy alterations and cerebral ammonia and glucose metabolism in cirrhotic patients with and without hepatic encephalopathy. Gut 2007; 56:1736.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/10/14506/abstract/14\">",
"      Cangiano C, Cardelli-Cangiano P, James JH, et al. Brain microvessels take up large neutral amino acids in exchange for glutamine. Cooperative role of Na+-dependent and Na+-independent systems. J Biol Chem 1983; 258:8949.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/10/14506/abstract/15\">",
"      Grippon P, Le Poncin Lafitte M, Boschat M, et al. Evidence for the role of ammonia in the intracerebral transfer and metabolism of tryptophan. Hepatology 1986; 6:682.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/10/14506/abstract/16\">",
"      James JH, Ziparo V, Jeppsson B, Fischer JE. Hyperammonaemia, plasma aminoacid imbalance, and blood-brain aminoacid transport: a unified theory of portal-systemic encephalopathy. Lancet 1979; 2:772.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/10/14506/abstract/17\">",
"      Cordoba J, Blei AT. Brain edema and hepatic encephalopathy. Semin Liver Dis 1996; 16:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/10/14506/abstract/18\">",
"      Jover R, Rodrigo R, Felipo V, et al. Brain edema and inflammatory activation in bile duct ligated rats with diet-induced hyperammonemia: A model of hepatic encephalopathy in cirrhosis. Hepatology 2006; 43:1257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/10/14506/abstract/19\">",
"      Donovan JP, Schafer DF, Shaw BW Jr, Sorrell MF. Cerebral oedema and increased intracranial pressure in chronic liver disease. Lancet 1998; 351:719.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/10/14506/abstract/20\">",
"      Blei AT, Olafsson S, Therrien G, Butterworth RF. Ammonia-induced brain edema and intracranial hypertension in rats after portacaval anastomosis. Hepatology 1994; 19:1437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/10/14506/abstract/21\">",
"      Vogels BA, van Steynen B, Maas MA, et al. The effects of ammonia and portal-systemic shunting on brain metabolism, neurotransmission and intracranial hypertension in hyperammonaemia-induced encephalopathy. J Hepatol 1997; 26:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/10/14506/abstract/22\">",
"      Laubenberger J, H&auml;ussinger D, Bayer S, et al. Proton magnetic resonance spectroscopy of the brain in symptomatic and asymptomatic patients with liver cirrhosis. Gastroenterology 1997; 112:1610.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/10/14506/abstract/23\">",
"      Moriyama M, Jayakumar AR, Tong XY, Norenberg MD. Role of mitogen-activated protein kinases in the mechanism of oxidant-induced cell swelling in cultured astrocytes. J Neurosci Res 2010; 88:2450.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/10/14506/abstract/24\">",
"      Wright G, Soper R, Brooks HF, et al. Role of aquaporin-4 in the development of brain oedema in liver failure. J Hepatol 2010; 53:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/10/14506/abstract/25\">",
"      Blei AT, Larsen FS. Pathophysiology of cerebral edema in fulminant hepatic failure. J Hepatol 1999; 31:771.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/10/14506/abstract/26\">",
"      Larsen FS, Gottstein J, Blei AT. Cerebral hyperemia and nitric oxide synthase in rats with ammonia-induced brain edema. J Hepatol 2001; 34:548.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/10/14506/abstract/27\">",
"      Chu CJ, Wang SS, Lee FY, et al. Detrimental effects of nitric oxide inhibition on hepatic encephalopathy in rats with thioacetamide-induced fulminant hepatic failure. Eur J Clin Invest 2001; 31:156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/10/14506/abstract/28\">",
"      Rose C, Michalak A, Pannunzio M, et al. Mild hypothermia delays the onset of coma and prevents brain edema and extracellular brain glutamate accumulation in rats with acute liver failure. Hepatology 2000; 31:872.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/10/14506/abstract/29\">",
"      H&auml;ussinger D, Kircheis G, Fischer R, et al. Hepatic encephalopathy in chronic liver disease: a clinical manifestation of astrocyte swelling and low-grade cerebral edema? J Hepatol 2000; 32:1035.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/10/14506/abstract/30\">",
"      H&auml;ussinger D, Roth E, Lang F, Gerok W. Cellular hydration state: an important determinant of protein catabolism in health and disease. Lancet 1993; 341:1330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/10/14506/abstract/31\">",
"      Rama Rao KV, Jayakumar AR, Norenberg DM. Ammonia neurotoxicity: role of the mitochondrial permeability transition. Metab Brain Dis 2003; 18:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/10/14506/abstract/32\">",
"      Raabe W. Effects of hyperammonemia on neuronal function: NH4+, IPSP and Cl(-)-extrusion. Adv Exp Med Biol 1993; 341:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/10/14506/abstract/33\">",
"      Raabe W. Ammonium ions abolish excitatory synaptic transmission between cerebellar neurons in primary dissociated tissue culture. J Neurophysiol 1992; 68:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/10/14506/abstract/34\">",
"      Allert N, K&ouml;ller H, Siebler M. Ammonia-induced depolarization of cultured rat cortical astrocytes. Brain Res 1998; 782:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/10/14506/abstract/35\">",
"      Mans AM, Biebuyck JF, Davis DW, et al. Regional cerebral glucose utilization in rats with portacaval anastomosis. J Neurochem 1983; 40:986.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/10/14506/abstract/36\">",
"      Lockwood AH, Ginsberg MD, Rhoades HM, Gutierrez MT. Cerebral glucose metabolism after portacaval shunting in the rat. Patterns of metabolism and implications for the pathogenesis of hepatic encephalopathy. J Clin Invest 1986; 78:86.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/10/14506/abstract/37\">",
"      G&ouml;rg B, Qvartskhava N, Keitel V, et al. Ammonia induces RNA oxidation in cultured astrocytes and brain in vivo. Hepatology 2008; 48:567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/10/14506/abstract/38\">",
"      Reinehr R, G&ouml;rg B, Becker S, et al. Hypoosmotic swelling and ammonia increase oxidative stress by NADPH oxidase in cultured astrocytes and vital brain slices. Glia 2007; 55:758.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/10/14506/abstract/39\">",
"      G&ouml;rg B, Qvartskhava N, Bidmon HJ, et al. Oxidative stress markers in the brain of patients with cirrhosis and hepatic encephalopathy. Hepatology 2010; 52:256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/10/14506/abstract/40\">",
"      Riggio O, Mannaioni G, Ridola L, et al. Peripheral and splanchnic indole and oxindole levels in cirrhotic patients: a study on the pathophysiology of hepatic encephalopathy. Am J Gastroenterol 2010; 105:1374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/10/14506/abstract/41\">",
"      Carpenedo R, Mannaioni G, Moroni F. Oxindole, a sedative tryptophan metabolite, accumulates in blood and brain of rats with acute hepatic failure. J Neurochem 1998; 70:1998.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/10/14506/abstract/42\">",
"      Moroni F, Carpenedo R, Venturini I, et al. Oxindole in pathogenesis of hepatic encephalopathy. Lancet 1998; 351:1861.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/10/14506/abstract/43\">",
"      Swapna I, Sathyasaikumar KV, Murthy ChR, et al. Changes in cerebral membrane lipid composition and fluidity during thioacetamide-induced hepatic encephalopathy. J Neurochem 2006; 98:1899.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/10/14506/abstract/44\">",
"      Swapna I, Kumar KV, Reddy PV, et al. Phospholipid and cholesterol alterations accompany structural disarray in myelin membrane of rats with hepatic encephalopathy induced by thioacetamide. Neurochem Int 2006; 49:238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/10/14506/abstract/45\">",
"      Schafer DF, Pappas SC, Brody LE, et al. Visual evoked potentials in a rabbit model of hepatic encephalopathy. I. Sequential changes and comparisons with drug-induced comas. Gastroenterology 1984; 86:540.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/10/14506/abstract/46\">",
"      Schafer DF, Jones EA. Hepatic encephalopathy and the gamma-aminobutyric-acid neurotransmitter system. Lancet 1982; 1:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/10/14506/abstract/47\">",
"      Ferenci P, P&uuml;sp&ouml;k A, Steindl P. Current concepts in the pathophysiology of hepatic encephalopathy. Eur J Clin Invest 1992; 22:573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/10/14506/abstract/48\">",
"      Zimmermann C, Ferenci P, Pifl C, et al. Hepatic encephalopathy in thioacetamide-induced acute liver failure in rats: characterization of an improved model and study of amino acid-ergic neurotransmission. Hepatology 1989; 9:594.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/10/14506/abstract/49\">",
"      Michalak A, Rose C, Butterworth J, Butterworth RF. Neuroactive amino acids and glutamate (NMDA) receptors in frontal cortex of rats with experimental acute liver failure. Hepatology 1996; 24:908.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/10/14506/abstract/50\">",
"      Butterworth RF. The astrocytic (\"peripheral-type\") benzodiazepine receptor: role in the pathogenesis of portal-systemic encephalopathy. Neurochem Int 2000; 36:411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/10/14506/abstract/51\">",
"      Panickar KS, Jayakumar AR, Rama Rao KV, Norenberg MD. Downregulation of the 18-kDa translocator protein: effects on the ammonia-induced mitochondrial permeability transition and cell swelling in cultured astrocytes. Glia 2007; 55:1720.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/10/14506/abstract/52\">",
"      P&uuml;sp&ouml;k A, Herneth A, Steindl P, Ferenci P. Hepatic encephalopathy in rats with thioacetamide-induced acute liver failure is not mediated by endogenous benzodiazepines. Gastroenterology 1993; 105:851.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/10/14506/abstract/53\">",
"      Baraldi M, Zeneroli ML, Ventura E, et al. Supersensitivity of benzodiazepine receptors in hepatic encephalopathy due to fulminant hepatic failure in the rat: reversal by a benzodiazepine antagonist. Clin Sci (Lond) 1984; 67:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/10/14506/abstract/54\">",
"      Bassett ML, Mullen KD, Skolnick P, Jones EA. Amelioration of hepatic encephalopathy by pharmacologic antagonism of the GABAA-benzodiazepine receptor complex in a rabbit model of fulminant hepatic failure. Gastroenterology 1987; 93:1069.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/10/14506/abstract/55\">",
"      Bosman DK, van den Buijs CA, de Haan JG, et al. The effects of benzodiazepine-receptor antagonists and partial inverse agonists on acute hepatic encephalopathy in the rat. Gastroenterology 1991; 101:772.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/10/14506/abstract/56\">",
"      Steindl P, P&uuml;sp&ouml;k A, Druml W, Ferenci P. Beneficial effect of pharmacological modulation of the GABAA-benzodiazepine receptor on hepatic encephalopathy in the rat: comparison with uremic encephalopathy. Hepatology 1991; 14:963.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/10/14506/abstract/57\">",
"      Basile AS, Gammal SH, Mullen KD, et al. Differential responsiveness of cerebellar Purkinje neurons to GABA and benzodiazepine receptor ligands in an animal model of hepatic encephalopathy. J Neurosci 1988; 8:2414.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/10/14506/abstract/58\">",
"      Basile AS, Pannell L, Jaouni T, et al. Brain concentrations of benzodiazepines are elevated in an animal model of hepatic encephalopathy. Proc Natl Acad Sci U S A 1990; 87:5263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/10/14506/abstract/59\">",
"      Basile AS, Hughes RD, Harrison PM, et al. Elevated brain concentrations of 1,4-benzodiazepines in fulminant hepatic failure. N Engl J Med 1991; 325:473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/10/14506/abstract/60\">",
"      Yurdaydin C, Gu ZQ, Nowak G, et al. Benzodiazepine receptor ligands are elevated in an animal model of hepatic encephalopathy: relationship between brain concentration and severity of encephalopathy. J Pharmacol Exp Ther 1993; 265:565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/10/14506/abstract/61\">",
"      Ahboucha S, Pomier-Layrargues G, Mamer O, Butterworth RF. Increased levels of pregnenolone and its neuroactive metabolite allopregnanolone in autopsied brain tissue from cirrhotic patients who died in hepatic coma. Neurochem Int 2006; 49:372.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/10/14506/abstract/62\">",
"      Keitel V, G&ouml;rg B, Bidmon HJ, et al. The bile acid receptor TGR5 (Gpbar-1) acts as a neurosteroid receptor in brain. Glia 2010; 58:1794.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/10/14506/abstract/63\">",
"      Norenberg MD. Astrocytic-ammonia interactions in hepatic encephalopathy. Semin Liver Dis 1996; 16:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/10/14506/abstract/64\">",
"      Bosman DK, Deutz NE, De Graaf AA, et al. Changes in brain metabolism during hyperammonemia and acute liver failure: results of a comparative 1H-NMR spectroscopy and biochemical investigation. Hepatology 1990; 12:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/10/14506/abstract/65\">",
"      Moroni F, Lombardi G, Moneti G, Cortesini C. The release and neosynthesis of glutamic acid are increased in experimental models of hepatic encephalopathy. J Neurochem 1983; 40:850.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/10/14506/abstract/66\">",
"      de Knegt RJ, Schalm SW, van der Rijt CC, et al. Extracellular brain glutamate during acute liver failure and during acute hyperammonemia simulating acute liver failure: an experimental study based on in vivo brain dialysis. J Hepatol 1994; 20:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/10/14506/abstract/67\">",
"      Oppong KN, Bartlett K, Record CO, al Mardini H. Synaptosomal glutamate transport in thioacetamide-induced hepatic encephalopathy in the rat. Hepatology 1995; 22:553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/10/14506/abstract/68\">",
"      Norenberg MD, Huo Z, Neary JT, Roig-Cantesano A. The glial glutamate transporter in hyperammonemia and hepatic encephalopathy: relation to energy metabolism and glutamatergic neurotransmission. Glia 1997; 21:124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/10/14506/abstract/69\">",
"      Knecht K, Michalak A, Rose C, et al. Decreased glutamate transporter (GLT-1) expression in frontal cortex of rats with acute liver failure. Neurosci Lett 1997; 229:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/10/14506/abstract/70\">",
"      Chan H, Hazell AS, Desjardins P, Butterworth RF. Effects of ammonia on glutamate transporter (GLAST) protein and mRNA in cultured rat cortical astrocytes. Neurochem Int 2000; 37:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/10/14506/abstract/71\">",
"      Ferenci P, Pappas SC, Munson PJ, Jones EA. Changes in glutamate receptors on synaptic membranes associated with hepatic encephalopathy or hyperammonemia in the rabbit. Hepatology 1984; 4:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/10/14506/abstract/72\">",
"      Michalak A, Butterworth RF. Selective loss of binding sites for the glutamate receptor ligands [3H]kainate and (S)-[3H]5-fluorowillardiine in the brains of rats with acute liver failure. Hepatology 1997; 25:631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/10/14506/abstract/73\">",
"      Saransaari P, Oja SS, Borkowska HD, et al. Effects of thioacetamide-induced hepatic failure on the N-methyl-D-aspartate receptor complex in the rat cerebral cortex, striatum, and hippocampus. Binding of different ligands and expression of receptor subunit mRNAs. Mol Chem Neuropathol 1997; 32:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/10/14506/abstract/74\">",
"      Cauli O, Rodrigo R, Llansola M, et al. Glutamatergic and gabaergic neurotransmission and neuronal circuits in hepatic encephalopathy. Metab Brain Dis 2009; 24:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/10/14506/abstract/75\">",
"      Fan P, Szerb JC. Effects of ammonium ions on synaptic transmission and on responses to quisqualate and N-methyl-D-aspartate in hippocampal CA1 pyramidal neurons in vitro. Brain Res 1993; 632:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/10/14506/abstract/76\">",
"      Vogels BA, Maas MA, Daalhuisen J, et al. Memantine, a noncompetitive NMDA receptor antagonist improves hyperammonemia-induced encephalopathy and acute hepatic encephalopathy in rats. Hepatology 1997; 25:820.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/10/14506/abstract/77\">",
"      Hermenegildo C, Marcaida G, Montoliu C, et al. NMDA receptor antagonists prevent acute ammonia toxicity in mice. Neurochem Res 1996; 21:1237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/10/14506/abstract/78\">",
"      Romero-G&oacute;mez M, Jover M, Del Campo JA, et al. Variations in the promoter region of the glutaminase gene and the development of hepatic encephalopathy in patients with cirrhosis: a cohort study. Ann Intern Med 2010; 153:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/10/14506/abstract/79\">",
"      Fischer JE, Baldessarini RJ. False neurotransmitters and hepatic failure. Lancet 1971; 2:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/10/14506/abstract/80\">",
"      Ferenci P, Wewalka F. Plasma amino acids in hepatic encephalopathy. J Neural Transm Suppl 1978; :87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/10/14506/abstract/81\">",
"      Morgan MY, Milsom JP, Sherlock S. Plasma ratio of valine, leucine and isoleucine to phenylalanine and tyrosine in liver disease. Gut 1978; 19:1068.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/10/14506/abstract/82\">",
"      Cuilleret G, Pomier-Layrargues G, Pons F, et al. Changes in brain catecholamine levels in human cirrhotic hepatic encephalopathy. Gut 1980; 21:565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/10/14506/abstract/83\">",
"      Zieve L, Olsen RL. Can hepatic coma be caused by a reduction of brain noradrenaline or dopamine? Gut 1977; 18:688.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/10/14506/abstract/84\">",
"      Montes S, Alcaraz-Zubeldia M, Muriel P, R&iacute;os C. Striatal manganese accumulation induces changes in dopamine metabolism in the cirrhotic rat. Brain Res 2001; 891:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/10/14506/abstract/85\">",
"      Krieger D, Krieger S, Jansen O, et al. Manganese and chronic hepatic encephalopathy. Lancet 1995; 346:270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/10/14506/abstract/86\">",
"      Rose C, Butterworth RF, Zayed J, et al. Manganese deposition in basal ganglia structures results from both portal-systemic shunting and liver dysfunction. Gastroenterology 1999; 117:640.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/10/14506/abstract/87\">",
"      Yurdaydin C, H&ouml;rtnagl H, Steindl P, et al. Increased serotoninergic and noradrenergic activity in hepatic encephalopathy in rats with thioacetamide-induced acute liver failure. Hepatology 1990; 12:695.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/10/14506/abstract/88\">",
"      Jellinger K, Riederer P, Kleinberger G, et al. Brain monoamines in human hepatic encephalopathy. Acta Neuropathol 1978; 43:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/10/14506/abstract/89\">",
"      Rao VL, Butterworth RF. Alterations of [3H]8-OH-DPAT and [3H]ketanserin binding sites in autopsied brain tissue from cirrhotic patients with hepatic encephalopathy. Neurosci Lett 1994; 182:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/10/14506/abstract/90\">",
"      Rao VL, Gigu&egrave;re JF, Layrargues GP, Butterworth RF. Increased activities of MAOA and MAOB in autopsied brain tissue from cirrhotic patients with hepatic encephalopathy. Brain Res 1993; 621:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/10/14506/abstract/91\">",
"      Bergqvist PB, Hjorth S, Wikell C, et al. p-Chloroamphetamine- and d-fenfluramine-induced brain serotonin release in experimental portal-systemic encephalopathy. Metab Brain Dis 1997; 12:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/10/14506/abstract/92\">",
"      Bergqvist PB, Hjorth S, Apelqvist G, Bengtsson F. Potassium-evoked neuronal release of serotonin in experimental chronic portal-systemic encephalopathy. Metab Brain Dis 1997; 12:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/10/14506/abstract/93\">",
"      Yurdaydin C, Herneth AM, P&uuml;sp&ouml;k A, et al. Modulation of hepatic encephalopathy in rats with thioacetamide-induced acute liver failure by serotonin antagonists. Eur J Gastroenterol Hepatol 1996; 8:667.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/10/14506/abstract/94\">",
"      Mousseau DD, Butterworth RF. The [3H]tryptamine receptor in human brain: kinetics, distribution, and pharmacologic profile. J Neurochem 1994; 63:1052.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/10/14506/abstract/95\">",
"      Michalak A, Chatauret N, Butterworth RF. Evidence for a serotonin transporter deficit in experimental acute liver failure. Neurochem Int 2001; 38:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/10/14506/abstract/96\">",
"      Lozeva V, Tuomisto L, Sola D, et al. Increased density of brain histamine H(1) receptors in rats with portacaval anastomosis and in cirrhotic patients with chronic hepatic encephalopathy. Hepatology 2001; 33:1370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/10/14506/abstract/97\">",
"      C&oacute;rdoba J, Cabrera J, Lataif L, et al. High prevalence of sleep disturbance in cirrhosis. Hepatology 1998; 27:339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/10/14506/abstract/98\">",
"      Steindl PE, Finn B, Bendok B, et al. Disruption of the diurnal rhythm of plasma melatonin in cirrhosis. Ann Intern Med 1995; 123:274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/10/14506/abstract/99\">",
"      Horowitz ME, Schafer DF, Molnar P, et al. Increased blood-brain transfer in a rabbit model of acute liver failure. Gastroenterology 1983; 84:1003.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/10/14506/abstract/100\">",
"      Goldbecker A, Buchert R, Berding G, et al. Blood-brain barrier permeability for ammonia in patients with different grades of liver fibrosis is not different from healthy controls. J Cereb Blood Flow Metab 2010; 30:1384.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/10/14506/abstract/101\">",
"      James JH, Escourrou J, Fischer JE. Blood-brain neutral amino acid transport activity is increased after portacaval anastomosis. Science 1978; 200:1395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/10/14506/abstract/102\">",
"      Hawkins RA, Jessy J. Hyperammonaemia does not impair brain function in the absence of net glutamine synthesis. Biochem J 1991; 277 ( Pt 3):697.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/10/14506/abstract/103\">",
"      Hawkins RA, Jessy J, Mans AM, De Joseph MR. Effect of reducing brain glutamine synthesis on metabolic symptoms of hepatic encephalopathy. J Neurochem 1993; 60:1000.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/10/14506/abstract/104\">",
"      Iversen P, S&oslash;rensen M, Bak LK, et al. Low cerebral oxygen consumption and blood flow in patients with cirrhosis and an acute episode of hepatic encephalopathy. Gastroenterology 2009; 136:863.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/10/14506/abstract/105\">",
"      Hindfelt B, Plum F, Duffy TE. Effect of acute ammonia intoxication on cerebral metabolism in rats with portacaval shunts. J Clin Invest 1977; 59:386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/10/14506/abstract/106\">",
"      Wasmuth HE, Kunz D, Yagmur E, et al. Patients with acute on chronic liver failure display \"sepsis-like\" immune paralysis. J Hepatol 2005; 42:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/10/14506/abstract/107\">",
"      Iacobone E, Bailly-Salin J, Polito A, et al. Sepsis-associated encephalopathy and its differential diagnosis. Crit Care Med 2009; 37:S331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/10/14506/abstract/108\">",
"      Papadopoulos MC, Davies DC, Moss RF, et al. Pathophysiology of septic encephalopathy: a review. Crit Care Med 2000; 28:3019.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/10/14506/abstract/109\">",
"      Licinio J, Wong ML. Pathways and mechanisms for cytokine signaling of the central nervous system. J Clin Invest 1997; 100:2941.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/10/14506/abstract/110\">",
"      Didier N, Romero IA, Cr&eacute;minon C, et al. Secretion of interleukin-1beta by astrocytes mediates endothelin-1 and tumour necrosis factor-alpha effects on human brain microvascular endothelial cell permeability. J Neurochem 2003; 86:246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/10/14506/abstract/111\">",
"      Shawcross DL, Wright G, Olde Damink SW, Jalan R. Role of ammonia and inflammation in minimal hepatic encephalopathy. Metab Brain Dis 2007; 22:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/10/14506/abstract/112\">",
"      Shawcross DL, Davies NA, Williams R, Jalan R. Systemic inflammatory response exacerbates the neuropsychological effects of induced hyperammonemia in cirrhosis. J Hepatol 2004; 40:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/10/14506/abstract/113\">",
"      Bode C, Kugler V, Bode JC. Endotoxemia in patients with alcoholic and non-alcoholic cirrhosis and in subjects with no evidence of chronic liver disease following acute alcohol excess. J Hepatol 1987; 4:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/10/14506/abstract/114\">",
"      Stadlbauer V, Mookerjee RP, Wright GA, et al. Role of Toll-like receptors 2, 4, and 9 in mediating neutrophil dysfunction in alcoholic hepatitis. Am J Physiol Gastrointest Liver Physiol 2009; 296:G15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/10/14506/abstract/115\">",
"      Wright G, Davies NA, Shawcross DL, et al. Endotoxemia produces coma and brain swelling in bile duct ligated rats. Hepatology 2007; 45:1517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/10/14506/abstract/116\">",
"      Rodrigo R, Cauli O, Gomez-Pinedo U, et al. Hyperammonemia induces neuroinflammation that contributes to cognitive impairment in rats with hepatic encephalopathy. Gastroenterology 2010; 139:675.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/10/14506/abstract/117\">",
"      Shawcross DL, Shabbir SS, Taylor NJ, Hughes RD. Ammonia and the neutrophil in the pathogenesis of hepatic encephalopathy in cirrhosis. Hepatology 2010; 51:1062.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/10/14506/abstract/118\">",
"      Shawcross DL, Wright GA, Stadlbauer V, et al. Ammonia impairs neutrophil phagocytic function in liver disease. Hepatology 2008; 48:1202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/10/14506/abstract/119\">",
"      Monfort P, Cauli O, Montoliu C, et al. Mechanisms of cognitive alterations in hyperammonemia and hepatic encephalopathy: therapeutical implications. Neurochem Int 2009; 55:106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/10/14506/abstract/120\">",
"      Gupta A, Dhiman RK, Kumari S, et al. Role of small intestinal bacterial overgrowth and delayed gastrointestinal transit time in cirrhotic patients with minimal hepatic encephalopathy. J Hepatol 2010; 53:849.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/10/14506/abstract/121\">",
"      Bajaj JS, Hylemon PB, Ridlon JM, et al. Colonic mucosal microbiome differs from stool microbiome in cirrhosis and hepatic encephalopathy and is linked to cognition and inflammation. Am J Physiol Gastrointest Liver Physiol 2012; 303:G675.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/10/14506/abstract/122\">",
"      Bajaj JS, Ridlon JM, Hylemon PB, et al. Linkage of gut microbiome with cognition in hepatic encephalopathy. Am J Physiol Gastrointest Liver Physiol 2012; 302:G168.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1257 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-61.234.146.186-3C008BD0A1-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_10_14506=[""].join("\n");
var outline_f14_10_14506=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H27\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      NEUROTOXINS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Ammonia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Impaired blood to brain transport of amino acids",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Increase in intracellular osmolarity in astrocytes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Altered neuronal electric activity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Oxidative stress",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Oxindole",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      IMPAIRMENT OF NEUROTRANSMISSION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      GABA-benzodiazepine neurotransmitter system",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Neurochemical studies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Neurobehavioral studies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Electrophysiologic studies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Endogenous benzodiazepines",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Neurosteroids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Glutamatergic neurotransmission",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Neurochemical studies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Glutamate receptors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Neurobehavioral studies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H129432728\">",
"      - Genetic studies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Catecholamines",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Serotonin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Histamine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Melatonin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      ALTERATION OF THE BLOOD-BRAIN BARRIER",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      ALTERED BRAIN ENERGY METABOLISM",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      SYSTEMIC RESPONSE TO INFECTIONS AND NEUROINFLAMMATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18224960\">",
"      BACTERIAL OVERGROWTH",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/1257\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/1257|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?0/34/556\" title=\"table 1\">",
"      Precipitants of HE in cirrhosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?18/9/18589\" title=\"table 2\">",
"      Rx of hepatic encephalopathy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/22/34153?source=related_link\">",
"      Clinical manifestations and diagnosis of hepatic encephalopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/5/15448?source=related_link\">",
"      Complications of transjugular intrahepatic portosystemic shunts",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/15/4346?source=related_link\">",
"      Hepatic encephalopathy in adults: Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/12/17608?source=related_link\">",
"      Hyponatremia in patients with cirrhosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?7/40/7810?source=related_link\">",
"      Patient information: Hepatic encephalopathy (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/46/13034?source=related_link\">",
"      Physiology and clinical use of melatonin",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f14_10_14507="Capillary hemodynamics";
var content_f14_10_14507=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F55674&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F55674&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Capillary hemodynamic forces",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 370px; height: 157px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Schematic representation of the capillary and interstitial fluid hydraulic (P) and oncotic (&Omicron;) pressures controlling fluid movement across the capillary wall between the plasma and the interstitial fluid. The arrows point in the direction of fluid movement induced by each of the forces.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_10_14507=[""].join("\n");
var outline_f14_10_14507=null;
var title_f14_10_14508="Sequelae of congenital CMV";
var content_f14_10_14508=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F51801&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F51801&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Sequelae in children after congenital cytomegalovirus infection",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Sequelae",
"       </td>",
"       <td class=\"subtitle1\">",
"        Symptomatic, percent (no.)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Asymptomatic, percent (no.)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sensorineural hearing loss",
"       </td>",
"       <td>",
"        58.0 (58/100)",
"       </td>",
"       <td>",
"        7.4 (22/299)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bilateral hearing loss",
"       </td>",
"       <td>",
"        37.0 (37/100)",
"       </td>",
"       <td>",
"        2.7 (8/299)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Speech threshold moderate to profound (60 to 90 dB)*",
"       </td>",
"       <td>",
"        27.0 (27/100)",
"       </td>",
"       <td>",
"        1.7 (5/299)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Chorioretinitis",
"       </td>",
"       <td>",
"        20.4 (19/93)",
"       </td>",
"       <td>",
"        2.5 (7/281)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        IQ &lt;70",
"       </td>",
"       <td>",
"        55.0 (33/60)",
"       </td>",
"       <td>",
"        3.7 (6/159)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Microcephaly, seizures or paresis/paralysis",
"       </td>",
"       <td>",
"        51.9 (54/104)",
"       </td>",
"       <td>",
"        2.7 (9/330)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Microcephaly",
"       </td>",
"       <td>",
"        37.5 (39/104)",
"       </td>",
"       <td>",
"        1.8 (6/330)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Seizures",
"       </td>",
"       <td>",
"        23.1 (24/104)",
"       </td>",
"       <td>",
"        0.9 (3/330)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Paresis/paralysis",
"       </td>",
"       <td>",
"        12.5 (13/104)",
"       </td>",
"       <td>",
"        0.0 (0/330)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Death",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        5.8 (6/104)",
"       </td>",
"       <td>",
"        0.3 (1/330)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     dB: decibels; IQ: intelligence quotient.",
"     <br>",
"      * For the ear with better hearing.",
"      <br>",
"       <font class=\"bullet\">",
"        &bull;",
"       </font>",
"       After newborn period.",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Pass RF, Fowler KB, Boppana S. Progress in cytomegalovirus research. In: Proceedings of the Third International Cytomegalovirus Workshop, Landini MP (Ed), Bologna, Italy, June 1991. London, Excerpta Medica, 1991. pp.3-10. Copyright &copy; 1991 Maria Paola Landini.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_10_14508=[""].join("\n");
var outline_f14_10_14508=null;
var title_f14_10_14509="Doses asthma reliever meds kids";
var content_f14_10_14509=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F59229&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F59229&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Usual doses for quick-relief asthma medications in children*",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Medication",
"       </td>",
"       <td class=\"subtitle1\">",
"        Dosage form",
"       </td>",
"       <td class=\"subtitle1\">",
"        0-4 years",
"       </td>",
"       <td class=\"subtitle1\">",
"        5-11 years",
"       </td>",
"       <td class=\"subtitle1\">",
"        Comments",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"5\">",
"        Inhaled short-acting beta",
"        <sub>",
"         2",
"        </sub>",
"        -agonists",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3_left\" colspan=\"5\">",
"        MDI",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Albuterol CFC",
"       </td>",
"       <td>",
"        90 mcg/puff, 200 puffs/canister",
"       </td>",
"       <td>",
"        1-2 puffs 5 minutes before exercise",
"       </td>",
"       <td>",
"        2 puffs 5 minutes before exercise",
"       </td>",
"       <td rowspan=\"4\">",
"        <p>",
"         Differences in potencies exist, but all products are essentially comparable on a per puff basis.",
"        </p>",
"        <p>",
"         An increasing use or lack of expected effect indicates diminished control of asthma.",
"        </p>",
"        <p>",
"         Not recommended for long-term daily treatment. Regular use exceeding 2 days/week for symptom control (not prevention of EIB) indicates the need for additional long-term control therapy.",
"        </p>",
"        <p>",
"         May double usual dose for mild exacerbations.",
"        </p>",
"        <p>",
"         Should prime the inhaler by releasing 4 actuations prior to use.",
"        </p>",
"        <p>",
"         Periodically clean HFA actuator, as drug may plug orifice.",
"        </p>",
"        <p>",
"         Children &lt;4 years may not generate sufficient inspiratory flow to activate an auto-inhaler.",
"        </p>",
"        <p>",
"         Nonselective agents (ie, epinephrine, isoproterenol, metaproterenol) are not recommended due to their potential for excessive cardiac stimulation, especially in high doses.",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Albuterol HFA",
"       </td>",
"       <td>",
"        90 mcg/puff, 200 puffs/canister",
"       </td>",
"       <td>",
"        2 puffs every 4-6 hours as needed",
"       </td>",
"       <td>",
"        2 puffs every 4-6 hours as needed",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Levalbuterol HFA",
"       </td>",
"       <td>",
"        45 mcg/puff, 200 puffs/canister",
"       </td>",
"       <td>",
"        Safety and efficacy not established in children &lt;4 years",
"       </td>",
"       <td>",
"        2 puffs every 4-6 hours as needed",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Pirbuterol CFC Autohaler",
"       </td>",
"       <td>",
"        200 mcg/puff, 400 puffs/canister",
"       </td>",
"       <td>",
"        Safety and efficacy not established",
"       </td>",
"       <td>",
"        Safety and efficacy not established",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3_left\" colspan=\"5\">",
"        Nebulizer solution",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Albuterol",
"       </td>",
"       <td>",
"        <p>",
"         0.63 mg/3 mL",
"        </p>",
"        <p>",
"         1.25 mg/3 mL",
"        </p>",
"        <p>",
"         2.5 mg/3 mL",
"        </p>",
"        <p>",
"         5 mg/mL (0.5 percent)",
"        </p>",
"       </td>",
"       <td>",
"        0.63-2.5 mg in 3 cc of saline every 4-6 hours, as needed",
"       </td>",
"       <td>",
"        1.25-5 mg in 3 cc of saline every 4-8 hours, as needed",
"       </td>",
"       <td>",
"        May mix with cromolyn solution, budesonide inhalant suspension, or ipratropium solution for nebulization. May double dose for severe exacerbations.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Levalbuterol (R-albuterol)",
"       </td>",
"       <td>",
"        <p>",
"         0.31 mg/3 mL",
"        </p>",
"        <p>",
"         0.63 mg/3 mL",
"        </p>",
"        <p>",
"         1.25 mg/0.5 mL",
"        </p>",
"        <p>",
"         1.25 mg/3 mL",
"        </p>",
"       </td>",
"       <td>",
"        0.31-1.25 mg in 3 cc every 4-6 hours, as needed",
"       </td>",
"       <td>",
"        0.31-0.63 mg, every 8 hours, as needed",
"       </td>",
"       <td>",
"        <p>",
"         Does not have FDA-approved labeling for children &lt;6 years of age.",
"        </p>",
"        <p>",
"         The product is a sterile-filled preservative-free unit dose vial.",
"        </p>",
"        <p>",
"         Compatible with budesonide inhalant suspension.",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     CFC: chlorofluorocarbon; ED: emergency department; EIB: exercise-induced bronchospasm; HFA: hydrofluoroalkane; IM: intramuscular; MDI: metered-dose inhaler; PEF: peak expiratory flow.",
"     <br>",
"      * Dosages are provided for those products that have been approved by the US Food and Drug Administration or have sufficient clinical trial safety and efficacy data in the appropriate age ranges to support their use.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: National Heart, Blood, and Lung Institute Expert Panel Report 3 (EPR 3): Guidelines for the Diagnosis and Management of Asthma. NIH Publication no. 08-4051, 2007.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_10_14509=[""].join("\n");
var outline_f14_10_14509=null;
var title_f14_10_14510="Suppurative cholangitis Endosc";
var content_f14_10_14510=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F69133&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F69133&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Suppurative cholangitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 261px; height: 226px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Endoscopy in a patient with suppurative cholangitis shows pus coming out of the ampulla of Vater (arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_10_14510=[""].join("\n");
var outline_f14_10_14510=null;
var title_f14_10_14511="Sinus biopsy 1";
var content_f14_10_14511=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F73721&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F73721&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Sinus biopsy 1",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 359px; height: 240px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_10_14511=[""].join("\n");
var outline_f14_10_14511=null;
